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ABSTRACT 
DONGYUN LIU: Water-in-oil Microemulsions and Hydrogel Nanoparticles in Water-in-Oil 
Microemulsions for Local Intestinal Delivery of Peptides and Proteins 
(Under the direction of Russell J. Mumper, Ph.D.) 
 
The objectives of the present studies were to develop water-in-oil (W/O) 
microemulsions (MEs) and hydrogel nanoparticles in W/O MEs for effective local intestinal 
delivery of peptide and protein drugs.  
Water-in-oil MEs consisting of Miglyol 812, Capmul MCM, Tween 80 and water were 
developed and characterized.  Selected W/O MEs containing a model peptide, 5-(and-6)-
carboxytetramethylrhodamine labeled HIV transactivator protein TAT (TAMRA-TAT), were 
evaluated both in vitro and in vivo.  In vitro enzymatic stability studies showed the half-life 
(t1/2) of TAMRA-TAT in ME was enhanced nearly three-fold compared to that in the water 
solution when challenged by modified simulated intestinal fluid.  In vivo studies in mice 
showed TAMRA-TAT ME resulted in greater fluorescence intensity in all intestinal sections 
(duodenum, jejunum, ileum and colon) compared to controls after oral administration.  The 
in vitro and in vivo studies together demonstrated that TAMRA-TAT was better protected in 
the W/O ME in an enzyme-containing environment, suggesting the W/O MEs developed in 
this study may serve as a delivery vehicle for local intestinal delivery of peptides or proteins.   
To further improve the current W/O ME formulations, a thermoreversible gelling 
polymer Pluronic F127 (PF127) was explored to engineer hydrogel nanoparticles in the W/O 
MEs.  Water-in-oil MEs with 14% PF127 were developed based on viscosity studies and 
construction of phase diagrams, and then physically characterized at different temperatures.  
After physical characterization, TAMRA-TAT loaded W/O MEs with 8% and 14% PF127, 
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were evaluated in vitro in enzymatic stability studies.  The results showed the t1/2 of TAMRA-
TAT in the W/O ME with 14% PF127 was shorter than that in the W/O ME without PF127.  
In contrast, the t1/2 of TAMRA-TAT in the W/O ME with 8% PF127 was almost the same as 
that in the W/O ME without PF127.  This observation was explained by the large increase in 
droplet diameter, polydispersity index and turbidity of the ME with 14% PF127, which 
indicated a possible aggregation and precipitation of PF127 from the ME at 37˚C.  
Consequently, the aggregation and precipitation of PF127 might have exposed more 
TAMRA-TAT associated with it to enzymes, resulting in faster TAMRA-TAT degradation.  
The formation of hydrogel nanoparticles in the W/O MEs was not completely achieved; 
further research is necessary to better understand and improve the formulation. 
In summary, the use of W/O ME systems proposed in this work is an attractive 
strategy to deliver peptides and proteins orally for the treatment of local intestinal 
pathologies such as inflammatory bowel diseases. 
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 Chapter I 
 
Local Intestinal Delivery of Peptides and Proteins: A Review 
 
 
 
1.1  Introduction 
With the advance of biotechnology, a wide variety of peptide and protein drugs have 
been produced on a commercial scale.  Their incredible selectivity and potency have made 
them the drugs of choice for the treatment of numerous diseases.  However, most of the 
peptide and protein drugs are administered by the parenteral route, which greatly limits their 
applications for the treatment of chronic diseases.  In contrast to this inconvenient route of 
drug administration, the oral route offers the advantages of self-administration with good 
patient compliance and potentially lower manufacturing cost as well [1].  Various strategies 
have been pursued to develop safe and effective oral delivery systems for peptides and 
proteins [1-11].  In this chapter, we summarize some approaches investigated for local 
intestinal delivery of peptides or proteins via the oral route, with colon-specific peptide and 
protein delivery as our primary focus.  
 
1.2  Brief Overview on the Anatomy and Physiology of the Colon 
Anatomically, the large intestine includes the caecum, colon, rectum and anal canal.  
The colon starts from the caecum and ends with the rectum.  The total length of the colon in 
adults is approximately 150 cm with a surface area of 0.3 m2 which is relatively small as
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compared to the surface area of the small intestine of 120 m2).  The average diameter of the 
colon is about 7 cm [12].  It is comprised of the ascending colon (right), transverse colon,
descending colon (left), and sigmoid colon.  The colon wall is composed of several 
overlapping layers, including the mucosa, submucosa, muscularis externa and the serona.  
The mucosa is the innermost layer of the colon wall, which opens to the lumen and directly 
contacts with luminal content.  The mucosa layer is further divided into epithelium, lamina 
propria and muscularis mucosa.  The epithelium consists of a single layer of columnar 
enterocytes and maintains the barrier function.  The lamina propria is a layer of connective 
tissue with blood vessels and lymphatic vessels embedded, which lies outside the 
epithelium. The muscularis mucosa is a thin layer of smooth muscle and is the outer layer of 
the mucosa.  The submucosa lies outside the mucosa, and contains lots of connective 
tissues with blood vessels, lymphatics and nerve vessels. The muscularis externa consists 
of an inner circular layer and an outer longitudinal layer of muscle.  The circular layer of 
muscle provides squeezing action and the longitudinal layer of muscle provides propelling 
action.  The serosa is the single cell layer on the outside of colon.  
Compared to the small intestine which is the primary site of nutrient digestion and 
absorption, the colon is mainly responsible for the maintenance of fluid and electrolyte 
balance through absorption of water, sodium and chloride.  In addition, the colon is also the 
site to form and store feces from undigested materials, residues of epithelial cell turnover 
and bacteria [13].  Similar to other part of the gastrointestinal (GI) tract, the colon functions 
as effective biophysical and biochemical barriers against the penetration of pathogens, 
toxins and other foreign substances into the body as well.  Compared to the small intestine, 
the colon also possesses at least five distinct characteristics affecting its potential as a drug 
delivery site.   
First, the colon has relatively a low volume of fluid and the luminal content in the 
colon is generally viscous.  Studies by Schiller et al. [14] showed the free fluid volume in 
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human ranged from 1 to 44 mL (median 8 mL) in the fasted state and from 2 to 97 mL 
(median 18 mL) in the fed state in the colon.  The limited free fluid volume may affect the 
drug distribution and dissolution in the colon, and likely resulting in higher local drug 
concentrations.   
Second, the overall proteolytic activity in the colon is about 20-60 times lower and 
different compared to the proteolytic activity in the small intestine [15, 16], which makes 
colon a more favorable site for local peptide and protein delivery.  Although, pancreatic 
peptidases are secreted in grams quantities every day, their residual levels in the colon is 
quite limited [17, 18].  It was reported that in the ileum, the trypsin and chymotrypsin 
activities were only one-half and one-third of that in the duodenum, respectively [19].  
Moreover, the pH drops to weakly acidic in the cecum and ascending colon compared to 
ileum, which fails to provide the optimum pH range of 7 to 8 for the activity of pancreatic 
enzymes [12, 20].  Meanwhile, the brush-border membrane associated peptidases are quite 
limited in the colon compared to those in the small intestines [21].   
Third, the microflora in the human colon is quite abundant and diverse, and the 
bacterial counts were reported as high as 1011-1012 colony forming units (CFU)/mL in the 
colon, and there may be more than 3,000 different species colonizing in the colon [22, 23].  
The microflora is able to ferment and metabolize a large range of polysaccharides, starch, 
dietary fiber and undigested proteins, and produce sugars, amino acids, short-chain fatty 
acids, branched chain fatty acids, hydrogen, methane and carbon dioxide etc. [12].  
Consequently, the fermentation products are able to influence the colonic environment, such 
as the viscosity, pH and redox potential [24].   
Fourth, the motility of the colon is relatively slow.  It involves the combination of 
segmental and peristaltic contractions by smooth muscle layers.  The segmental 
contractions are responsible for the mixing of luminal content, while the peristaltic 
contractions are associated with propulsive movements to propel the luminal content toward 
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the rectum [25]. Due to the special motility pattern and the infrequent propulsive movements, 
the overall motility is slow, which corresponds to a long colon transit time from several hours 
up to several days [26].  The slow and lengthy transit combined with a progressive decrease 
in colon fluid volume would make a healthy colon a reservoir system for both therapeutic 
drugs and unabsorbed nutrients.   
Fifth, the luminal pH in normal GI tract progressively increases from the duodenum to 
the distal ileum, decreases in the cecum, and then increases slowly along the colon to the 
rectum.  Compared to the luminal pH in the range of 6.5 to 7.5 in the distal ileum, the pH in 
the caecum and ascending colon drops to the range of 5.5 to 7.5, and then gradually rises in 
the descending colon and rectum to 6.1 to 7.5 [27].  Studies have also indicated the colonic 
mucosal pH in healthy subjects was consistently higher at all segments than the luminal pH, 
ranging from 7.1 to 7.5 [28].  Some data also reported the pH in the ascending colon was 
reduced in patients with active ulcerative colitis [27].  Since the disease state may affect the 
colonic pH, it should be considered when designing pH-dependent delivery systems. 
Colon delivery has been used in clinic for the treatment of inflammatory bowel 
diseases (IBDs) [29, 30].  The benefits of local delivery of steroidal and non-steroidal anti-
inflammatory drugs for long-term therapy of IBD have been well recognized.  Local colonic 
delivery is also considered beneficial for the treatment of various colonic cancers and other 
local pathologies like some parasitic diseases affecting the colon.  By targeting the drug to 
the local disease site, like the site of inflammation, colonic drug delivery can avoid extensive 
drug degradation and unneeded absorption in the upper GI tract, maximize local drug 
concentration thereby efficacy and minimize potential systemic side effects.  Recently, colon 
delivery has been considered not only suitable for the treatment of local pathologies, but 
also as a promising strategy to improve systemic absorption of some drug molecules, 
especially those hydrophilic peptide and protein drugs that would undergo extensive 
enzymatic degradation in the upper GI tract.  In summary, the colon’s anatomical and 
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physiological properties has confirmed that the colon is an attractive site for local oral 
peptide and protein delivery. 
 
1.3  Approaches to Achieve Colon Delivery 
Various colon delivery systems for local oral peptide and protein delivery have been 
investigated and published [5, 8, 11, 31-33].  These systems are generally designed based 
on the typical variations in the physiological parameters along the GI tract, such as the 
abundance of microflora, luminal pH, intra-luminal pressure, and transit or residence time in 
each intestinal segment.  Some systems utilized one of the above mentioned parameters 
[34-39], while others utilized a combination of two or more parameters to achieve a better 
targeting effect [40]. 
 
1.3.1  Microflora-dependent delivery systems 
In humans, the GI tract is inhabited by a large variety of microflora species.  In the 
stomach and small intestine, there are roughly 103-104 colony forming units (CFU)/mL [29].  
However, the concentration of microflora increases significantly to 1011-1012 CFU/mL 
passing from the distal ileum to the ascending colon [41].  The predominant species include 
Bacteroides, Bifidobacterium, and Eubacterium [42].  Anaerobic gram-positive Cocci, 
Clostridia, Enterococci, and various species of Enterobacteriaceae are also commonly found 
[43].  These bacteria survive by fermenting various substrates left undigested from the small 
intestines, such as oligosaccharides, di-, tri-polysaccharides, mucopolysaccharides [44].  
The enzymes produced to ferment these substrates include azoreductase, β-glucuronidase, 
β-xylosidases, β-galactosidase, α-arabinosidase, nitroreductase, dextranase, deaminase, 
urea hydroxylase, etc. [43, 45, 46].  The unique ability of colonic bacteria species to catalyze 
degradations of substrates that do not undergo major dissolution, degradation or absorption 
in the small intestine is exploited for local colonic drug delivery. 
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Prodrugs 
This microflora-dependent strategy was first pursued in a prodrug-based delivery 
system for local colonic delivery.  In 1972, Peppercorn and Goldman [47] observed that 
salicylazosulfapyridine (SAS) was converted to sulphapyridine (SP) and 5-aminosalicylic 
acid (5-ASA) by the mammalian intestinal microflora via the reduction of the azo bond.  In 
1977, Khan et al. [48] found that the active moiety effective in IBD was 5-ASA and SP was 
only a carrier.  After realizing the association of side effects with SP, several 5-ASA 
prodrugs, ipsalazide, balsalazide [49] and olsalazine [50] were designed accordingly.  
Ipsalazide and balsalazide are able to release one 5-ASA molecule and one nontoxic carrier, 
while olsalazine can generate two 5-ASA molecules after reduction of the azo bond by colon 
bacterial enzymes.  Based on the same principle, Parkinson et al. [51] synthesized a 
polymeric prodrug to deliver 5-ASA.  The 5-ASA precursor was attached to a polymeric 
compound through an azo-linkage.  When the polymer passed through the mammalian GI 
tract, the azo-linkage was cleaved by colon bacteria and 5-ASA was released to the colon.  
Similar to the azo-linkage, several other linkages susceptible to bacterial hydrolysis in the 
colon (such as amide linkage, glycosidic linkage, glucuronide linkage and ester linkage) 
were utilized to design a variety of prodrugs for colon targeted delivery.  The drug carrier 
moiety could be small molecules such as amino acid, glucose, galactose, glucuronic acid, or 
some synthetic or naturally occurring polymers.  A large variety of prodrugs evaluated for 
local colon-specific drug delivery based on colonic bacterial enzymes were well summarized 
by Sinha et al. [43], and most of them showed great or promising colon targeting effects.  
However, the prodrug approach for local colon delivery was mostly investigated for 
the delivery of small molecule drugs, and reports on prodrugs of peptides or proteins for 
either local or systemic colon delivery purposes were quite rare.  A recent publication by 
Kennedy et al. [52] reported the synthesis of azo-prodrugs of nonsteroidal anti-inflammatory 
agents and antimicrobial peptides for local colonic delivery to treat infection and 
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inflammation by the bacterial pathogen Clostridium difficile.  The structural design of the 
azo-prodrugs is shown in Figure 1.1.  An antibacterial peptide temporin A analogue L512TA 
was linked to the anti-inflammatory agent 4-aminophenylacetic acid by an α-methylalanine 
linker via an azo bond.  It was hypothesized that both components would stay inactive 
before reaching colon, thereby avoiding side effects from NSAID or disruption of commensal 
microflora in the upper GI tract.  The authors reported the synthesis and purification of the 
prodrugs, but no further in vitro or in vivo evaluation data were available.  
The prodrug approach is one of the options to solve many drug delivery related 
problems, such as poor chemical stability, or low aqueous solubility, but it is still very 
challenging when applied to peptide and protein delivery.  The use of prodrugs to chemically 
or physically stabilize peptides or proteins has not been well evaluated yet, and for site-
specific targeting of peptides or proteins to the colon, it becomes even more difficult for 
several reasons.   
First, in general, the prodrug approach is not very versatile and it depends on the 
functional groups available on the drug for chemical conjugation.  For peptides and proteins, 
which are polymers of amino acids, site-selective chemical conjugation is more difficult and 
complicated than that for small molecules.  Meanwhile, to protect peptides or proteins from 
degradation in the upper GI tract, it involves many peptide bonds vulnerable to proteolytic 
enzymes.  Proteolysis may happen at N-terminus, C-terminus, or at any distinct endo 
residues in a peptide or protein drug.  Modification at one site may improve its stability to 
some enzymes but the peptide or protein may still be susceptible to other enzymes.   
Second, for colon targeting, chemical conjugation to polymer carriers that are 
specifically degraded by colon bacteria has shown promising results for the colonic delivery 
of small molecule drugs [53].  However, when peptide or protein drugs are conjugated to 
these polymer carriers, the molecular weight, composition and 3D structure, hydrophobicity 
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and flexibility of both moieties have to be considered, and the conjugation chemistry, 
purification and characterization processes become more complicated.   
Third, to successfully deliver the peptide or protein drugs to the target site in vivo 
with preserved biological activity is also very challenging for the design of peptide and 
protein prodrugs.  Random conjugation may cause the loss of biological activity of the 
peptide or protein drug.   
Fourth, prodrugs of peptides or proteins are new chemical entities and may become 
immunogenic or toxic, and will require a lot of additional evaluations before being used as 
drug carriers.  The prodrug approach for local peptide and protein colon targeting is 
promising but not well studied yet, and publications on this topic are relatively limited.   
 
Bacterial degradable polymer systems  
Based on the abundance of colon microflora, many synthetic polymers like azo-
polymers, and various naturally occurring polymers such as chitosan, pectin, dextran, guar 
gum, inulin, amylose, chondroitin sulphate, have been investigated for colon specific drug 
delivery [54-57].  Some attempts of using microbially-triggered polymer systems have been 
made for colonic peptide or protein delivery. 
Azo-polymers were synthesized and evaluated as coating materials or hydrogel 
forming matrix according to their susceptibility to cleavage by azoreductase in the large 
intestine.  Saffran et al. [39] did the early pioneering studies on the feasibility of oral colon 
delivery of insulin and other peptide drugs using the azo-polymer coating approach.  Divinyl-
azobenzene or substituted divinylazobenzene cross-linked copolymers of styrene and 
hydroxyethylmethacrylate (HEMA) were synthesized and used as water impervious film 
coating agents.  The azoaromatic polymer coated capsules or pellets of vasopressin and 
insulin were tested in rats.  The mean time to peak antidiuresis after oral administration of 
vasopressin protected by the azoaromatic polymers was about 2.5 h, while after 
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vasopressin in solution was only around 23 min.  The difference was highly significant.  
However, the variation of the vasopressin response time was large, with a clustered of them 
around 2 h, and others ranging from 5 to 8 h.  The azo-polymer coated pellets containing 
insulin were tested in streptozotocin-induced diabetic rats and resulted in a prolonged 
decrease in blood glucose levels compared to no decrease in blood glucose after given 
control pellets.  However, the same formulation was shown to have reduced effects in non-
diabetic rats.  Saffran et al. [39] showed that the azo-aromatic polymer delivery system 
worked in principle, and could deliver its drug load to the colon, although more work was 
required for further characterization and optimization.  Later, the same strategy based on 
azo-polymer coating was investigated using hard-gelatin capsules containing highly-dosed 
insulin [10]. The azo-polymer applied was a terpolymer of styrene, hydroxyethylmethacrylate 
and N,N’-bis (β-styrylsulphony)-4,4’-diaminoazobenzene.  Bovine insulin was formulated into 
azo-polymer coated capsules along with a stoichiometric mixture of 5-methoxysalicylic acid 
and sodium bicarbonate.  5-methoxysalicylic acid functioned as an absorption enhancer to 
improve insulin bioavailability.  Meanwhile, the mixture of bicarbonate and acid would 
produce carbon dioxide after water penetrated the hydrogel coating and the gelatin capsule, 
which would help rupture the gelatin capsule and release the insulin rapidly as a bolus.  The 
capsules containing bovine insulin were orally administered to pancreatectomized dogs in a 
single dose or multiple doses, and then multiple responses were measured, such as the 
plasma glucose, plasma insulin, hepatic glucose production rate, hepatic plasma flow rate, 
and glucogon-like immunoactivity.  Single oral doses of insulin produced plasma insulin 
peaks, and transient decreases in plasma glucose and other responses.  Following intensive 
multiple dosing regimen, the data showed multiple peaks of plasma insulin and a continuous 
reduction in glucose as compared to pretreatment values.  However, the total 
pancreatectomy eliminated the source of digestive enzymes in the small intestine and might 
have contributed to the preservation of insulin integrity in the GI luman.  The authors [10] 
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performed another two trials with insulin in azo-polymer-coated capsules administered to 
normal dogs.  They observed decreases in plasma glucose levels, which provided 
justification to the above experimental condition.  Brondsted et al. [58] investigated novel 
azo-aromatic polymer-based hydrogels as enzymatic degradable protein carriers for site-
specific systemic colon delivery.  The hydrogels were prepared from newly synthesized azo-
polymers of hydrophilic N-substituted (meth) acrylamides, N-tert-butylacrylamide and acrylic 
acid cross-linked with 4,4’-di(methacryloylamino)azobenzene (DMAAB).  At low acidic pH, 
the hydrogels had a low degree of swelling and thus protected the drug against enzyme 
digestion in the stomach.  As the hydrogels passed down the GI tract, the degree of swelling 
increased, and in the colon, the degree of swelling made the cross-links accessible to 
azoreductases and mediators.  The hydrogel then was degraded and the drug was released 
from the gel.  In vitro permeability experiments showed that the insulin permeability through 
the hydrogel membranes was lower at pH 2 than 7.4.  Later, Cheng et al. [37] studied the 
feasibility of using azo-polymer-coated hard gelatin capsules for peptide and protein colonic 
delivery.  DMAAB cross-linked copolymers of styrene and HEMA were used, and the 
resulting azo-polymer exhibited a pH-dependent swelling behavior.  When the pH reached 
6.8 and higher, it gradually gained weight due to water uptake. After in vitro formulation 
screening with different coating levels, capsules with around 10 mg/cm2 of azo-polymer 
coating containing pork insulin were administered to dogs.  Compared to plain uncoated 
capsules with the same level of insulin, the azo-polymer coated capsules provided slightly 
decreased glucose levels, and a higher average insulin level, but extreme large variation 
was observed in this study and the pharmacological response was inadequate.  Therefore, 
more efforts were required for further improvement.  Tozaki et al. [36] studied novel azo-
polymer-coated pellets containing insulin and (Asu1,7)eel-calcitonin for colon specific delivery.  
Azo-containing polyurethanes were prepared and coated over the drug-containing pellets.  
Camostat mesilate was incorporated into the pellet as a protease inhibitor.  In vitro release 
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experiments showed markedly increased release of a model drug from azo-polymer-coated 
pellets in the presence of rat cecal contents compared to that in phosphate buffered saline. 
After oral administration of azo-polymer-coated pellets containing insulin and (Asu1,7)eel-
calcitonin to rats, hypoglycemic and hypocalcemic effects were observed, respectively.  The 
co-administration of camostat mesilate further increased the hypoglycemic effects dose-
dependently.  The hypocalcemic effects of (Asu1,7)eel-calcitonin were improved by co-
administration of camostat mesilate as well.  These results suggested the feasibility of using 
azo-polymer-coated pellets as useful carriers for colon-specific peptide or protein delivery.   
Due to some debate on azo-polymer potential toxicity, naturally occurring 
saccharide-based polymers have attracted a great deal of research interest.  
Polysaccharides such as chitosan, pectin, dextran, guar gum, inulin, amylose, chondroitin 
sulphate, are generally considered as safe and being actively investigated in the field for 
drug colon targeting.     
Pectin is a group of non-starch linear polysaccharides found in the cell walls of many 
plants.  It mainly consists of α-(1-4)-linked D-galacturonic acid residues interrupted by 1,2-
linked L-rhamnose residues [43, 59].  Pectin is commercially available with an average 
molecular weight ranging from around 50,000 to 150,000 Dalton, and has been widely used 
as a stabilizer or thickening agents in the food industry.  Pectin is stable in the physiological 
condition of stomach and small intestine, and degraded by the colon bacteria especially 
Bacteroides [60].  Its safety profile and microflora-dependent degradation have stimulated 
numerous studies using pectin as an excipient for small molecule and peptide/protein colon 
delivery.  To avoid premature release in the upper GI tract, Rubinstein et al. [61] utilized 
calcium pectinate as a drug carrier, which is less water-soluble compared to pectin.  Insulin 
and a low water soluble molecule indomethacin were formulated into plain matrix and 
compression coated calcium pectinate tablets.  In vitro indomethacin release studies 
showed that in the absence of pectinolytic enzymes, indomethacin was retained in both 
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plain matrix and compression coated tablets in simulated gastric and intestinal fluids, 
although a small percentage of drug leakage was observed from plain matrix tablets without 
compression coating.  Calcium pectinate compression coated tablets containing insulin in an 
inner core with an outer layer of calcium pectinate coating, and insulin plain matrix tablets 
were given orally to pancreatectomized dogs.  Soybean trypsin inhibitor and an absorption 
enhancer sodium cholate were mixed in both types of formulations.  Compression coated 
tablets delayed the insulin absorption after a lag time of around 5-8 h, which was consistent 
with their colon arrival time.  In contrast, plain matrix tablets were not able to delay the drug 
release and provided a sustained insulin absorption followed by a slow decline of the blood 
glucose level.  The colonic bacterial surface adhesion onto solid dosage forms and their 
potential implications on the colon delivery system were investigated by Rubinstein et al. 
[62].  Paper strips loaded with recombinant human insulin, sodium deoxycholate and 
aprotinine were completely covered with pre-cast pectin films and implanted to the cecal 
region of rats.  The blood glucose level dropped when antibiotics was co-administered, 
indicating the adhesion of colon bacteria onto the pectin film surface interfered with the 
insulin release.  In vitro studies showed the number of bacteria cells adhering to pectin 
surfaces decreased with increasing agitation rate.  It was concluded that biodegradable 
polymers such as pectin will function as colon delivery system only if the enzymatic 
degradation was accompanied with physical erosion.  The bacterial adherence to the 
surface of the dosage form would interfere with the polymer erosion and drug release.  
Another study by Musabayane et al. [11] investigated using amidated pectin hydrogel beads 
to deliver human insulin orally in streptozotocin (STZ)-diabetic rats.  Oral administration of 
human insulin once (30 or 46 µg) or twice (60 µg) daily for 2 weeks significantly decreased 
blood glucose levels compared to untreated rats.  In contrast, significant increase in blood 
insulin level was only observed following the high doses of 46 µg once a day and twice (60 
µg) daily regimens.  Pharmacokinetic parameters in STZ-diabetic rats showed that orally 
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administered pectin-insulin beads (30 µg) were more effective to maintain blood insulin 
levels than a subcutaneous insulin injection.  It was inferred that the insulin release from the 
pectin beads and absorption were not limited to the colon, and mostly started from the upper 
intestine already. Overall, the results suggested the amidated pectin hydrogel beads could 
produce sustained release of insulin, but not enough to limit the drug delivery to the colon 
specifically, and the combination with polymeric coatings and other strategies was 
suggested.  To develop colonic delivery system, Cheng et al. [38] engineered calcium 
pectinated nanoparticles containing porcine insulin, which were expected to undergo 
bacteria-triggered degradation in the colon very quickly based on their nano-scale 
dimension. Two types of pectin and the formulation pH were evaluated on the 
characteristics of the nanoparticles.  Particles with a narrow size distribution were obtained 
by ionotropic gelation and purified by cross-flow filtration method.  The pH of the formulation 
significantly influenced the insulin association efficiency and the stability of the particles.  
Increasing the pH from 2 to 3 enhanced the insulin association efficiency by 3-fold, which 
was correlated to the charge density on the pectin molecules as a function of pH.  The 
insulin release from the particles was dependent on the extent of the dilution and the pH of 
the dissolution medium.  However, the in vitro release of insulin in simulated gastric fluid 
was high, which indicated that these calcium peptinate particles were probably not able to 
protect insulin release from the upper GI tract.  In addition, there were no enzymes in the 
tested dissolution medium.  Therefore, the potential of calcium pectinate nanoparticles for 
colon-specific delivery required further thorough evaluation.  Calcium peptinate beads for 
colonic peptide delivery were also evaluated using bovine serum albumin (BSA) as a model 
peptide by Atyabi et al. [63].  Calcium pectinate beads containing BSA were prepared by 
extruding BSA-loaded solution into calcium chloride solution during agitation, and pectinate 
beads were instantly formed by ionotropic gelation.  The entrapment efficiency of BSA was 
high.  The presence of pectinolytic enzymes in the in vitro release medium facilitated the 
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drug release.  However, additional experiments would be necessary to confirm the feasibility 
of the proposed formulation. 
Chitosan is a high molecular weight cationic polysaccharide, poly(N-glucosamine), 
derived from naturally occurring chitin in crab and shrimp shells by deacetylation.  Chitosan 
has been shown to be biocompatible and biodegradable with extremely low toxicity [64].  
Chitosan is degraded by colon-rich microflora, and has been evaluated as an excipient for 
colonic specific drug delivery.  Enteric-coated chitosan capsules were evaluated by Tozaki 
and Yamamoto et al. [35, 65] for colonic delivery of peptides including insulin.  In vitro 
release studies using a marker molecule 5(6)-carboxyfluorescein (CF) showed little release 
of CF from the capsules in either artificial gastric juice (pH 1) or artificial intestinal juice (pH 
7), but a marked release in the presence of rat cecal contents.  Chitosan capsules 
containing insulin with or without differing protease inhibitors (bacitracin, aprotinin, and 
soybean trypsin inhibitor) and absorption enhancers (sodium glycocholate, sodium oleate 
and n-dodecyl-β-D-maltopyranoside) were enterically coated with hydroxypropyl 
methylcellulose phthalate (HPMCP) and intragastrically administered to rats.  The chitosan 
capsules were able to function as an effective carrier to deliver insulin to the colon and 
increase insulin blood concentration in the presence of sodium glycocholate, as compared 
to gelatin capsules containing insulin or insulin solution.  Hypoglycemic effects accompanied 
the increase in plasma insulin levels.  The hypoglycemic effects were further increased by 
the co-administration of various protease inhibitors and absorption enhancers, especially in 
the presence of sodium glycocholate and aprotinin.  The times to peak plasma insulin levels 
and hypoglycemic effects were in agreement with the GI transit time of chitosan capsules as 
measured in the same animal model, which supported the hypothesis that enteric-coated 
chitosan capsules were site-specifically delivered insulin to the colon.  Similarly, Fetih et al. 
[66] evaluated using chitosan capsules for colonic delivery of (Asu1,7)eel calcitonin (ECT).  
Chitosan capsules containing ECT and different absorption enhancers (S-nitroso-N-acetyl-
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D,L-penicillamine, sodium glycocholate) and protease inhibitors (bacitracin, aprotinin) were 
enteric-coated with hydroxypropyl methylcellulose phthalate (HPMCP) and administered to 
rats.  The hypoglycemic effects appeared 6-8 h after oral administration and sustained for 
24 h.  The greatest hypoglycemic effects were observed with chitosan capsules containing 
ECT with all four additives in combination.  These results confirmed the feasibility of using 
enteric-coated chitosan capsules for colonic peptide or protein delivery.  Bayat et al. [67] 
explored nanoparticles engineered from chitosan, triethylchitosan (TEC) and 
dimethylethylchitosan (DMEC) by polyelectrolyte complexation for colon delivery of insulin.  
TEC and DMEC were synthesized by partial quaternization of chitosan.  Chitosan is 
positively charged at pH <6.5, and quaternized chitosan derivatives are permanently 
positively charged.  In contrast, insulin is negatively charged at pH above its isoelectric point 
(apparent PI: 6.4).  Therefore, insulin nanoparticles could be easily prepared by electrostatic 
interaction between positively charged chitosan or its derivatives and negatively charged 
insulin.  Due to the harsh synthetic conditions, the molecular weight of quaternized 
derivatives was reduced, which resulted in smaller particle size.  The insulin loading was 
more than 80% for all three types of nanoparticles (chitosan-insulin, TEC-insulin, and 
DMEC-insulin nanoparticles).  The in vitro release showed a small burst release and then 
sustained release for 5 h.  The release from TEC-insulin and DMEC-insulin nanoparticles 
was higher than chitosan-insulin nanoparticles due to higher solubility of TEC and DMEC 
polymers at neutral and alkaline pH.  In vivo studies in streptozotocine-induced diabetic rats 
showed enhanced colon absorption of insulin via these nanoparticle carriers compared to 
free insulin.  However, the slow in vitro release pattern of insulin might suggest that these 
nanoparticles of chitosan and its derivatives alone were not able to site-specifically release 
insulin in the colon and a combination with other targeting strategies would probably provide 
better targeting effects.  Zhang et al. [68] performed in vitro evaluation of chitosan hydrogel 
beads containing bovine serum albumin (BSA) as a model protein for colon-specific delivery 
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of macromolecules.  The hydrogel beads were prepared by polyelectrolyte complexation of 
chitosan with its counterion, tripolyphosphate (TPP).  The protein release was markedly 
accelerated by the rat cecal and colonic medium independent of the pre-treatment 
conditions.  A commercial almond beta-glucosidase preparation was less effective to 
degrade the chitosan containing beads, and therefore could not substitute for rat cecal and 
colonic enzymes for the in vitro assessment.  The large amount of protein release in 
simulated intestinal fluid containing porcine pancreatin suggested a potential premature 
protein release in the upper GI tract, which was later confirmed to be attributed to the 
enzyme function of porcine pancreas lipase.  Whether human lipase shares the same 
property to degrade chitosan needs further investigation.  Degradation of chitosan-TPP 
beads in the rat cecal and colonic medium indicated the potential of the chitosan-containing 
beads to deliver macromolecules specifically to the colon.  Smoum et al. [69] completed a 
proof-of-concept study of using a new chitosan-pentaglycine-phenylboronic acid conjugate 
as a multifunctional colonic-specific vehicle for oral delivery of salmon calcitonin.  It was 
hypothesized that chitosan conjugates linked to a boronic acid protease inhibitor could 
protect peptide or protein drugs against proteolysis by serine protease. 4-
formylphenylboronic acid was conjugated to chitosan with or without two spacers of 
glycylglycine and pentaglycine.  Enzyme-inhibitory assays showed all the chitosan 
conjugates containing phenylboronic acid with or without spacers did not inhibit serine 
proteases, which was probably because the conjugates were too bulky to access the active 
sites of the enzymes.  After incubation with chitosanase, the chitosan-pentaglycine-
phenylboronic acid conjugates demonstrated inhibitory effects toward trypsin and elastase, 
and the inhibitory activity increased with the increase of substitution.  Chitosan-pentaglycine-
phenylboronic acid conjugates with the highest degree of substitution (43%) were able to 
decrease the salmon calcitonin degradation rate by trypsin in the presence of chitosanase, 
but still 60% of salmon calcitonin was lost in 10 min.  The overall protection effect from the 
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proposed inhibitor conjugates was far enough to guarantee a colon-specific delivery, but it 
provided a proof-of-concept for further research to identify boron-based protease inhibitors.   
Inulin is another naturally occurring polysaccharide found in plants.  It consists of β-
2-1 linked D-fructose molecules, and most fructose chains have a glucose unit at the 
reducing end [70].  It is not significantly hydrolyzed by the enzymes from endogenous 
secretions of human digestive tract [71].  However, colon bacteria, especially Bifidobacteria, 
which constitute up to 25% of normal human gut microflora, are known to ferment inulin [72, 
73].  Inulin hydrogels have been investigated for colon drug delivery.  In vitro degradation of 
inulinHP (inulin with an average degree of polymerization of 23) suspended in Eudragit RS 
films by human fecal bacteria was observed by Vervoot et al. [74].  To develop inulin 
hydrogels, Vervoot et al. [75] synthesized a methacrylated inulin (MA-IN) derivative.  Cross-
linked inulin hydrogels were prepared by free radical polymerization.  The resulting 
hydrogels were shown to be degraded by the presence of inulinase concentration-
dependently.  To characterize MA-IN hydrogels with respect to their release properties, BSA 
or lysozyme was used as model proteins [34].  The results showed the in vitro release of 
incorporated protein from the MA-IN hydrogels was influenced by many factors such as drug 
loading procedure, loading concentration, protein molecular weight, the feed composition 
and degree of substitution of inulin.  Protein release was greatly enhanced by the presence 
of inulinase. These hydrogels showed interesting properties related to colon-specific drug 
delivery systems, but more work like selection and optimization of the hydrogels and further 
in vitro and in vivo evaluations would be investigated for colonic drug delivery.  More 
recently, Tripodo et al. [76] developed novel UV induced polysaccharide/poly(amino acid) 
hydrogels using human IgG as a model protein for colon delivery of peptide and protein 
drugs. A poly(amino acid), α,β-poly[N-(2-hydroxyethyl)-D,L-aspartamide], was functionalized 
with methacrylic anhydride, and the polysaccharide, inulin, was functionalized with 
methacrylic anhydrideand succinic anhydride.  The hydrogels were engineered by UV 
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irradiation at low temperature without the use of radical initiators and in the presence or 
absence of a co-crosslinker, PEGDM550.  The obtained hydrogels were degradable by 
inulinase, did not cause significant variation in Caco-2 cell viability and the human IgG 
released from the hydrogels retained their biological activity.  However, these hydrogels 
were not able to delay the protein release even in the release buffer without any enzymes.  
The hydrogels with the co-crosslinker showed pronounced burst release with about 70% of 
the entrapped protein released in 15 min, while hydrogels without the co-crosslinker showed 
a slower but steady protein release rate since time zero.  These results indicated these 
hydrogels alone were not able to prevent the protein release into the upper GI tract.    
Dextrans are polysaccharides composed of a linear backbone with mainly 1,6-α-β-
glucopyraonosidic linkage.  Dextrans are degraded by dextranases, enzymes secreted by 
gram negative bacteria in the colon especially Bacteroides [77].  Dextrans have been used 
as drug carriers for the formation of conjugates/prodrugs [43], and other type of dosage 
forms have been investigated as well.  Basan et al. [78] studied dextran hydrogels for colon-
specific delivery of salmon calcitonin (sCT).  Biodegradable dextran hydrogels were 
synthesized by crosslinking dextran (T-70) with epichlorohydrin (ECH) in the presence or 
absence of ethanol at 10 and 23°C.  In vitro biodegradation studies showed that dextran-
ECH hydrogels were slowly degraded in buffer with dextranase at pH 5 and 7.  In vitro 
release studies showed rapid sCT release from hydrogels prepared in the presence of 
ethanol in simulated colonic medium containing dextranase.  However, without dextranase 
in the release medium, the sCT release was also substantial, although lower than that in the 
medium with dextranase, which indicated this dextran hydrogel system could provide 
sustained release of peptides or proteins, but probably not able to sufficiently protect them 
from premature release in the upper GI tract.   
Starch is a naturally occurring polysaccharide most common in human diet.  It is 
highly stable, safe, nontoxic, biodegradable, and has been used as an excipient in many 
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drug products.  However, it is easily digestable by enzymes and acid in the upper digestive 
tract. For colon delivery purposes, starch was modified by cross-linking and pre-
gelatinization to make it more resistant to digestion and acidolysis in upper GI tracts [79].  
The modified starch was called resistant starch.  Dry-coated matrix tablets consisting of a 
core with BSA and cross-linked pre-gelatinized starch shell were evaluated in simulated 
gastric fluid (SGF) for 2 h, and then in simulated intestinal fluid (SIF) for 6 h,  and then in  
simulated colonic fluid (SCF) for additional 28 h.  The BSA release in the SGF and SIF for 
the first 8 h was around 10%, and then dramatically increased in SCF, and reached 90% 
after 36 h.  Overall, the cross-linked pre-gelatinized starch tablets showed a potential for 
targeting peptide and protein drugs to the colon. The same research group also investigated 
using acetylated maize starch as a tablet coating agent for colon targeting of 
biomacromolecule drugs [80].  Tablets based on microcrystalline cellulose containing BSA 
were coated with starch acetate with different degrees of substitution using a pan-coating 
apparatus.  Similar in vitro release studies were performed in SGF, SIF and SCF.  A higher 
degree of substitution by acetylation resulted in slower degradation of starch acetate.  The 
release of BSA from uncoated tablets quick and 100% released within 4 h, while from starch 
acetate coated tablets in SGF and SIF after 6 h was less than 10%.  The BSA release was 
greatly increased when incubated in SCF made of rat colonic content compared to buffer 
without colonic content.  The results showed starch acetate coated tablets could potentially 
help the protein drug pass though the upper GI tract.  Their further study on resistant starch 
acetate (RSA) coated pellets also showed promising results [81].  The effects of plasticizer 
content, film coating thickness, drug loading and drug molecular weight on drug release 
were investigated.  An RSA film coating thickness of 7% (w/w) with 15% of plasticizer 
resulted in 12.8% drug release after the initial 8 h, and 68.2% drug release after 48 h.  The 
drug release from RSA film coated pellets containing HGF, insulin and BSA, respectively, 
showed the diffusion of higher molecular weight through the RSA film was slower.  SEM 
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examination showed the RSA film stayed intact in SGF and SIF, but showing cracks and 
holes in SCF after incubation.  Collectively, the results indicated the potential of RSA film 
coated pellets as a colon-specific drug delivery system.   
A novel targeted delivery system (CODESTM) containing lactulose was investigated 
by Katsuma et al. [40, 82, 83].  Lactulose is a synthetic disaccharide, which is not absorbed 
in the upper GI tract, but degraded by enterobacteria to organic acids in the lower GI tract 
[84].   The concept of the CODES is shown in Figure 1.2 [40].  This system mainly included 
three components: a tablet core containing lactulose and drug, an inner acid-soluble coating 
layer, and an outer enteric coating layer.  In the stomach, the drug was protected by the 
enteric coating layer and was not released.  After reaching the small intestine, the enteric 
coating layer dissolved, but the drug was still not released from the core due to the presence 
of its inner acid soluble coating layer. However, the gastrointestinal fluid started to penetrate 
into the tablet core causing lactulose to dissolve during the small intestinal transit.  When it 
arrived in the colon, lactulose leached out through the acid-soluble coating and was 
degraded by the colon bacteria producing organic acids.  The organic acids would then 
dissolve the acid-soluble coating layer and release the drug.  The onset of drug release in 
vivo from the CODES tablets using a model drug was proven to be dependent on the 
colonic availability rate of lactulose [83].  The CODES system was also explored for oral 
delivery of insulin to the colon [82].  Tablet cores containing insulin, lactulose and sodium 
glycocholate with or without other adjuvants were first coated with a mixture of Eudragit® 
E100 and RL100, and then coated with a layer of hydroxypropylmethylcellulose (HPMC) 
2910 as an undercoating, and finally coated with enterosoluble Eudragit  L100 as the outer 
layer.  The colon-specific delivery of insulin from the CODES system was evaluated in 
beagle dogs.  Results showed a sharp and sustained decrease in plasma glucose as well as 
an increase in insulin plasma levels after 6 h following oral administration of insulin-CODES 
tablets containing sodium glycocholate.  The further addition of other adjuvants did not bring 
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significant changes in these data.  The CODES system was shown to be a promising colon-
targeting delivery system. 
 
Limitations of microflora-dependent delivery systems 
Criticisms have been raised on the microflora-dependent approach, especially 
because of the variability in the intestinal microflora.  It is believed that the change of diet, 
stress, disease state or ongoing therapies may strongly affect the intestinal microflora 
composition, resulting in more intra- and inter-subject variation in delivery efficacy.  
Moreover, the application of synthetic polymers will likely add extra work load to the drug 
regulatory approval process because they are new chemical entities and require 
comprehensive safety evaluations before being used as drug delivery systems.  Some 
criticism also questions the robustness of the microbiota-triggered degradation process of 
some polymers, like azo-polymers.  It was pointed out that the azo function in azo-polymers 
was not always reduced in the same way as in small azo-aromatic molecules and the 
resulting degradation products were not always as thought to be aromatic amines [85].  
Kimura et al. [86, 87] showed the azo bonds in polyurethanes were reduced to hydrazo 
intermediates after incubation with a culture of intestinal flora, because they did not observe 
any molecular weight reduction.  Therefore, the drug release from pellets with these azo-
polymer coatings was thought to be a result of a conformational change and breakdown of 
coating film.  Schacht et al. [88] also observed that azo-containing polyamides were reduced 
to hydrazo intermediates or amines.  It is also indicated that the microflora-triggered polymer 
degradation is strongly influenced by polymer hydrophilicity. If the polymer is too 
hydrophobic, enzymes cannot penetrate into the polymer network, leading to very slow 
polymer degradation.  Only polymers with enough hydrophilicity can be degraded within an 
acceptable time frame, but too high hydrophilicity will lead to premature drug release before 
the colon is reached.  In addition, the toxicity of azo-polymers is still under debate, and the 
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possible toxicity of the degradation products must also be considered [89].  The application 
of naturally occurring polymers is more preferred in the safety aspect, but more concerns 
are raised on their hydrophilicity and in some cases, they failed to effectively prevent the 
drug release from the upper GI tract.  Some chemical modifications have been considered 
based on polymers of natural origin, but sometimes these derivitization products are less 
prone to degradation because they are no longer recognizable by the enzyme system 
responsible for biodegradation.  
 
1.3.2  pH-dependent delivery systems 
The pH-dependent delivery systems utilize the progressive increase in pH values 
along the GI tract.  In this approach, enteric-soluble polymers are most often used as 
coating materials to prevent the drug dissolution and release from the upper GI tract.  Some 
pH-dependent colonic delivery systems for peptide and protein drugs mostly using insulin as 
a model protein were reviewed as follows.   
 
Enteric-coated capsules   
Touitou et al. [90] investigated the effectiveness of colon-targeted delivery using 
small soft gelatin capsules filled with porcine insulin and a surfactant mixture (sodium laurate 
and cetyl alcohol) in arachis oil, and coated with mixtures of acrylic polymers (Eudragit® RS, 
L and S) at differing ratios.  Two formulations without much premature release at pH < 7.0 
were selected for an in vivo rat study, and showed promising hypoglycemic effects after 
approximately 2 h following oral administration.  Interestingly, they also observed that the 
pre-administration of capsules only containing surfactants did not affect the glycemic profile, 
while the post-administration extended the hypoglycemic effect by one hour.  This was 
explained as the results of differing absorption rates of the insulin and the enhancers 
employed.  Ritschel et al. [91-93] explored colonic delivery of insulin in gel microemulsions 
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(MEs) encapsulated in formaldehyde-treated hard-gelatin capsules, which were further 
coated with a combination of acrylic polymers (Eudragit S100 and Eudragit NE 30D at a 3:7 
ratio), followed by another coating layer of cellulose acetate phthalate.  Five MEs containing 
insulin gelled by adding silicon dioxide were encapsulated, coated and orally administered to 
beagle dogs.  One of them with ME consisting of polyoxylated caprylcaprinic acid glycerides 
(Labrasol®), polyglycerol isostearate (Plurol Isostearique), oleic acid decylester (Cetiol V) 
and triethanolamine/HCl buffer pH 7.4 showed greater pharmacological availability (PA) 
compared to its non-encapsulated liquid insulin ME and an insulin-free colon-targeted 
capsules, as well as the other four encapsulated gel MEs containing insulin. PA was 
calculated as the ratio of area under the curve (AUC) of glucose reduction vs. time profile 
after oral dosing to that after intravenous injection (i.v.), then corrected for dose strength.  
However, after in situ injected into isolated GI segments of rats, the liquid ME was able to 
lower blood glucose level only when insulin was delivered to the small intestine [91, 92].  It 
was suggested that bile salts and lipase in the small intestine played an important role for 
drug absorption when delivered by microemulsions.  Gwinup, Elias and Domurat [94] 
reported a preliminary investigation of using methacrylic acid copolymer (soluble at pH >7) 
coated hard gelatin capsules for oral colonic delivery of bovine insulin.  These copolymer 
coated capsules had shown to remain intact until they reached cecal area and then rapidly 
disintegrated via X-ray studies.  Four to five hours after intake by three healthy volunteers, 
the plasma insulin concentrations increased significantly with a concomitant fall in the C-
peptide concentration, which reflected the exogenous origin of the administered bovine 
insulin. This study demonstrated methacrylic copolymer coated capsules were able to 
deliver insulin to the proximal colon in a safe and simple manner.  To measure both the 
portal and systemic insulin concentrations and glucose concentrations, recombinant human 
insulin encapsulated in methacrylic acid polymer (Eudragit S) coated capsules was 
introduced into the cecum of pancreatectomized pigs directly [95].  Following administration 
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of the insulin-containing coated capsules, both plasma insulin concentrations in the portal 
vein and systemic circulation increased greatly and peaked at 75 min.  The increase in 
plasma insulin levels was accompanied by a corresponding decrease in glucose levels.  The 
co-administration of a protease inhibitor aprotinin further enhanced insulin concentrations.  
Later, they also investigated orally administered insulin in enteric-coated capsules to 
streptozotocin-induced chronic diabetic pig model [96].  Similarly, recombinant human 
insulin-containing capsules were coated with pH-sensitive methacrylic acid copolymer and 
administered directly into the cecal lumen of the diabetic pigs.  Results showed an increase 
in serum insulin with peak insulin concentrations observed between 2.5 to 4 h after insulin 
administration, and a decrease in serum glucose levels with nadir values seen between 3.5 
to 5 h after insulin administration.  After diabetic pigs received encapsulated insulin 
intracecally for 8 days, the serum glucose concentrations were comparable to those 
achieved with once-daily injections of subcutaneously administered insulin, and no 
injectable insulin supplementation was needed.  However, the effects observed in the 
streptozotocin-induced chronic diabetic pig model appeared later and were not as good as 
reported in the acutely pancreatectomized pigs [95].  The difference was explained as due 
to the ablation of the glucogan-secreting cells in pancreatectomized pigs.  Enteric-coated 
hard gelatin capsules containing microspheres were also investigated for oral colonic 
peptide delivery by Geary et al. [97].  Porcine insulin microspheres were prepared by a 
rotating disk method using Paramont X and Grocol 600E (triglycerides) as the matrix.  In situ 
experiments in rats showed sodium glycocholate and Na2EDTA could enhance the colonic 
absorption of insulin.  Different formulations were tested using another marker molecule in 
rats and dogs.  Insulin lipid microspheres were dry-mixed with Carbopol® 934 (1:1 by 
weight), sodium glycocholate and Na2EDTA, and then encapsulated into Eudragit
 S100 
coated hard gelatin capsules, and administered to two nondiabetic dogs.  A modest but 
prolonged reduction in plasma glucose levels was observed.  However, the limited animal 
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number (n = 2) impaired the statistical analysis of the data.  More recently, Hong et al. [98] 
investigated the colon-targeted local delivery of a cell-permeable NFκB inhibitory peptide 
using colon-specific polymer coated capsules.  To prepare colon-targeted capsules, rodent 
capsules containing a selected potent NFκB inhibitory peptide, CTP-NBD, were dip-coated 
with a layer of azo-containing polyurethane [87], which was further overlaid with Eudragit  
S100 for mechanical strength.  Capsules coated only with Eudragit S100 were termed as 
enteric capsules.  The colon targetability of the azo-polymer and Eudragit S100 coated 
capsules (colon-targeted capsules) were confirmed by X-ray studies with barium sulfate and 
FITC.  The in vivo efficacy studies in 2,4,6-trinitrobenzenesulfonic acid (TNBS) induced rat 
colitis model showed that CTP-NBD in colon-targeted capsules ameliorated the rat colitis in 
a dose dependent manner with a parallel decrease in myeloperoxidase activity and levels of 
inflammatory mediators, while the colon-target NBD capsules and enteric CTP-NBD 
capsules did not improve the inflammatory events in the inflamed colonic tissue.  It was 
suggested that the anti-inflammatory activity of the CTP-NBD observed via the colon-
targeted capsules was mainly through local action, which was supported by a further study 
showing ameliated rat colitis after intracolonic treatment with CTP-NBD via the rectal route.  
A sharp concentration decrease of CTP-NBD-FITC in the submucosal layer compared to 
mucosal layer provided further supporting evidence for this argument.  The overall results 
suggested that colon-specific targeted capsules were a viable approach to deliver cell-
penetrating peptide conjugated therapeutic peptides locally to the colon for the treatment of 
colonic diseases, such as IBDs.   
 
Enteric polymer-based microspheres  
Enteric soluble polymers, such as Eudragit S100, were also investigated as coating 
or matrix-forming excipients to engineer microspheres for colon-targeted peptide and protein 
delivery.  Paul et al. [99] explored the feasibility of using calcium phosphate ceramic 
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microspheres coated with a pH-sensitive methacrylate polymer for insulin colonic delivery.  
Tricalcium phosphate (TCP) is a safe and biocompatible material that has been used in 
human as bone substitutes by FDA and as a matrix for protein purification.  Ceramic porous 
TCP microspheres in the size range of 106-200 µm were prepared by a standard procedure, 
loaded with porcine or human insulin by diffusion filling, and then coated with Eudragit S100.  
Insulin released in simulated intestinal fluid (SIF, pH 6.8) preserved the native conformation 
without showing any aggregation as assessed by Photon Correlation Spectroscopy (PCS) 
and Circular Dichroism (CD).  In vitro release studies showed minimal insulin release in 
simulated gastric fluid (SGF, pH 1.2), a slow release in SIF and rapid release when the 
medium was switched to simulated intestinal fluid (SIF, pH 7.4).  After oral delivery to 
streptozotocin-induced diabetic rats, enteric coated TCP microspheres containing either 
porcine or human insulin resulted in a decrease in elevated glucose level up to 50% of the 
initial value.  The delivery of porcine insulin induced a dose-dependent response, while for 
human insulin the decrease in blood glucose level was much delayed, indicating the 
variation in action with different species of insulin.  Jain et al. [100] studied microspheres 
using Eudragit S100 as the matrix-forming agent for oral colonic delivery of peptide drugs 
like insulin.  Insulin-loaded microspheres were prepared by water-in-oil-in-water (w/o/w) 
double-emulsion solvent evaporation method with polysorbate 20 as a dispersing agent in 
the interal aqueous phase and polyvinyl alcohol (PVA)/polyvinyl pyrrolidone as a stabilizer in 
the external aqueous phase.  The PVA stabilized microspheres showed a mean particle size 
of 32.51 ± 20 µm by laser diffractometry.  Permeation enhancers were not used to avoid 
potential damage to the intestinal mucosa.  In vitro release studies showed a 2.5% of insulin 
release at pH 1.0 in 2 h, while an initial burst release of 22% in 1 h followed by an additional 
28% release over the next 5 h in phosphate buffer of pH 7.4.  Oral administration of PVA-
stabilized microspheres containing insulin in normal albino rabbits showed a remarkable 
decrease in blood glucose levels, with maximum glucose reduction in 2 h and lasted for up 
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to 6 h.  Results indicated Eudragit  S100 microspheres were promising delivery vehicles for 
protein and peptide oral intestinal delivery.  Similarly, Jelvehgari et al. [101] formulated 
insulin microspheres using Eudragit S100 as the matrix by a water-in-oil-in-oil (w/o/o) double 
emulsion solvent evaporation method.  Formulations with different drug/polymer ratios were 
prepared and characterized.  The selected formulation showed a drug loading efficiency of 
77% with a mean particle size of 222 µm.  In vitro enzymatic degradation studies indicated 
insulin could be protected in the microspheres without much degradation after trypsinic 
incubation.  After orally gavaged to streptozotocin-treated diabetic rats, insulin microspheres 
with or without protease inhibitor aprotinin yielded similar hypoglycemic effect.  Torres et al. 
[102] explored using enteric soluble hydroxypropylmethylcellulose acetate succinate 
(HPMCAS) to encapsulate bovine insulin containing lipid microspheres for colon targeted 
delivery.  The insulin microspheres were prepared by a modified solvent evaporation 
technique with the drug incorporated as a solid (s/o/w) or as a solution (w/o/w).  Chitosan 
was added to the lipid (tetraglycerol pentastearate) matrix of insulin-loaded cores to provide 
potential mucoadhesive and absorption enhancing properties to the system. To encapsulate 
the lipid cores, a solvent extraction technique was employed, in which the microspheres 
were first suspended in an HPMCAS methylene chloride solution and then emulsified into 
PVA solution under mechanical stirring.  The resulting pH-sensitive polymer coated 
microspheres showed a mean particle size around 170 µm.  In vitro release studies in 
phosphate buffer of pH 7.4 showed a controlled and progressive release of insulin from lipid-
chitosan cores made through both s/o/w and w/o/w methods.  The HPMCAS lipid-chitosan 
cores represented a promising approach for the specific delivery of peptide to the colon 
region, but further work would be necessary to tailor the controlled release profile. 
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pH-sensitive hydrogels 
pH-sensitive hydrogels using various polymers were also investigated as potential 
colon delivery systems for peptide and protein drugs.  Mahkam [103] designed a hydrogel 
delivery system based on copolymers of 2-hydroxyethyl methacrylate (HEMA) and 
methacrylic acid (MAA) cross-linked with cubane-1,4-bis (methacryloyloxyethyl) carboxylate 
(CA) by free radical copolymerization.  In the pH range of the stomach, the gels had a low 
degree of swelling and the drug would be protected against digestion by enzymes.  The 
swelling of the hydrogels increased with increased pH as it passed down the GI tract.  In the 
colon, the hydrogels swelled to a high degree and the drug was released.  Insulin hydrogels 
were prepared by adding hydrogels in the insulin buffer, which was then dried under vacuum 
at room temperature.  Insulin was physically adsorbed to the copolymers and stayed stable 
during in vitro release studies.  The drug release of insulin showed to be depended on the 
swelling and hydrolysis of the network polymers, which were significantly affected by 
polymer composition.  According to the different hydrolysis rate at pH 1 and pH 7.4, these 
hydrogels would be potential candidates for colon-specific drug delivery.  Ramkissoon-
Ganorkar et al. [104] investigated using pH/thermosensitive polymeric beads prepared from 
terpolymers of N-isopropylacrylamide (NIPAAm) (temperature-sensitive), butyl methacrylate 
(BMA) and acrylic acid (AA) (pH-sensitive) of various molecular weight at feed molar ratio of 
85/5/10 for peptide/protein oral delivery.  Insulin, as a model protein drug, was loaded into 
the beads by dropping a polymer solution with insulin prepared at low pH (pH 2.0) and 
below the lower critical solution temperature (LCST) into an oil bath above the LCST (35°C).  
In vitro release studies were performed at pH 2.0 and 7.4 at 37°C.  Negligible insulin release 
was observed at pH 2.0, while at pH 7.4, substantial insulin release at varying release rate 
as a function of polymer molecular weight was observed.  The high molecular weight 
polymeric beads swelled slowly and gradually released the loaded insulin over 8 h due to 
increased cross-linking.  The loaded and released insulin were confirmed to be fully 
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bioactive.  The high molecular weight polymeric beads could be potentially used to target 
protein drugs to the colon.   
pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system 
was reported by Chiu et al. [105].  This pH-sensitive dextran hydrogel system was designed 
for colon drug delivery based on two reasons: (1) the hydrogels exhibited a low degree of 
swelling at low pH, and increased swelling with pH increase along the GI tract, which would 
protect bioactives from enzymatic degradation; and (2) the hydrogel swelling and enzymatic 
degradation in the colon would facilitate site-specific drug release.  To prepare pH-sensitive 
dextran hydrogels, dextran was activated by 4-nitrophenyl chloroformate, and then 
conjugated with 4-aminobutyric acid and cross-linked with 1,10-diaminodecane.  
Incorporation of carboxylpropyl groups in dextran hydrogels led to a faster swelling at high 
pH.  BSA was used as a model protein in release studies.  The BSA release from one of the 
hydrogels showed relatively slow release at pH 2.0, highly enhanced release in a pH 7.4 
buffer and further increased and complete release by adding dextranase in the buffer of pH 
7.4.  The polymer swelling extent was a primary factor to determine the drug release rate.  
Lowman and Peppas et al. [5] investigated the use of pH-responsive, poly(methacrylic-g-
ethylene glycol) (abbreviated as P(MAA-g-EG)) hydrogels for insulin oral intestinal delivery.  
Microparticles of P(MAA-g-EG) were prepared by a free-radical polymerization of 
methacrylic acid and poly(ethylene glycol) monomethacrylate (PEGMA).  The resulting 
polymer exhibited pH sensitive swelling behavior because of the reversible formation of 
interpolymer complexes, which were stabilized by hydrogen bonding between the carboxylic 
acid protons and the etheric groups on the grafted chains.  In the stomach, these gels were 
unswollen due to the polymer complexation, and at the basic and neutral pH in the lower GI 
tract, the complexes dissociated and resulted in rapid gel swelling and drug release.  
Porcine insulin was loaded to P(MAA-g-EG) microparticles by equilibrium partition.  The 
insulin loaded microparticles were then dried under vacuum, encapsulated into gelatin 
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capsules and orally administered to healthy and streptozotocin-induced diabetic rats.  Within 
2 h following oral administration of insulin-containing complex gels, strong dose-dependent 
hypoglycemic effects were observed in healthy rats, and even much stronger hypoglycermic 
effects were obtained in the diabetic rats.  These hypoglycermic effects lasted for up to 8 h 
and were observed without the addition of protease inhibitors or absorption enhancers.  A 
comparison study to Eudragit L100 microspheres in healthy rats showed insulin in these 
complex gels induced much greater hypoglycemic effects than the Eudragit L100 
microspheres because of the presence of PEG grafts in the complex gels, which stabilized 
insulin.  Due to the neutral to weakly alkaline pH encountered in the lower small intestine, 
insulin in these complex gels was probably delivered and released into the distal small 
intestine.  The neutral to weakly alkaline pH values in the distal small intestine proposed a 
potential hurdle for all the pH-dependent formulations for colonic drug delivery.  A 
combination with other colon-targeting strategies would make pH-dependent formulations 
more applicable to deliver drugs specifically to the colon.       
  
1.3.3  Time-dependent delivery systems  
The time-controlled oral delivery system for colon-targeting relied on the reasonably 
predictable small intestine transit time, which was remarkably constant in the range of 3 ± 1 
h (mean ± SD) independent of the dosage forms and fasting or fed states of the subjects 
[106, 107].  Contrary to the constant small intestinal transit, the gastric emptying time was 
highly variable and affected by many factors, such as the quantity and nature of the food, or 
the nature of the dosage forms.  To design time-dependent systems for colon delivery, the 
dosage forms had to stay intact in the stomach during the unpredictable gastric resident 
time, and after entering the duodenum, they would be triggered to start a lag time of at least 
3 h, during which the drug should still be protected without significant release before the 
colon was reached.  The trigger to initiate the lag time in the small intestine was generally 
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based on the sharp change in the pH between the stomach and the intestine, and thus, a 
layer of enteric coating is often used.  Based on different design characteristics and release 
mechanisms, the most often encountered time-dependent delivery systems could be 
categorized into reservoir, capsular and osmotic platforms [108].  Reservoir systems were 
the largest and most versatile among these three categories.  They mostly comprised an 
inner drug-containing core and an outer release-controlling layer, and could be further 
differentiated into erodible, rupturable, and diffusive reservoir systems.  Erodible systems 
were mainly obtained by the application of hydrophilic swellable polymers.  Hydrophilic 
cellulose derivatives, such as hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose 
(HEC) and hydroxypropylcellulose (HPC), were widely used mainly because of their safety 
profile, versatility and cost-effectiveness.  The application of these polymers was generally 
done by press-coating, spray-coating and powder-layering techniques.  When contacting 
aqueous media, these polymers underwent swelling, dissolution and erosion, so to delay the 
onset of drug release for a certain lag time depending on the polymer type and coating 
thickness.  Additionally, a mixture of wax and surfactant was also explored as an erodible 
coating material [109].  With the polymeric or wax coating layer, plus another enteric coating 
as the outer layer, the erodible systems using the combination of both pH- and time-
dependent principles had exhibited very promising colon targeting results.  The rupturable 
reservoir systems for time-dependent drug release to the colon were often composed of 
inner drug cores coated with a water insoluble and modestly permeable polymeric film.  
Ethylcellulose (EC) in combination with a plasticizer and/or a pore-forming agent was 
frequently used.  In general, the polymeric film was ruptured mechanically by the expansion 
of the core formulation.  For diffusive reservoir systems, the drug release was delayed by 
the time lapse required for full water penetration through the diffusive layer, which should 
prevent drug release from the upper GI tract during transit.  For example, drug-containing 
cores coated with a layer of Eudragit RS mixed with pore-forming agents delayed drug 
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release until the pore-forming agents were entirely dissolved and a pore network was 
formed in the outer coating layer, which allowed water influx and drug release to be 
accomplished [110].  With a layer of diffusive coating, a fast drug release following the lag 
time could be hard to achieve. Capsular systems for potential colon targeting were designed 
in the form of capsules with a release-controlling polymeric plug inserted in their body 
opening.  The physical-chemical properties, size and position of the plug all would influence 
the duration of the lag time.  An example is the device of Pulsincap® (Scherer DDS Ltd), 
which consisted of a water-soluble cap and a rigid, insoluble and impermeable body filled 
with the drug and sealed with a hydrogel plug of crosslinked PEG8000 [111].  When 
contacting with the aqueous media, the cap quickly dissolved and the plug started swelling 
until ejection from the body, thus releasing the drug.  Osmotic time-dependent systems were 
also explored for colonic drug delivery.  A recent example is a tablet system containing a 
bronchodilator for the treatment of nocturnal asthma using sodium chloride as an osmotic 
agent [112].  This osmostic system contained a low swellable HPMC layer and an outer 
insoluble and moderately permeable film composed of Eudragit RS/Eudragit RL mixtures.  
In vitro studies showed pulsatile delivery after delayed times depending on the external 
coating thickness, and the delivery was unaffected by pH.  Through these varieties of 
mechanisms, i.e., programmable disruption, swelling/erosion, dispersion, pH-induced 
dissolution, water-permeation of the polymeric coatings, or a timed ejection or a progressive 
erosion of matrix plugs sealing capsular devices etc., time-based colon delivery approaches 
have accomplished promising results. Some examples using time-based systems for 
peptide and protein colon delivery are described as follows.   
A time-dependent delivery platform (ChronotopicTM) was investigated for oral colonic 
delivery of insulin by Marino et al. [113].  The influence of manufacturing process and 
storage conditions on bovine insulin was evaluated.  Insulin and its degradation products 
were assayed after each processing steps by HPLC.  The powder mixing, direct 
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compression of the insulin-loaded cores, and aqueous spray-coating of HPMC at elevated 
temperature showed no major impact on insulin content and its corresponding degradation 
products.  After long-term storage at 4°C for one year, approximately 5% of insulin was 
degraded with a slightly increase in degradation products, which were still within their 
compendia limits.  The insulin in vitro release behavior from the ChronotopicTM formulation in 
terms of the lag time and release kinetics was unchanged after the one year storage (4°C) 
as well.  In addition, the compatibility of insulin with a selected protease inhibitor (camostat 
mesilate) and absorption enhancer (sodium glycocholate) in solid state (physical and 
compacted power mixtures) was assessed [114].  After storage at 4°C for 12 months, the 
decrease in insulin content and increase in degradation products were not significant and all 
within the compendia limits.  The HPMC coated unit containing insulin and the adjuvants 
(camostat mesilate and sodium glycocholate) showed a fast and quantitative release of 
insulin and the adjuvants after a reproducible lag time.  Based on a hypothesis that the 
adjuvant release prior to that of the protein could potentially further improve the protein 
absorption, Del Curton et al. [114] investigated using a two-pulse time-based system for 
colonic delivery of protein drugs and protease inhibitors/absorption enhancers.  This system 
consisted a drug-containing immediate-release tablet cores, an inner swellable/erodible low-
viscosity HPMC coating, an intermediate adjuvant layer and an additional outer layer of 
HPMC coating.  For gastro-resistant systems, another enteric coating of Eudragit L 30D-55 
layer was applied.  Different thickness of the HPMC coating layers and the camostat 
mesilate/sodium glycocholate coating layers were applied to the immediate-release cores 
containing bovine insulin.  The outer HPMC layer was applied to delay the adjuvant release 
in the small intestine, while the inner HPMC layer was designed to delay the insulin release.  
In vitro release studies in hydrochloric acid medium (pH 1.2) for 2 h and then phosphate 
buffer (pH 6.8) showed that all the systems exhibited satisfactory pulsatile release behavior, 
with a programmable lag phase before the protease inhibitor/absorption enhancer release, 
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and another lag phase before insulin release.  This two-pulse time-based system could be 
easily modulated in terms of the lag times by HPMC coating thickness and could be an 
interesting candidate for colon-specific delivery of peptide and protein drugs.   
Although showing promising results in vitro and some even in animals, criticisms 
have arisen on time-based colon delivery systems.  One of the criticisms related to the 
highly variable and unpredictable gastric emptying time, which varied with the feeding 
conditions (such as fasted or fed, light meal or heavy meal) and the physical forms of the 
drug formulations, etc. [107].  To develop effective time-based delivery systems, the drug to 
be delivered has to be completely protected while in the stomach before exploring the 
subsequent relatively constant small intestinal transit time (3 ± 1 h, Mean ± SD) [106, 107].  
Another criticism is related to the formulation evaluation methods.  It is generally hard to set 
up in vitro performance evaluation experiments that would correlate very well to the in vivo 
situations because of many factors involved, such as pH, ionic strength, surfactants, 
enzymes, microorganisms, viscosity, gas, intraluminal pressure, intestinal motion and water 
content in different GI segments [115].  In vivo evaluations have been investigated using 
animal models, but this approach has been criticized for being poorly representative of the 
human GI transit.  Therefore, in vivo scintigraphic imaging studies have been performed on 
human subjects.  For example, Hodges et al. [116] utilized scintigraphy imaging to evaluate 
colon-targeting pectin-HPMC tablets in six healthy volunteers.  The pectin-HPMC coating 
was applied by press-coating method.  Scintigraphy studies provided solid proof that the 
pectin-HPMC coating was robust enough to protect the tablets during transit until they 
reached colon intact in all the subjects without any premature release in the upper GI tract.  
Human scintigraphic imaging studies are effective in vivo evaluations tools, but they are 
costly and not always easy to access.   
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1.3.4  Other formulations 
In addition to the aforementioned three major types of colon-specific delivery 
systems, several other types of formulations have been explored for targeting peptide and 
protein drugs to the colon as well. 
 
Microspheres/Spheres  
Kimura et al. [117] explored using poly(vinyl alcohol)-gel spheres to delivery insulin 
to the lower intestine of diabetic rats.  The insulin-containing PVA spheres were prepared by 
ultrasonic agitation.  After intragastric administration of PVA spheres containing insulin with 
or without aprotinin or bacitracin to streptozotocin-induced diabetic rats, significant and 
prolonged reduction of blood glucose levels were observed.  The prolonged residence time 
of PVA spheres in the lower intestine and synchronous release of insulin and the protease 
inhibitor were accounted for the improved hypoglycemic effects. Jiang et al. [118] 
investigated bioadhesive fluorescent microspheres as visible carriers for local delivery of 
proteins, and insulin was used as a model protein in the study.  Intrinsic fluorescent 
microspheres were prepared using a combination of a fluorescent polyanhydride, poly(p-
(carboxyethylformamido) benzoic anhydride) (PCEFB), and poly(lactide-co-glycolide) 
(PLGA) by the water-in-oil-in-water (w/o/w) double emulsion solvent evaporation method.  
The application of intrinsic fluorescent microspheres as drug carriers could circumvent the 
complex fluorescent dye labeling process and avoid the interference from free dye leached 
into the tissue.  In vitro release studies in PBS at pH 7.4 showed sustained release of insulin 
over a period of around 4 days.  The insulin-loaded PCEFB/PLGA microspheres with the 
diameter of less than 5 µm (70 % of spheres < 2 µm) were further evaluated in 
streptozotocin-induced diabetic rats [119].  After oral feeding of a single dose of 
microspheres, plasma glucose levels were reduced to subcritical levels within 4 h and the 
hypoglycemic effects lasted up to 6 h.  Fluorescence microscopy studies showed these 
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microspheres could adhere to the intestinal epithelium and traverse the absorptive cells.  
The intrinsic fluorescence highlighted these microspheres for convenient in vitro and in vivo 
evaluations.  With combination of other colon-targeting strategies, these microspheres could 
be potentially applied for local intestinal peptide/protein delivery, such as colon-specific 
delivery.  Lamprecht et al. had developed microparticles [120] and nanoparticles [121] for 
colonic drug delivery.  They studied the size-dependent deposition of microparticles and 
nanoparticles to the inflamed colonic mucosa in trinitrobenzenesulfonic acid (TNBS) induced 
colitis rat models after oral administration [122].  Their results showed significantly increased 
deposition of particles at the thicker mucus layer and in the ulcerated regions compared to 
that in the healthy control group.  The accumulation of particles also size-dependently 
increased with the decrease of particle size from 10 µm to 0.1 µm.  These results shed 
some light on considerations of designing particulate carriers for local delivery of drugs for 
the treatment of inflammatory bowel disease (IBD).      
 
Nanoparticles 
Nanoparticle-based delivery systems have also been explored to target drugs to the 
colon, especially for the treatment of IBDs.  Theiss et al. [33] reported oral delivery of a 
biologically active protein, prohibitin (PHB), by nanoparticles encapsulated in hydrogel to the 
colon.  Prohibitin1 (PHB) is an evolutionarily conserved, multifunctional 30 kDa protein, 
which is decreased in mucosal biopsies from IBD patients and in animal models of colitis.  
Restoration of PHB has shown to reduce the severity of colitis.  The nanoparticles were 
prepared by double emulsion solvent evaporation method.  Recombinant human PHB was 
complexed to polyethyleneimine (PEI) and then to bovine serum albumin (BSA).  The PHB 
complex was surrounded by poly(lactic acid) (PLA) in a water-in-oil emulsion to form the 
core, which was then further coated with polyvinyl alcohol (PVA) in a second water-in-oil-in-
water emulsion.  The resulting nanoparticles had a diameter of around 440 nm.  The PHB-
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loaded nanoparticles were then encapsulated into a polysaccharide solution of alginate (7 
g/L) and chitosan (3 g/L).  This PHB-loaded nanoparticles in polysaccharide solution was 
orally gavaged to dextran sodium sulfate (DSS) treated mice, followed by oral administration 
of the chelation solution of calcium chloride and sodium sulfate.  A hydrogel containing 
nanoparticles was then formed inside the mouse stomach.  The PLA/PVA based 
nanoparticles had shown previously to release content at pH 6.0, so as to protect drugs from 
degradation at acidic pH and by digestive enzymes [123].  Mice treated with PHB-loaded 
nanoparticles showed increased levels of PHB in the colon surface epithelium and 
ameliorated DSS-induced colitis as indicated by body weight loss, clinical score, 
myeloperoxidase activity, proinflammatory cytokine expression, histological score and 
protein carbonyl content.  This approach was also investigated to deliver an anti-
inflammatory tripeptide Lys-Pro-Val (KPV) to the colon [123].  These nanoparticles were 
shown to be safe and did not affect cell viability or barrier functions.  After oral administration 
of dextran-FITC-loaded nanoparticles in the polysaccharide solution/chelation solution to 
mice, a much higher level of dextran-FITC was observed in the colon than in other GI tissue 
sections, indicating that nanoparticle release from the polysaccharide hydrogel happened 
mostly in the colonic lumen compared to other parts of the GI tract.  Oral gavage of KPV-
loaded nanoparticles in alginate and chitosan solution with a following oral administration of 
chelation solution resulted in significantly reduced DSS-induced colonic inflammation.  Using 
these nanoparticles with polysaccharide hydrogel, KPV could be delivered at a much lower 
(12,000-fold lower) concentration than using KPV free solution, while still eliciting similar 
therapeutic efficacy. The system of PLA/PVA-based nanoparticles in a polysaccharide 
solution/chelation solution with a double gavage method seemed to be a feasible platform 
for colon-specific peptide and protein delivery.  More recently, Coco et al. [32] compared 
using three different polymeric nanoparticles to deliver peptide or protein drugs to the 
inflamed colon.  Ovalbumin (OVA) was used as a model drug.  pH sensitive nanoparticles 
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were prepared from Eudragit S100 by a water-in-oil-in-water (w/o/w) method.  Mucoadhesive 
nanoparticles were engineered with trimethylchitosan (TMC) by ionic complexation/gelation 
method.  PLGA-based nanoparticles were prepared from the mixture of PLGA, PEG-PLGA 
and PEG-PCL by a w/o/w double emulsion solvent evaporation method.  Immune cell 
targeting ligands (GSQSHPRH and mannose) were grafted onto the PEG chain of PCL and 
incorporated into the PLGA-based nanoparticles.  Ex vivo studies in horizontal diffusion 
chambers were set up using healthy mouse colon or inflamed colon from DSS-treated mice.  
Mannose-grafted PLGA nanoparticles resulted in the highest accumulation of OVA in the 
inflamed colon compared to the other formulations.  Results suggested nanoparticles 
targeting immune cells in the inflamed colon might be a promising approach for the 
treatment of IBD.   
  
Multiple emulsions 
Matsuzawa et al. [124] investigated using w/o/w emulsions as carriers for insulin 
intestinal delivery.  The emulsions were prepared by a two-step emulsification procedure.  
Gelatin was added to the inner phase containing insulin, which was then emulsified into the 
oil phase of 5% lecithin, 20% Span 80 and 75% soybean oil.  Water containing 3% Tween 
80 was used as the outer aqueous phase.  A significant hypoglycemic effect was observed 
after administration of the emulsion into the cecum and colon using an in situ loop method.   
Later, two highly purified polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), were incorporated into the insulin w/o/w emulsions and 
evaluated in in situ and in vivo experiments [125]. Water-in-oil-in-water emulsions containing 
insulin and 2% DHA or EPA resulted in potent increase of serum insulin levels and decrease 
of serum glucose levels after administered into the colonic and rectal loops in situ.  Insulin 
dose-related responses were observed, especially with the presence of DHA.  In the in vivo 
absorption experiments, rectal administration of insulin emulsion with 2% DHA produced 
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rapid but short increase of serum insulin levels along with a strong decrease of serum 
glucose levels lasted for 4 h.  Lactate dehydrogenase (LDH) release studies showed 
emulsions with 2% DHA or EPA did not induce significant LDH release.  These findings 
indicated that the w/o/w emulsions with highly purified long-chain polyunsaturated fatty acid 
could be potential carriers for intestinal delivery of insulin, and other protein and peptide 
drugs.  
 
Liposomes  
Manosroi et al. [126] studied the gastrointestinal delivery of human insulin and an 
human insulin complex using different liposomes.  The insulin-DEAE (diethylaminoethyl) 
dextran complex was designed to avoid leakage of insulin from liposomes by increased 
molecular size and potentially improve its intestinal uptake. When administered 
intravenously in normal rats, the human insulin and human insulin-DEAE dextran complex 
exhibited same blood glucose lowering effects.  Positive, neutral and negative liposomes 
were prepared by high pressure homogenization using a hydrogenated soy lecithin.  The 
human insulin-DEAE complex in reconstituted positive liposomes resulted in more effective 
blood glucose lowering effects when injected into the colon compared to the duodenum of 
normal rats. The complexed insulin in positive liposomes seemed to be more stable and 
better absorbed in the colon than in the duodenum.  Goto et al. [31] investigated intestinal 
mucosal delivery of insulin using novel fusogenic liposomes (FLs), which can directly deliver 
encapsulated contents to the cytoplasma through membrane fusion with the help of 
envelope proteins of Sendai virus (SeV).  Unilamellar liposomes containing insulin were 
prepared by the freeze-thawing method with or without insulin-degrading enzyme (IDE) 
inhibitor PCMB. Then, the unilamellar liposomes were mixed with SeV and incubated at 
37°C for 2 h, which were further purified by sucrose density-gradient centrifugation.  
Following in situ administration of into the colonic and rectal segments, insulin-loaded FLs 
40 
 
resulted in a significant increase in plasma insulin levels with a decrease in blood glucose 
levels compared to insulin solution or insulin liposomes. These effects were further improved 
by the addition of IDE inhibitor into insulin FLs.  In contrast, after the insulin-loaded FLs were 
administered into the ileal segment in situ, no apparent increase in plasma insulin levels or 
decrease in blood glucose levels were observed, which was because the mucous/glycocalyx 
layers over the ileal epithelium functioned as a barrier to hinder the fusion of liposomes to 
the ileal membrane.  This was confirmed by enhanced SeV viral gene expression in the 
ileum not the colon or the rectum with hyaluronidase pretreatments. LDH leakage 
experiment showed that insulin-loaded FLs did not cause intestinal mucosal damage.  
These results suggested fusogenic liposomes might be a novel mucosal delivery method to 
improve the targeting of macromolecules, such as peptides, proteins or gene, to the colon 
region.  Liposomes have been widely studied as drug delivery carriers for many bioactive 
molecules. They can be easily modified with a variety of targeting moieties to improve their 
site-specific delivery.  However, liposomes as drug delivery systems are also limited by 
some potential problems, such as the leakage of water-soluble drugs during GI transit, the 
low drug entrapment efficiency, the heterogeneity of particle size, the poor batch to batch 
reproducibility, the instability of liposome formulations and the short circulation half-life [127]. 
Some of the issues have been resolved, such as increasing stability by lyophilization, but 
there are still more to be improved to develop effective clinically applicable formulations.  
 
1.4  Concluding Remarks 
Intestinal delivery, and especially colonic delivery of peptide and protein drugs, has 
gained a great deal of attention in the past two decades.  The colon as a multi-functional 
organ possesses unique anatomical and physiological properties that distinguish itself from 
other part of the GI tract.  Local colonic delivery has been considered beneficial not only for 
the treatment of local diseases, such as IBDs, but also for its potential to improve systemic 
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delivery of peptide and protein drugs.  For either local or systemic delivery, peptide and 
protein drugs need to be successfully protected from the harsh acidic environment in the 
stomach and the extensive enzymatic digestion in the small intestine, and safely arrive at 
the colon to exert their local therapeutic effects or to be absorbed into systemic circulation.  
A wide variety of colonic delivery strategies have been explored based on the unique 
features of the colonic environment, such as pH values, enzymes produced by colonic 
bacteria, and GI transit time.  Accordingly, these approaches are classified into three major 
categories: microflora-dependent systems, pH-dependent systems and time-dependent 
systems.  The chemical modification of drugs or carriers based on enzymes in the colon has 
been successful for colonic delivery of small molecules, such as sulphasalazine, but has not 
extensively been explored for peptide and protein drugs, most likely due to the constraints of 
preserving their biological activities and the requirement for safety and efficacy profiles for 
the resulting derivatives and degradation products. Other microflora-dependent systems are 
mostly developed based on azo-polymers and polysaccharide-based polymers. These 
polymers are specifically degraded by colonic bacteria, and have been used as coatings 
and/or matrix forming agents.  Due to the debate on the potential toxicities related to azo-
polymers, natural-occurring polysaccharides become more popular.  However, some of 
them are too hydrophilic leading to premature release in the upper GI tract.  To resolve this 
problem, chemical modifications were done to make polysaccharide derivatives with 
increased hydrophobicity.  Microflora-based systems have showed promising results based 
on its design principle.  pH-dependent systems have been used as a colon delivery platform 
in clinic for the treatment of IBD patients.  Based on the progressive increase in pH values 
along the GI tract, various pH-responsive materials, such as Eudragit S100, were applied as 
coatings, matrices or hydrogels for colon-targeted delivery.  Time-dependent systems were 
designed based on the relative constant small intestinal transit time (3 ± 1 h).  The pH 
difference between the stomach and small intestine was often used as a trigger signal to 
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initiate the lag time before the drug was released in the colon.  Time-based devices for 
colonic delivery can be classified into reservoir, capsular and osmotic delivery systems.  
Scintigraphy studies have proved the feasibility for colon-specific delivery using some of the 
time-based systems.  The above mentioned GI physiology-based systems for peptide and 
protein colonic delivery have shown promising results with success to different extent.  
However, these systems are susceptible to the GI physiological changes, which are often 
affected by diet, stress and medications etc.  Meanwhile, the GI physiology is known to be 
affected by the patient disease state.  For example, patients with active ulcerative colitis 
showed a wide range of pH values in the cecum and ascending colon and lots of them 
showed much lower pH values compared to that in healthy subjects [27].  Therefore, a 
combination of different colon targeting strategies is recommended to achieve effective local 
peptide and protein colon-targeting.  Furthermore, the patient disease state should be 
considered during formulation design and the delivery efficacy of the colon-targeting 
formulations should be evaluated in patients as well.  In addition to these GI physiology-
based formulations, a variety of other formulations were also explored for intestinal or 
colonic delivery of peptide and protein drugs, such as microspheres, nanoparticles, 
liposomes, multiple emulsions.  Most of these formulations showed better delivery efficacy 
compared to the controls.  Finally, numerous studies have observed enhanced colonic 
peptide or protein delivery when protease inhibitors were co-administered or co-formulated.  
Therefore, after qualitative and quantitative selection, protease inhibitors might be able to 
further enhance the colonic peptide/protein delivery.  Since the co-formulated protease 
inhibitor(s) would be selectively released into the colon, it would raise less concerns about 
their potential influence on the digestive enzymes in the upper GI tract.        
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Table 1.1  Properties of human GI-tract related to local oral peptide and protein deliverya. 
 
GI region pH 
Transit time 
(h) 
Bacterial concentration 
(CFU/mL) 
Stomach 1-3.5 0.5-4.5 < 103 
Small 
intestine 
Proximal 5.5-7.0 
3-4 103-104 
Distal 6.5-7.5 
Large 
intestine 
Cecum/Ascending 
colon 
5.5-7.5 
18-144 1011-1012 
Descending colon/ 
Rectum 
6.5-7.5 
a  Adapted from References [18, 27, 41, 128]. 
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Figure 1.1  The structural design of the azo-prodrugs (Reprinted with permission from 
reference [52].  Copyright © 2011, American Chemical Society). 
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Figure 1.2  The concept of CODES for colon-targeted drug delivery (Reprinted with 
permission from reference [40].  Copyright © 2002, Elsevier). 
  
 
 
Chapter II 
 
In Vitro and In Vivo Evaluation of a Water-in-Oil Microemulsion System 
for Enhanced Peptide Intestinal Delivery 
 
2.1  Summary 
Peptide and protein drugs have become the new generation of therapeutics, yet 
most of them are only available as injections, and reports on oral local intestinal delivery of 
peptides and proteins are quite limited.  The aim of this work was to develop and evaluate a 
water-in-oil (W/O) microemulsion system in vitro and in vivo for local intestinal delivery of 
water-soluble peptides after oral administration.  A fluorescent labeled peptide, 5-(and-6)-
carboxytetramethylrhodamine labeled HIV transactivator protein TAT (TAMRA-TAT), was 
used as a model peptide.  Water-in-oil microemulsions consisting of Miglyol 812, Capmul 
MCM, Tween 80 and water were developed and characterized in terms of appearance, 
viscosity, conductivity, morphology and particle size analysis.  TAMRA-TAT was loaded and 
its enzymatic stability was assessed in modified simulated intestinal fluid (MSIF) in vitro.  In 
in vivo studies, TAMRA-TAT intestinal distribution was evaluated using fluorescence 
microscopy after TAMRA-TAT microemulsion, TAMRA-TAT solution and placebo 
microemulsion were orally gavaged to mice.  The half-life of TAMRA-TAT in microemulsion 
was enhanced nearly three-fold compared to that in the water solution when challenged by 
 
Liu D, Kobayashi T, Russo S, Li F, Plevy SE, Gambling TM, Carson JL,and Mumper RJ, “In 
Vitro and In Vivo Evaluation of a Water-in-Oil Microemulsion System for Enhanced Peptide 
Intestinal Delivery.”  The AAPS Journal, 2013, Jan; 15(1):288-98. Epub 2012 Nov 30.
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MSIF.  The treatment with TAMRA-TAT microemulsion after oral administration resulted in 
greater fluorescence intensity in all intestine sections (duodenum, jejunum, ileum and colon) 
compared to TAMRA-TAT solution or placebo microemulsion.  The in vitro and in vivo 
studies together suggested TAMRA-TAT was better protected in the W/O microemulsion in 
an enzyme-containing environment, suggesting that the W/O microemulsions developed in 
this study may serve as a potential delivery vehicle for local intestinal delivery of peptides or 
proteins after oral administration. 
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2.2  Introduction 
With biotechnological advances, peptide- and protein-based drugs have gained an 
increasing and irreplaceable share of the pharmaceutical market.  However, the majority of 
peptide and protein pharmaceuticals such as insulin, monoclonal antibody-based drugs, 
human growth hormone and interferon-α require administration as injections [129].  As a 
consequence, more widespread applications to treat chronic conditions where the patient 
can self-medicate are limited.  The past decades have seen a great deal of efforts to 
develop nonparenteral routes of delivery for peptides and proteins.  Oral delivery may be the 
most attractive route yet arguably the most challenging due to poor chemical and physical 
stability of these molecules.  Being polymers of amino acids linked together by peptide 
bonds with specific three-dimensional conformations [130], most peptides and proteins are 
hydrophilic with poor membrane permeability, susceptible to proteolytic degradation and low 
gastric pH.  To overcome these obstacles, many strategies have been applied, such as 
macromolecular chemical modifications [131-133] and simple and complex formulation 
approaches [5, 134, 135].  Among various formulation approaches, microemulsions [130, 
136] have received considerable attention for the oral delivery of peptides and proteins, 
especially for enhanced oral absorption [137, 138].   
Microemulsions are thermodynamically stable dispersions of two immiscible liquids 
stabilized by surfactants [138], and mainly classified into three categories: (a) oil-in-water 
(o/w); (b) water-in-oil (W/O); and (c) bicontinuous microemulsions.  Oil-in-water 
microemulsions are promising in improving the bioavailability of hydrophobic molecules, 
including hydrophobic peptides, such as cyclosporine A [139].  Water-in-oil microemulsions, 
on the other hand, have shown potential to improve the oral delivery of hydrophilic peptides 
or proteins [137, 138, 140, 141].  The mechanisms proposed for improved bioavailability 
using W/O microemulsions were based on increased protection from luminal enzymatic 
degradation and/or enhancer-induced structural and fluidity changes in the mucosal 
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membrane [140, 142, 143].  The safety evaluation of several orally delivered W/O 
microemulsions has been investigated [137, 138, 141], and histological examination showed 
no intestinal tissue damage or irritation upon acute dosing of the specific vehicles.  
However, so far, most investigations of W/O microemulsions for peptide or protein 
oral delivery have been focused on systemic absorption, while the local intestinal delivery of 
peptides or proteins for the treatment of local pathologies has been less studied.  In this 
work, the potential of W/O microemulsions for local intestinal delivery of water-soluble 
peptides after oral administration was explored.  The ultimate goal of this work was to 
develop an oral dosage form to deliver therapeutic peptides locally to the gastrointestinal 
tract for the treatment of gastrointestinal inflammatory disorders.  In gastrointestinal 
inflammatory disorders, like inflammatory bowel disease (IBD), there is a significant unmet 
need to deliver immunomodulatory compounds directly to the intestinal mucosa to maximize 
local concentrations (thereby efficacy) and to minimize systemic toxicity.  A novel nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF- κB) inhibitor peptide, 8K-NBD 
(KKKKKKKKGG-TALDWSWLQTE), has shown efficacies in vitro and in vivo to inhibit 
activated NF-κB, a hallmark of chronic inflammation, but not basal NF-κB activity, and 
ameliorated intestinal inflammation in experimental IBD models [144].  The selective 
targeting of 8K-NBD to activated NF-κB makes it an excellent therapeutic candidate and our 
research interest.  However, a significant challenge for oral delivery of 8K-NBD is the 
chemical and biological degradation in the gastrointestinal tract.  To address this issue and 
deliver 8K-NBD or other water-soluble peptides locally to the inflamed intestine, the peptide 
will be incorporated into W/O microemulsions, which will be followed by encapsulation of the 
optimal W/O microemulsion into enteric-coated capsules to further enhance local peptide 
delivery in the GI where needed.  The current work is to test the first part of the hypothesis 
that W/O microemulsions may provide protection to the peptide incorporated when 
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challenged in vitro and in vivo, and serve as a viable oral delivery system to enhance 
intestinal delivery of intact and biologically active water-soluble peptides.  
Based on some prior research results [137, 138, 140, 141], W/O microemulsions 
were developed using several commercially available and pharmaceutically acceptable lipid-
based excipients.  Miglyol 812 and Capmul MCM are medium-chain (C8/C10) glycerides, 
generally recognized as safe, and meet the requirements of the United States 
Pharmacopeia (USP) and the National Formulary as medium-chain triglycerides (MCTs) and 
mono- and di-glycerides [145, 146], respectively.  Tween 80 is a nonionic surfactant 
included in the FDA Inactive Ingredients Database for oral, IV, IM, topical, and many other 
preparations [147].  Phase diagrams were constructed and microemulsion windows were 
defined.  Representative microemulsions across the microemulsion window of interest were 
characterized for formulation screening.  To test the protective effect of the W/O 
microemulsions, a fluorescent labeled peptide, 5-(and-6)-carboxytetramethylrhodamine 
labeled HIV transactivator protein TAT (TAMRA-TAT), which has similar cationic content 
and cell penetrating properties to 8K-NBD [148], was used as a model peptide.  TAMRA-
TAT was loaded into a selected W/O microemulsion and evaluated in vitro and in vivo. 
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2.3  Materials and Methods 
2.3.1  Materials 
Miglyol 812 (Caprylic/Capric triglycerides, neutral) was provided by Sasol Germany 
GmbH (Eatontown, NJ, USA).  The fatty acid distribution of Miglyol 812 according to the 
manufacturer is 57.7% caprylic acid (C8), 41.6% capric acid (C10), 0.2% caproic acid (C6), 
and 0.3% lauric acid (C12).  Capmul MCM NF (C8/C10 mono- and diglycerides) was supplied 
by Abitec Corporation (Janesville, WI, USA). Capmul MCM contains 53.6% of 
monoglycerides with 6.3% free glycerol and its fatty acid distribution is 82.6% caprylic acid 
and 17.4% capric acid.  Tween 80 (polyoxyethylene sorbitan monooleate, NF grade) was 
purchased from Spectrum Chemical MFG. Corporation (Gardena, CA, USA).  5-(and-6)-
Carboxytetramethylrhodamine-labeled TAT (47-57) peptide (sequence: TAMRA-
YGRKKRRQRRR) was purchased from ANASPEC Inc. (Fremont, CA, USA).  4,4-Difluoro-
5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (BODIPY® FL C12) was 
purchased from Invitrogen (Eugene, OR, USA).  Pancreatin from porcine pancreas (8 × USP 
specifications) was purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).  
Tissue-Tek O.C.T. Compound (O.C.T. stands for Optimal Cutting Temperature) was 
supplied by Sakura Finetek USA (Torrance, CA, USA).  Fluoro-Gel II, with 4',6-diamidino-2-
phenylindole (DAPI), was purchased from Electron Microscopy Sciences (Hatfield, PA, USA).  
Purified deionized water from a Milli-Q Advantage System was used for all of the sample 
preparation.  All other chemicals were of analytical grade.   
 
2.3.2  Microemulsion preparation and phase diagrams 
Three pseudoternary phase diagrams were constructed to define the microemulsion 
windows using the following four components: (a) Miglyol 812, a neutral oil of medium-chain 
(C8/C10 triglyceride) fatty acid triglyceride; (b) Capmul MCM, a low hydrophilic-lipophilic 
balance (HLB) surfactant (HLB = 5.5-6.0); (c) Tween 80, a high HLB non-ionic surfactant 
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(HLB = 15.0); and (d) deionized water.  Miglyol 812 and Capmul MCM were combined 
together at three weight ratios (4:1, 65:22, and 2:1, w/w).  The mixture of Miglyol 812 and 
Capmul MCM at each weight ratio occupied one apex of the ternary phase diagram, and 
Tween 80 and water occupied the other two apices, respectively.  Samples were prepared 
by mixing appropriate amounts of Miglyol 812, Capmul MCM, Tween 80, and water in 
screw-capped scintillation vials at room temperature by shaking.  Hundreds of samples were 
prepared to define the phase boundaries in each phase diagram.  Each sample was further 
allowed to equilibrate at room temperature for at least 24 h before evaluation, and re-
examined after 1 week.  The existence of the microemulsion window was identified as the 
region where clear and transparent formulations were obtained upon visual inspection.  All 
samples were stored at room temperature and the stability of each sample was accessed by 
visual inspection in terms of clarity over time.  
 
2.3.3  Microemulsion characterization 
Rheological properties 
The shear viscosity of the W/O microemulsions was measured using a Brookfield 
LVDV-III + Cone and Plate Rheometer (Brookfield Engineering Laboratories, Inc., 
Middleboro, MA, USA).  The temperature was controlled by coupling to a Brookfield TC-500 
Refrigerated Bath.  Instrument calibration was performed using Brookfield silicone viscosity 
standards.  A CPE 40 spindle was utilized for sample measurements.  The shear stress, 
shear rate, and viscosity of a series of representative microemulsion samples in the 
microemulsion window of interest were measured.  The relationship of shear stress (dynes 
per square centimeter) versus shear rate (per second) was utilized to assess the 
microemulsion flow behavior. 
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Photon correlation spectroscopy  
The droplet diameter of the microemulsion was measured by photon correlation 
spectroscopy (PCS) using a Zetasizer Nano ZS (Malvern Instruments Inc., Worcestershire, 
UK) by backscattering at a fixed angle of 173˚ at 25°C.  All the samples were measured in 
triplicates without any dilution.  
 
Conductivity measurements 
The conductivity of the microemulsions was measured using YSI 3200 conductivity 
meter (Yellow Spring Instruments Co. Inc., Yellow Springs, OH, USA) coupled to YSI 3252 
dip cell with a cell constant of 1.0 cm-1.  The instrument was calibrated using YSI 
conductivity calibrators.  Samples were measured at ambient temperature.  
 
Freeze fracture transmission electron microscopy (FFTEM) 
The morphology of the W/O microemulsion was characterized by examination of 
freeze fracture replicas using transmission electron microscopy (TEM).  A tiny drop of 
microemulsion was sandwiched between gold double-replica mounts and frozen in liquid 
nitrogen-cooled Freon.  Next, the specimens were fractured in a Balzers BAF 400T freeze 
fracture device at a stage temperature of -100ºC under vacuum.  The fractured surfaces 
were shadowed unidirectionally with evaporated platinum and stabilized by carbon 
evaporation.  The resulting replicas and sample residues were rinsed in distilled water, 
followed by washing in a solution of 5% sodium dichromate in 50% sulfuric acid.  Replicas 
were then transferred to distilled water, placed onto standard copper microscopy grids, 
examined, and photographed with a Zeiss EM 900 Transmission Electron Microscope at an 
accelerating voltage of 60 kV (Carl Zeiss, Thornwood, NY, USA).  
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2.3.4  Phase inversion behavior of W/O microemulsions 
To investigate the phase inversion behavior of W/O microemulsions upon dilution, a 
lipophilic fluorescent marker BODIPY FL C12 was incorporated into a selected W/O 
microemulsion at the concentration of 0.1% by weight, followed by dilutions of 2-, 5-, 10-, 
50-, and 250-fold by weight with water.  The W/O microemulsion with BODIPY FL C12 
before and after dilution were examined under a Nikon Eclipse TE 300 Fluorescence 
Microscope (Fryer Co. Inc., Huntley, IL, USA).  The structure of the diluted sample was 
further investigated by TEM.  The W/O microemulsion after a tenfold dilution in water was 
negatively stained as follows: a drop of diluted microemulsion in water was placed on a 
copper grid, followed by removal of excess sample with filter paper, and then a drop of 2% 
uranyl acetate was placed on the copper grid for 2 min and subsequently examined by TEM. 
To elucidate the phase inversion behavior of samples across the microemulsion 
window, microemulsions incorporating 5% water and with varying amounts of oil and 
surfactants were diluted 100-fold in water by weight, and the appearance and particle size of 
diluted samples were assessed.  
 
2.3.5  In vitro stability studies in modified simulated intestinal fluid 
Modified simulated intestinal fluid (MSIF) was prepared based on USP 34 (Solutions 
/ Test Solutions).  Briefly, 0.68 g of monobasic potassium phosphate was dissolved in 75 mL 
of water and mixed with 7.7 mL of 0.2 N sodium hydroxide.  Pancreatin (0.125 g) was added 
and mixed well.  The pH was adjusted to 6.8 ± 0.1.  Water was added to q.s. to 100 mL, and 
then 1 mL was taken and diluted with 999 mL phosphate buffer of pH 6.8 (10 mM) to a total 
of 1000 mL.  
TAMRA-TAT microemulsion was prepared by incorporating a defined amount of the 
TAMRA-TAT water solution to the mixture of Miglyol 812, Capmul MCM, and Tween 80 to a 
final composition of Miglyol 812/Capmul MCM/Tween 80/TAMRA-TAT solution at the weight 
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ratio of 62.8/21.2/7/9 with TAMRA-TAT at 60 µg/g of the microemulsion.  In the in vitro 
stability studies, 100 µL of MSIF was added to 50 mg of TAMRA-TAT microemulsion or 
TAMRA-TAT solution (Soln., 60 µg/g) and incubated at 37˚C.  At specified time points, the 
incubation was terminated by adding 300 µL of acetone with 2% (v/v) of trifluoroacetic acid.  
The clear fraction containing TAMRA-TAT was taken after centrifugation at 16,000 × g at 
4˚C for 10 min, and then lyophilized and reconstituted in acetonitrile/water with 0.1% 
trifluoroacetic acid (19/81, v/v).  TAMRA-TAT in the reconstituted sample was determined by 
high-performance liquid chromatography (HPLC) with fluorescence detection.  Briefly, 
TAMRA-TAT was detected using a reverse-phase column (Vydac 238 MS C18 5 µm, 4.6 × 
250 mm, Grace Davison, Deerfield, IL, USA) on a Thermo Finnigan Surveyor Plus HPLC 
system with a FL Plus detector using a binary gradient elution.  Mobile phase A consisted of 
0.1% trifluoroacetic acid in acetonitrile and mobile phase B consisted of 0.1% trifluoroacetic 
acid in deionized water.  The initial eluent contained 19% phase A and 81% phase B, and 
then phase A was increased to 37% in 14.5 min.  The eluent composition was held at 37% 
phase A for 1 min and then changed back to the initial composition and equilibrated for 5 
min before the next injection.  The flow rate was kept constant at 1 mL/min.  The sample 
injection volume was 10 µL and the excitation and emission wavelengths were 545 and 579 
nm, respectively. 
 
2.3.6  In vivo studies for intestinal delivery 
C57/BL6 female mice were obtained from the Charles River Labs and maintained in 
specific pathogen-free conditions.  All experiments involving mice were carried out 
according to the protocol approved by the UNC Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill.  Twelve-week-old C57/BL6 
female mice (18-20 g) were fed with standard chow and grouped randomly and treated with 
TAMRA-TAT microemulsion (2.5 mg/kg) or TAMRA-TAT solution (2.5 mg/kg) or placebo 
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microemulsion.  TAMRA-TAT microemulsion and TAMRA-TAT solution were prepared as 
described above with TAMRA-TAT concentration at 250 µg/g.  Placebo microemulsion was 
prepared in the same manner but using water as the aqueous phase instead of TAMRA-
TAT stock.  All treatments were administered by oral gavage with a single dose.  Mice were 
sacrificed 4 h later and intestinal tissue was harvested.  Intestinal samples from duodenum, 
jejunum, ileum, and colon were snap frozen in O.C.T. Compound and cut into 7-µm-thick 
sections onto microscope slides.  Tissue on the slides was counterstained with DAPI and 
examined using fluorescence microscopy on an Olympus I×70 Fluorescence Microscope 
(Olympus America).  Fluorescence intensity (FI) was quantified using ImageJ and expressed 
as integrated density over the total field of each picture, the same region of interest (ROI).  
The background was subtracted from each picture by setting up a threshold value.  Data are 
presented as mean ± SD.  The statistical differences among the three treatments (TAMRA-
TAT microemulsion, TAMRA-TAT solution, and placebo microemulsion) and different 
intestinal sections (duodenum, jejunum, ileum, and colon) were evaluated by linear 
regression.  The statistical significance between the treatments for each intestinal section 
was assessed by one-way ANOVA with Bonferroni post-tests.  A value of p < 0.05 was 
considered statistically significant. 
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2.4  Results and Discussion 
2.4.1  Phase diagrams 
The partial pseudoternary phase diagrams of Miglyol 812/Capmul MCM/Tween 
80/water system were constructed and are presented in Figure 2.1.  Miglyol 812 was the oil 
phase, Tween 80 was the surfactant, Capmul MCM was the co-surfactant, and water was 
the aqueous phase.  Capmul MCM has an HLB value of 5.5-6.0.  It was utilized since it has 
the same carbon chain length as Miglyol 812.  Tween 80 is a water-soluble surfactant with 
an HLB value of 15.  The combination of Capmul MCM and Tween 80 created a more 
flexible water/oil interface, which in turn stabilized the W/O microemulsions with an overall 
HLB value in the range from 7 to 9.  The weight ratio of Miglyol 812 to Capmul MCM was 
kept constant at 4:1, 65:22, and 2:1 (w/w), respectively.  The advantage for keeping the 
weight ratio of Miglyol 812 to Capmul MCM constant was that when the sample composition 
changed, the sample HLB value would change according to the Tween 80 to Capmul MCM 
ratio in each phase diagram.  As described in the “Materials and Methods” section, the 
microemulsion window was defined as the region where formation of clear and transparent 
formulations upon visual examination occurs.  During the visual examination process, the 
flow property of the samples was also considered when the Tween 80 concentration was 
higher than 50% by weight.  Samples that were very viscous and unable to flow when the 
vial was turned upside down were excluded from the microemulsion window in this study.  
When comparing the area obtained from these three phase diagrams, the apparent 
microemulsion window was larger when the oil to co-surfactant ratio was lower.  However, 
during the formulation screening process, a stable system with lower amount of surfactants 
and similar water incorporation capacity was preferred due to the potential lower cytotoxicity 
[149].  Meanwhile, since a lower viscosity was also preferred and microemulsion viscosity 
increases with the increase of Tween 80 concentration, the weight ratio of Miglyol 
812/Capmul MCM at 65:22 (w/w) was selected.  With this ratio, microemulsions with the 
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Tween 80 concentration at 10% by weight could incorporate up to around 9% water by 
weight.  Clear samples inside the microemulsion window were stored at room temperature 
and monitored over time to assess whether precipitation, phase separation, or any clarity 
change occurred.  All clear samples remained clear for at least six months at room 
temperature, which clearly demonstrated the excellent stability of the optimized systems.   
A similar W/O microemulsion system has been reported by Constantinides and 
colleagues [138, 150, 151] for systemic peptide delivery.  They reported greatly enhanced 
bioavailability of Calcein and a water-soluble RGD peptide using the system of Captex 
355/Capmul MCM/Tween 80/Aqueous (65/22/10/3, in percent w/w).  In current studies, 
Miglyol 812, which has more defined fatty acid distribution and different product 
specifications compared to Captex 355, served as the oil phase and up to 9% water was 
incorporated in the W/O microemulsions.  The feasibility of these formulations for local 
intestinal delivery of peptides via oral administration was investigated both in vitro and in 
vivo.   
 
2.4.2  Characterization of W/O microemulsions 
Rheological properties and conductivity 
The rheological properties of microemulsion samples in the microemulsion window 
were characterized by measuring their shear stress versus shear rate.  Several 
representative samples across the microemulsion window incorporating 5% water and 
varying amounts of Tween 80 (Figure 2.2A) were measured.  As shown in Figure 2.2B, all of 
the 11 microemulsion samples showed apparent Newtonian fluid behavior wherein there 
was a linear relationship between shear stress and shear rate.  The viscosity of the 11 
samples was obtained by linear regression, and the slope of each regression line was the 
apparent viscosity of each sample.  As shown in Figure 2.2C, the viscosity of the 
microemulsion samples increased with an increase in Tween 80 concentration.  The 
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viscosity data also indicated the presence of a threshold (at the line around 42% Tween 80).  
When the Tween 80 concentration was lower than this threshold, the effect of Tween 80 on 
the microemulsion viscosity was minor; however, when the Tween 80 concentration was 
above this threshold, the effect of Tween 80 on the microemulsion viscosity was more 
pronounced.  This phenomenon indicated that there might be a microemulsion structure 
change when the Tween 80 concentration increased up to around 42% (wt. %) (Figure 
2.2C), which was consistent with the results of the dilution studies discussed later.  The 
detailed microstructure is not yet understood.  We hypothesize that below this threshold, the 
W/O microemulsion droplets and micelles coexisted, and the enhanced viscosity was due to 
the increase of micelle number and size.  Moreover, above this threshold, there was the 
existence of a bicontinuous microemulsion where Tween 80 and Miglyol 812 existed as two 
continuous phases with Capmul MCM dispersed in the interfacial layer and water dispersed 
in the continuous Tween 80 phase or associated with the polar head group of Tween 80 in 
the interfacial layer.  Thus, the viscosity increase above this threshold was attributed to the 
increase of bulk Tween 80.   
To elucidate the sample properties inside the microemulsion window, a series of 
microemulsion samples at different Miglyol 812/Capmul MCM (65:22, w/w) to Tween 80 ratio, 
such as 85:10, 70:25, 50:45, and 30:65, were prepared and characterized.  The viscosity of 
these microemulsion samples is shown in Figure 2.3A.  At each fixed oil to surfactant ratio, 
the viscosity increased slowly with increasing water content.  This increase was most likely 
due to the increase in both droplets number and size which enhanced the dispersed phase 
droplet interaction.  In addition, consistent with the results above, as the Tween 80 
concentration increased, the viscosity increased accordingly.  
Conductivity is an important parameter which might reflect the microstructure of the 
microemulsions [152].  The conductivity of series of microemulsion samples with different oil 
to surfactant ratios is shown in Figure 2.3B.  With increasing water concentration at each 
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fixed oil to surfactant ratio, the conductivity increased accordingly, most likely due to the 
increase in both droplets number and size [153].  Related, with increasing Tween 80 
concentration, the conductivity also gradually increased, which was probably due to the 
increased interaction between droplets which facilitated the ion exchange between droplets 
[153].  Overall, the low conductivity of these microemulsions was an indication of the 
formation of W/O microemulsions [154].  
 
Photon Correlation Spectroscopy and FFTEM 
Photon correlation spectroscopy was employed for microemulsion droplet size 
analysis.  As shown in Figure 2.3C, samples in the microemulsion window with water 
concentration higher than 3% and Tween 80 concentration lower than 20% showed smaller 
polydispersity index (PI) with more uniform droplet diameter in the range of 10-40 nm (data 
not shown).  While samples in the microemulsion window with Tween 80 concentration at 20% 
(w/w) or higher, or with water concentration lower than 3% (w/w) were polydisperse with a 
greater PI.  The size analysis reports indicated that those samples with a larger PI (e.g., PI > 
0.3) were too polydisperse for data analysis.  The high PI values of the microemulsion 
samples were likely an indication of the presence of an excess amount of Tween 80 
surfactant.  Since samples with uniform size distribution were preferred, microemulsion 
samples with smaller PI (PI < 0.1) were identified for further evaluation.  
To investigate the morphology and confirm the droplet size of the W/O 
microemulsions, FFTEM was utilized.  Figure 2.4 shows the FFTEM results of one of the 
placebo microemulsion formulations of interest (Table 2.1), which was plotted and 
highlighted by a red circle and a red arrow in Figure 2.3C.  The droplets were spherical with 
an average diameter around 20 nm, which was consistent with the results obtained by 
photon correlation spectroscopy. 
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2.4.3  Phase inversion behavior of W/O microemulsions 
The W/O microemulsions developed in this work were primarily designed for oral 
delivery route.  After oral administration, the W/O microemulsions will likely be phase-
inverted into o/w emulsions and/or water-in-oil-in-water (w/o/w) double emulsions.  Since the 
phase inversion behavior might affect the in vivo fate of the drug incorporated [155], it is 
important to investigate this behavior.  The first experiment performed was a dilution study 
using fluorescence microscopy.  A fluorescent fatty acid, BODIPY FL C12, was dissolved in 
a W/O microemulsion formulation (84% mixture of Miglyol 812/Capmul MCM (65:22, w/w), 
10% Tween 80, and 6% water), and then diluted in water by different dilution factors.  The 
purpose of this dilution study was: (1) to confirm the phase inversion behavior and (2) to find 
out the minimal dilution factor required for the phase inversion to occur.  As expected, 
before dilution the microemulsion with BODIPY FL C12 appeared clear with strong green 
fluorescence (Figure 2.5A).  However, upon a fivefold or more dilution, the W/O 
microemulsion was readily inverted into coarse o/w-type emulsions with large and 
polydisperse green fluorescent droplets (Figure 2.5C-F), while with a twofold dilution, the 
W/O microemulsion was only partially phase-inverted as large continuous green fluorescent 
area occupied close to half of the examined field (Figure 2.5B).  This study visually 
demonstrated the occurrence of phase-inversion behavior of W/O microemulsions upon 
dilution. 
To further examine the detailed structure of the resulting emulsion from dilution, a 
W/O microemulsion formulation (84% mixture of Miglyol 812/Capmul MCM (65:22, w/w), 10% 
Tween 80, and 6% water) diluted tenfold by weight in water was negatively stained using 2% 
uranyl acetate, and subsequently examined using TEM.  The results showed that the large 
droplets seen under fluorescence microscope contained numerous smaller droplets 
associated together (Figure 2.6), and there was no clear indication of the formation of 
double or multiple emulsions.  The dark area between those smaller droplets might be an 
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indication of the presence of aqueous phase, which may be able to host water-soluble drug 
molecules and protect the drug molecules from acidic and enzymatic degradation.  The oil 
phase might also be able to bring the peptide to the proximity of mucosa surface quicker 
and so that the peptide stands more chance to be internalized before the degradation 
occurrence in the lumen.  The phase inversion studies using fluorescence microscopy 
together with TEM provide a high resolution perspective of phase inversion from W/O 
microemulsions to coarse o/w emulsions upon dilution using aqueous phase. 
To provide an overview of the phase inversion behavior of samples across the 
microemulsion window, samples with 5% water and different oil to surfactant ratios were 
diluted 100-fold in water by weight.  The results showed that as the weight ratio of Miglyol 
812/Capmul MCM (65:22, w/w) to Tween 80 was 40:55 (#7 in Figure 2.7A) or less, such as 
40:60, 30:65, 20:75, 10:90 (corresponding to #8, 9, 10, and 11 in Figure 2.7A), the 
microemulsion was inverted to stable clear or translucent microemulsion (Figure 2.7A) with 
uniform size distribution (Figure 2.7B).  However, when the weight ratio of Miglyol 
812/Capmul MCM (65:22, w/w) to Tween 80 was 45:50 (#6 in Figure 2.7A) or higher, the 
microemulsion was inverted to turbid emulsions.  These results were consistent with the 
viscosity data which showed the existence of a threshold around the line of 42% Tween 80.  
Together, the viscosity data and dilution data indicated there might be a microstructure 
change of microemulsions with Tween 80 concentration close to 42-50% by weight in the 
microemulsion window of the selected phase diagram.  In addition, since the microemulsion 
with the weight ratio of Miglyol 812/Capmul MCM (65:22, w/w) to Tween 80 at 40:55 (#7 in 
Figure 2.7A) or lower exhibited similar dilution properties of self-microemulsifying drug 
delivery systems [156, 157], these microemulsions might find applications to enhance oral 
absorption of poorly water-soluble and/or poorly permeable drugs, which is beyond the 
scope of the current study. 
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2.4.4  In vitro stability studies in modified simulated intestinal fluid 
MSIF was prepared using pancreatin from porcine pancreas, which contains a 
broad-spectrum of digestive enzymes, including amylase, trypsin, lipase, ribonuclease, and 
protease.  The pancreatin from porcine pancreas contains similar enzymes as the 
pancreatic fluid which a drug might encounter when it enters the intestines following oral 
administration.  To test the hypothesis that W/O microemulsion can provide protection to the 
water-soluble peptide incorporated from enzymatic degradation, the stability of TAMRA-TAT 
in microemulsion and TAMRA-TAT in solution in MSIF at 37ºC was determined by HPLC 
with fluorescence detection.  The TAMRA-TAT peak in HPLC chromatogram was well 
separated from its degradation products.  Spike-recovery studies of TAMRA-TAT in the 
presence of placebo microemulsion using the sample processing method described under 
“Materials and Methods” section was 100.11% ± 6.24% (n = 3).  The kinetics of TAMRA-
TAT degradation was determined by following the loss of TAMRA-TAT as a function of time 
[158].  As shown in Figure 2.8, the kinetics of TAMRA-TAT microemulsion and solution in 
MSIF followed pseudo-first-order rates, which were described by the equation y = b × e-kt.  In 
this equation, y represents the percentage (normalized concentration) of TAMRA-TAT at 
time t, b is the initial TAMRA-TAT concentration (percentage), t is the reaction time in 
minutes, and k is the pseudo-first-order rate constant [158].  For TAMRA-TAT solution, the 
TAMRA-TAT degradation kinetics fit the equation y = 96.78 e-0.1034 t (R2 = 0.9977), and the 
half-life (t1/2) calculated from the resulting rate constant was 6.7 min.  For TAMRA-TAT 
microemulsion, the TAMRA-TAT kinetics followed y = 91.56 e-0.0357 t (R2 = 0.991) with a 
calculated t1/2 of 19.4 min, which was nearly threefold greater than that of the TAMRA-TAT 
solution.  
The HIV TAT (47-57) moiety in TAMRA-TAT contains positively-charged amino acids 
arginine and lysine, which makes it highly susceptible to proteolysis by tryptic enzymes [158].  
A review article [159] pointed out seven potential trypsin cleavage sites (48, 49, 50, 51, 52, 
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54, and 56), and Grunwald et al. [158] also identified a few fragments by MS in in vitro TAT 
(47-57) proteolysis studies, which include GRKKRRQRRR, GRKKRRQRR, GRKKRRQR, 
YGRKKRRQR, and YGRKKRRQRR.  In our study, the kinetics of TAMRA-TAT degradation 
was followed by the detection of the loss of parent TAMRA-TAT.  The stability of the 
TAMRA-TAT was significantly enhanced by the W/O microemulsion when challenged by 
MSIF.  A similar protective effect from a different W/O microemulsion system to a rhPTH1-
34 peptide in the presence of pepsin and trypsin was also reported by Guo et al. [160] in an 
in vitro enzymatic stability study.  Another study by Cheng et al. [137] stated that after their 
W/O microemulsion system was phase inverted following a 800-fold dilution, only 7% loaded 
peptide was detected in the aqueous phase and the rest of the peptide was still detected in 
the upper coarse emulsion after separation by centrifugation.  Although, there was no direct 
evidence, it is possible that even after dilution, the peptide loaded to the microemulsion 
might be still associated with the coarse emulsion when phase inversion happens, which 
renders protection to the peptide loaded from enzymatic degradation.  These peptide 
stability data further supported the results from the following in vivo mouse studies and the 
hypothesis that W/O microemulsion may provide protection to the peptide incorporated in 
the enzymatic environment compared to peptide water solution.   
 
2.4.5  In vivo studies for intestinal delivery    
The initial aim of this work was to develop and optimize a W/O microemulsion that 
has the potential to increase the delivery of a potent peptide to inflamed intestinal tissue.  If 
successful, the W/O microemulsion could then be incorporated into enteric-coated hard 
gelatin capsules to further enhance the delivery where and when needed.  Therefore, it was 
not the intention to develop a W/O microemulsion that would be given orally as an oral 
microemulsion drink.  To facilitate the initial aim, a commercially available fluorescent 
TAMRA-TAT peptide was used as a model therapeutic peptide, considering it has similar 
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cationic content and cell-penetrating properties to 8K-NBD, a potent NF-κB inhibitor.  
TAMRA-TAT was loaded to one of the W/O microemulsion templates (Table 2.1) and orally 
gavaged to mice.  TAMRA-TAT solution and placebo microemulsion were administered in 
parallel as controls.  The physical properties of the W/O microemulsion with and without 
TAMRA-TAT are shown in Table 2.1.  The actual TAMRA-TAT loading was 96.6 ± 1.69% (n 
= 5) compared to the theoretical loading as measured by HPLC. 
The intestinal distribution of TAMRA-TAT was evaluated using a semiquantitative 
method, fluorescence microscopy.  The FI was quantified using Image J and represented as 
integrated density over the same ROI.  As shown in Figure 2.9, the FI from the treatment of 
TAMRA-TAT microemulsion in all the intestinal sections are significantly greater than that 
from the treatment of TAMRA-TAT solution or placebo microemulsion.  Linear regression of 
FI versus treatments (TAMRA-TAT microemulsion, TAMRA-TAT solution. and placebo 
microemulsion) and FI versus intestinal sections (duodenum, jejunum, ileum, and colon) 
showed p values of 1.51 × 10-26 and 3.52 × 10-6, respectively, which indicated FI was 
strongly correlated with the treatments, meanwhile, FI was associated with intestinal 
sections, but to a lesser extent.  To compare the overall FI in the small intestines to that in 
the large intestine, the linear regression coefficients of FI versus treatments in each 
intestinal section were calculated.  The average linear regression coefficient from the 
duodenum, jejunum, and ileum was 5.9-fold greater than that from the colon, which 
suggested that overall, the FI difference among three treatments in the small intestine was 
greater than that in the large intestine.  Representative images from each intestinal section 
are shown in Figure 2.10. 
In summary, the in vivo mouse experiment showed that FI resulting from the 
TAMRA-TAT microemulsion treatment was significantly greater than that from the TAMRA-
TAT solution or placebo microemulsion treatment in all intestinal sections.  Although a 
semiquantitative method was employed in these in vivo studies, it was likely that the 
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fluorescence observed was mostly due to intracellular fluorescence since the intestine tissue 
was washed before fluorescence imaging.  Moreover, only intact TAMRA-TAT should be 
taken up intracellularly, so the presence of more fluorescence in the tissue was an indication 
of the presence of more intracellular TAMRA-TAT.  Therefore, results from the in vivo 
studies showed that the TAMRA-TAT W/O microemulsion enhanced the intestinal delivery of 
TAMRA-TAT compared to the TAMRA-TAT solution and placebo micromeulsion.  However, 
the overall FI in the small intestine was still greater than that in the large intestine after oral 
administration, which will be addressed by encapsulation of the W/O microemulsion into 
enteric-coated capsules to facilitate the local delivery to the target region of the intestinal 
tract, such as the colon.  Some preliminary experiments on the compatibility of the W/O 
microemulsion and hard gelatin capsules were carried out.  The results showed that hard 
gelatin capsules containing Miglyol 812, Capmul MCM, Tween 80, and the W/O 
microemulsion, respectively, remained stable at room temperature for at least 1 year.  There 
were no obvious changes to capsule stiffness or shape.  The W/O microemulsion inside the 
hard gelatin capsules stayed clear with the same particle size after 1 year at room 
temperature.  The compatibility of the excipients in W/O microemulsions contained in hard 
gelatin capsules was also supported by a review [161].  After capsules containing W/O 
microemulsion were enteric coated, the microemulsion stayed clear and stable in enteric-
coated capsules at room temperature or at 4˚C in a refrigerator for at least 1 week before 
being used for experiments.  Results from the mouse experiments were also supported by 
the data from the TAMRA-TAT in vitro stability studies, which provided direct evidence on 
the protective effect of W/O microemulsion to the peptide incorporated when challenged by 
the enzyme-containing environment.  Together, the in vitro and in vivo studies indicated that 
the W/O microemulsion system may serve as a viable oral delivery vehicle to enhance the 
intestinal delivery of water-soluble peptides.  
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Intestinal delivery of peptides and proteins have been reported [162], but most of the 
reports have focused on the improvement of systemic absorption.  There are quite limited 
reports on the local intestinal delivery of peptides or proteins for the treatment of local 
pathologies, like IBDs.  Coco et al. [32] investigated the potential of three polymeric 
nanoparticles for colon-specific protein delivery via in vitro and ex vivo approaches.  Hong et 
al. [98] reported promising peptide local intestinal delivery using colon-targeted enteric-
coated capsules.  In our study, W/O microemulsions as a potential oral delivery vehicle for 
local intestinal delivery of a cell-permeable peptide was investigated.  The hydrophobic oil 
phase, Miglyol 812, together with Capmul MCM served as a protective vehicle to shield the 
peptide from acidic and enzymatic attack and protect the peptide incorporated during 
transition.  In addition, Miglyol 812 as medium-chain triglycerides might also be converted to 
monoglycerides in the presence of lipase and enhance intracellular delivery [163].  In our 
study, the protective effect of the W/O microemulsion to the peptide incorporated was clearly 
presented.  Incorporation of therapeutic peptides into the W/O microemulsion developed in 
the current study followed by encapsulation into enteric-coated capsules will be evaluated in 
larger animal models, like pig colitis models and will be the focus of our future studies.  
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2.5  Conclusions 
This work demonstrates the potential of using W/O microemulsions as an oral 
delivery vehicle to deliver a cell-permeable peptide to the local murine intestines.  Water-in-
oil microemulsions were developed, characterized, and evaluated.  The in vitro peptide 
stability studies provided direct evidence of the protective effect from the W/O 
microemulsion to the peptide incorporated against the enzymatic degradation.  The in vivo 
mouse studies exhibited enhanced intestinal delivery of the model peptide TAMRA-TAT to 
the mouse small and large intestines using the W/O microemulsion system.  Since the W/O 
microemulsions developed in this work might exhibit dual mechanisms by providing both 
enhanced protection and intracellular delivery, their applications are not limited to cell-
penetrating peptides.  Meanwhile, the W/O microemulsions developed in this work were 
thermodynamically stable, and formed spontaneously at room temperature without the 
application of heating or high shear stress.  These microemulsion systems may serve as a 
platform for oral intestinal delivery of water-soluble and heat-labile peptides or proteins by 
their incorporation into enteric-coated capsules.   
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Table 2.1 Characterization of placebo and TAMRA-TAT W/O microemulsions (n = 3). 
W/O 
Microemulsions 
Viscosity 
(cP) 
Mean droplet 
diameter (nm) 
Polydispersity 
index 
Conductivity 
(µS/cm) 
Placebo ME 43.7 ± 1.2 20.6 ± 2.3 0.023 ± 0.030 0.690 ± 0.013 
TAMRA-TAT ME 43.2 ± 0.6 21.4 ± 3.3 0.059 ± 0.036 0.681 ± 0.017 
 
Note: 
 
This W/O microemulsion composition was Miglyol 812/Capmul MCM/Tween 80/Aqueous at 
the weight ratio of 62.8/21.2/7/9.  The aqueous for placebo microemulsion (ME) is water and 
for TAMRA-TAT microemulsion is TAMRA-TAT stock. 
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Figure 2.1  Partial pseudo-ternary phase diagrams of the system comprising Miglyol 
812/Capmul MCM/Tween 80/Water for the development of W/O microemulsions.  The 
weight ratio of Miglyol 812/Capmul MCM was kept constant at (A) 4:1; (B) 65:22; and (C) 2:1, 
respectively. The green dots represent clear samples, the red dots represent turbid samples 
and the shaded area is the microemulsion window. 
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Figure 2.2  The mapping (A), rheological property (B) and viscosity (C) of 11 microemulsion 
samples containing 5% water inside the microemulsion window for characterization. The 
sample numbers on the legend of B correspond to the samples shown in A. 
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Figure 2.3  The viscosity (A), conductivity (B) and polydispersity index (C) of microemulsion 
samples across the microemulsion window with the weight ratio of Miglyol 812/Capmul MCM 
at 65:22 (w/w).  Each data point is color coded and the height of each bar also indicates the 
relative value of each data.  The circled data point with a red arrow corresponds to the 
placebo microemulsion shown in Table 2.1. 
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Figure 2.4  The FFTEM of a selected placebo water-in-oil (W/O) microemulsion. 
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Figure 2.5  Fluorescence microscopy of water-in-oil (W/O) microemulsion upon dilution in DI 
water.  (A) W/O microemulsion with BODIPY FL C12, (B) W/O microemulsion with BODIPY 
FL C12 by a twofold dilution, (C) fivefold dilution, (D) tenfold dilution, (E) 50-fold dilution, and 
(F) 250-fold dilution, respectively.  The composition of the W/O microemulsion was Miglyol 
812/Capmul MCM/Tween 80/water at the weight ratio of 62.8/21.2/10/6.  All the images 
shown were taken with ×10 objective lens (with a total of ×100 magnification). 
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Figure 2.6  TEM of a W/O microemulsion sample after a tenfold dilution.  The W/O 
microemulsion composition was the same as stated under Figure. 2.5. 
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Figure 2.7  The phase inversion behavior of W/O microemulsions.  (A) The picture shows 
the phase inversion behavior of samples across the microemulsion window.  Eleven 
microemulsion samples with the weight ratio of Miglyol 812/Capmul MCM (65:22, w/w) to 
Tween 80 at 85:10, 80:15, 70:25, 60:35, 50:45, 45:50, 40;55, 40:60, 30:65, 20:75, and 10:90 
were diluted 100-fold by weight with water, respectively. (B) The droplet size analysis of 
diluted samples corresponds to samples labeled in Figure. 2.7A. 
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Figure 2.8  The stability of TAMRA-TAT microemulsion versus TAMRA-TAT solution (Soln.) 
in MSIF at 37˚C.  The remaining TAMRA-TAT was normalized with respect to the initial 
concentration.  Three samples were prepared for each time points for both TAMRA-TAT 
microemulsion and TAMRA-TAT solution.  Data are presented as mean ± SD (n = 3) on a 
logarithmic scale.  The degradation profiles of TAMRA-TAT in microemulsion and solution in 
MSIF at 37˚C were described by pseudo-first-order kinetics. 
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Figure 2.9 The fluorescence intensity in different mouse intestinal sections after oral 
administration of TAMRA-TAT microemulsion (n = 4 mice), TAMRA-TAT solution (Soln.; n = 
4 mice) and placebo microemulsion (n = 3 mice).  The data are presented as mean ± SD.  
*** p < 0.001, comparisons. 
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Figure 2.10  Representative fluorescence microscopic images from intestines of C57/BL6 
mice treated with TAMRA-TAT microemulsion, TAMRA-TAT solution (Soln.) and placebo 
microemulsion (ME) 4 h after oral gavage.  Scale bar represents 50 µm. 
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Chapter III 
 
Hydrogel Nanoparticles in Water-in-Oil Microemulsions for Peptide Oral Delivery: 
Formulation Optimization and In Vitro Evaluation 
 
3.1  Summary 
The objective of the current studies was to develop hydrogel nanoparticles in water-
in-oil (W/O) microemulsions (MEs) for improved oral intestinal delivery of peptide drugs.  An 
amphiphilic triblock copolymer Pluronic F127 (PF127) was selected based on its 
thermoreversible gelation property and its wide applications in the drug delivery field.  14% 
PF127 (w/w) was selected as the intial concentration to prepare hydrogel nanoparticles 
based on its viscosity as a function of temperature.  A pseudo-ternary phase diagram of 
Miglyol 812/Capmul MCM/Tween 80/14% PF127 was constructed and facilitated the 
formulation screening process.  Several W/O MEs with 14% PF127 in the ME window were 
characterized in terms of viscosity, droplet diameter, polydispersity index (PI), turbidity, 
conductivity and freeze-etch electron microscopy (FEEM).  A selected formulation of W/O 
ME with 14% PF127 was further evaluated in in vitro enzymatic stability studies using 
TAMRA-TAT as a model peptide.  The half-life (t1/2) of TAMRA-TAT in the W/O ME with 14% 
PF127 was two-fold greater than that in water solution, while the t1/2 of TAMRA-TAT in the 
W/O ME without PF127 was three-fold greater than that in the water solution in the 
presence of MSIF at 37°C.  The less protective effect from the W/O ME with 14% PF127 
was explained based on the physical/chemical characterization data.  The increased droplet 
diameter from around 30 nm to around 3 µm along with greatly increased turbidity, PI, and   
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decreased conductivity suggested that PF127 aggregated and precipitated out from the 
water droplets of the W/O ME at 37°C, which exposed the TAMRA-TAT associated with it 
directly to enzymic degradation, resulting in a compromised protective effect compared to 
the W/O ME without PF127.  To find out whether a W/O ME with PF 127 that could stay 
clear at 37°C was more protective or not, a W/O ME with 8% PF127 was characterized and 
evaluated in an in vitro enzymatic stability study.  The W/O ME with 8% PF127 appeared 
clear with a small droplet size increase (29 nm to 55 nm) when temperature increased to 
37°C, which rendered a superimposable TAMRA-TAT degradation profile compared to the 
W/O ME without PF127.  The similar protective effect supported the earlier explanation of 
why the W/O ME with 14% PF127 was less protective, but also indicated the concentration 
of 8% PF127 was probably too low to form hydrogel nanoparticles in the W/O MEs.  
Therefore, the hydrogel formation of PF127 in the nano-sized water droplets in the W/O ME 
system was yet achieved.  More efforts are necessary to provide some insight into the 
polymer gelation process in the ME microenvironment, and to develop an improved hydrogel 
nanoparticle in ME-based formulation for peptide intestinal delivery.   
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3.2  Introduction 
3.2.1  Peptide and protein oral delivery 
Oral delivery of peptide and protein drugs has been an attractive alternative to their 
parenteral delivery, but remains a challenge in the drug delivery field.  Some issues 
associated with peptide and protein oral delivery mainly include the following [2]: (1) 
peptides and proteins are large molecular weight biopolymers with poor permeability 
through various biological membranes; (2) most peptides and proteins are susceptible to 
acid-induced hydrolysis in the stomach and enzymatic degradation throughout the GI tract 
by digestive enzymes and/or luminal microorganisms.  Many strategies have been pursued 
to overcome these barriers [1, 2, 4, 129, 164, 165] and to develop safe and effective oral 
delivery systems for peptides and proteins. Among the various formulation approaches, 
microemulsions have attracted much attention in the past decades.       
 
3.2.2  Microemulsion 
Microemulsions [166] are defined as “a system of water, oil and an amphiphile which 
is a single optically isotropic and thermodynamically stable liquid solution”.  Microemulsions 
were first introduced by Hoar and Schulman in 1943 [167, 168] and since then, different 
theories of microemulsion formation and stability have been proposed, mainly including 
interfacial or mixed film theories [169], solubilization theories [170, 171], and thermodynamic 
theories [172, 173].  A simplified version of the thermodynamic theories is presented as 
follows.  The free energy of microemulsion formation can be expressed using the Equation 
3.1:  
                                        ΔGform = ΔA•γ – T• ΔS                                       (Equation 3.1) 
In this equation, the ΔGform is the free energy of formation, ΔA is the change in the 
interfacial area on microemulsification, γ is the interfacial tension of the oil and water 
interface at temperature T (Kelvin), ΔS is the change in entropy of the system, and T is the 
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temperature.  When a microemulsion is formed, the change in ΔA is very large due to the 
formation of a large number of very small droplets, and ΔS is positive as well.  As long as 
the surfactants can produce extremely low interfacial tension (approximately 0.01 mN/m), 
the condition ΔA•γ ≤ T• ΔS will be fulfilled, which will result in a negative free energy of 
formation (ΔGform < 0).  In such cases, microemulsion will be formed spontaneously and the 
resulting microemulsion is thermodynamically stable [136].  
The most common microemulsions are: (a) oil-in-water; (b) bicontinuous; and (c) 
water-in-oil microemulsion (Figure 3.1).  For oil-in-water (o/w) type of microemulsion, oil 
droplets are dispersed in water and the volume fraction of oil is generally low.  Conversely, 
for water-in-oil (W/O) type of microemulsion, water droplets are dispersed in oil phase and 
likely the volume fraction of water is low.  For a bicontinuous microemulsion, the volume 
fractions of water and oil are similar, and both water and oil exist as a continuous phase.  
The microemulsion type or structure is essentially determined by the nature of the 
surfactant, cosurfactant and oil.  Microemulsons have been investigated over years in the 
drug delivery field [139, 150, 156, 174, 175].  Oil-in-water microemulsions have been 
researched for the delivery of hydrophobic molecules [139, 176, 177], while W/O 
microemulsions have aroused interest for the delivery of water-soluble molecules, like heat-
labile peptides and proteins [137, 150].  
In our earlier study [178], we developed W/O microemulsions for oral local intestinal 
delivery of water-soluble peptides and demonstrated promising enhanced local peptide 
delivery.  However, this W/O microemulsion system bears the same dilution issues as all 
other W/O microemulsions, i.e., phase inversion upon addition of excess amount of aqueous 
phase, which can affect the drug release both in vitro and in vivo [155].  This phase 
inversion behavior has been studied in vitro, but in vivo how quick and to what extent it will 
happen are hard to predict.  To overcome this drawback, an improved formulation, hydrogel 
nanoparticles in the W/O microemulsions was designed.  Hydrogel nanoparticles formed in 
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the nanosized droplets will provide further protection in addition to the W/O microemulsion.  
Therefore, the incorporated peptide will still be protected in the gel matrix even when phase 
inversion occurs. 
  
3.2.3  Pluronic F127 
Based on prior research [179, 180], an amphiphilic polymer of Pluronic F127 was 
pursued.  Pluronic F127 is a triblock copolymer of poly(ethylene oxide)-poly(propylene 
oxide)-poly(ethylene oxide) (PEO-PPO-PEO) as shown in Figure 3.2.  It contains 70-79% 
polyoxyethylene with a nominal molecular weight of 12,600 and an HLB ranges from 18-23.  
Pluronic F127 is a registered trademark of BASF Corporation and also known as Poloxamer 
407.   
The Pluronics are available in a range of molecular weights as presented in Figure 
3.3 [180].  These Pluronic PEO-PPO-PEO copolymers vary in the PPO/PEO ratio, the PEO 
block length, the PPO block length, and the total chain length, which result in different 
properties of average molecular weight, melting point, viscosity, surface tension, cloud point, 
hydrophilic-lipophilic-balance.  Therefore, they meet widespread pharmaceutical and 
cosmetic applications as detergents, foaming agents, emulsifying agents, and lubricating 
agents.  The critical micellization concentration (CMC) and thermoreversible gelation 
process are important properties related to many of their applications, which have been 
investigated by various groups [181-184].  Typically, a PEO-PPO-PEO copolymer exists as 
unimers in water at a low temperature and/or concentration, and forms micelles when the 
temperature is above its critical micellization temperature (CMT) or the copolymer 
concentration is above its CMC.  This micellization happens through the hydrophobic 
association of the PPO blocks.  In other words, at low temperatures, the PPO blocks are 
less hydrophobic and can be dissolved in water through hydrogen bonding or just 
surrounded by water molecules.  However, at high temperatures (above CMT), the 
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hydrophobic PPO blocks squeeze out water molecules and associate together to form 
micelles.  When the micelle concentration approaches the volume fraction of 0.53, the 
micellar liquid may freeze into a cubic crystal and gelation occurs [185].  At even higher 
temperatures, the gel may “dissolve” again [180].  Vadnere et al. investigated the gelation 
process of nine Pluronic PEO-PPO-PEO copolymers [181].  Two trends were noted: (1) The 
concentration required for gel formation was similar to coplolymers with the same weight of 
PPO blocks; (2) While for a given PPO/PEO ratio, the polymer concentration required for gel 
formation decreased with inceasing molecular weight at a given temperature.  
In the Pluronic family, Pluronic F127 is the most extensively studied member [179, 
183, 184, 186-188].  It has a relatively large average molecular weight (Mw = 12,600), and 
an appropriate PPO/PEO ratio with about 70% ethylene oxide content, which renders both 
good water solubility through the high PEO content and a capacity of hydrophobic 
association through the long PPO block.  Compared to other Pluronics, Pluronic F127 
requires the lowest concentration for gel formation at a given temperature, and shows the 
lowest gelation temperature at the same copolymer concentration [181].  Its special 
thermoreversible gelation profile attracted lots of research interest for many pharmaceutical 
applications.  The effect of additives on the gelation properties of Pluronic F127 has also 
been studied by several groups [183, 184, 186, 189, 190].  The gel-sol transition 
temperature decreased as the benzoic acid concentration increased [189].  When adding a 
homologous series of para-hydroxybenzoate esters, methyl, ethyl, propyl and butyl, the 
more lipophilic esters resulted in a greater decrease in Pluronic F127 gel-sol transition 
temperature for all the concentrations studied.  Conversely, the addition of PEG increased 
the gelation temperature and the extent of the increase depended on the the PEG chain 
length and concentration.  The effects of polymers and solutes were also investigated by 
Malmsten et al. [183, 184].  The homopolymer PEO of intermediate molecular weight 
induced the gel to “melt”, while the addition of PPO homopolymer tended to increase the 
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stability region of the gel, depending on the PPO molecular weight [184].  The gel formation 
of Pluronic F127 was also affected by the presence of salts.  Sodium chloride (NaCl) shifted 
the whole gel region to lower temperatures, while the presence of NaSCN displaced the 
whole gel region to higher temperatures [183].  It has also been reported that the addition of 
Na2HPO4, NaH2PO4 [191, 192], benzalkonium chloride [193], sodium alginate, and carbopol 
[194] lowered the gelation temperature of Pluronic F127, while cyclodextrins in Pluronic 
F127 solution increased the gelation temperature [195].  
Pluronic F127 is generally considered to be a nontoxic and nonirritant material [196] 
and has been included in the FDA inactive ingredient database for oral, topical, ophthalmic 
and periodontal products [147].  It has also been investigated in rectal [194, 197] and local 
injectable formulations [198].  Studies indicated that Pluronic F127 promoted stabilization of 
peptides and proteins [199-203].  Based on its thermoreversible gelation profile and wide 
applications as a nontoxic pharmaceutical excipient, Pluronic F127 was selected for the 
current study to develop hydrogel nanoparticles in the W/O microemulsions.  Figure 3.4 
depicts (A) an illustration of the W/O microemulsion developed earlier; (B) the W/O 
microemulsion with the aqueous phase replaced by a Pluronic F127 solution; and (C) the 
temperature-induced thermo-gelation of Pluronic F127 inside the nanosized water droplets 
of W/O microemulsions.  The concept is that even when the W/O microemulsion with 
Pluronic F127 undergoes potential phase inversion after oral administration, the peptide 
incorporated in the W/O microemulsion may still be protected by the gel matrix of Pluronic 
F127.  Therefore, it was hypothesized that peptides would be better protected in the W/O 
microemulsion with Pluronic F127 compared to that in the W/O microemulsion without 
Pluronic F127 or an aqueous solution. 
In this study, we first measured the viscosity of Pluronic F127 in water as a function 
of temperature and concentration, and then constructed a pseudo-ternary phase diagam 
using one of the Pluronic F127 solutions as the aqueous phase.  Several formulations of 
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W/O microemulsion with Pluronic F127 were characterized, and selected formulations were 
further evaluated via conductivity measurements, freeze-etch electron microscopy, and in 
vitro enzymatic stability studies using TAMRA-TAT as a model peptide.  
 
3.3  Materials and Methods  
3.3.1  Materials 
Miglyol 812 (Caprylic/Capric triglycerides, neutral) was provided by Sasol Germany 
GmbH (Eatontown, NJ, USA).  The fatty acid distribution of Miglyol 812 according to the 
manufacturer is 57.7% caprylic acid (C8), 41.6% capric acid (C10), 0.2% caproic acid (C6), 
and 0.3% lauric acid (C12).  Capmul MCM NF (C8/C10 mono- and di-glycerides) was supplied 
by Abitec Corporation (Janesville, WI, USA).  Capmul MCM contains 53.6% of 
monoglycerides with 6.3% free glycerol and its fatty acid distribution is 82.6% caprylic acid 
and 17.4% capric acid.  Tween 80 (polyoxyethylene sorbitan monooleate, NF grade) was 
purchased from Spectrum Chemical MFG. Corporation (Gardena, CA, USA).  5-(and-6)-
Carboxytetramethylrhodamine-labeled TAT peptide (sequence: TAMRA-YGRKKRRQRRR) 
was purchased from ANASPEC Inc. (Fremont, CA, USA).  Pluronic F127 (Poloxamer 407; 
polyethylene-polypropylene glycol, NF grade) was purchased from Spectrum Chemical MFG. 
Corporation (Gardena, CA, USA).  Pancreatin from porcine pancreas (8 × USP 
specifications) was purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).  
Purified deionized water from a Milli-Q Advantage System was used for all of the sample 
preparation.  All other chemicals were of analytical grade.   
 
3.3.2 Viscosity studies of Pluronic F127 as a function of concentration and 
temperature 
Pluronic F127 was weighed out and added to deionized water, followed by magnetic 
stirring at 4˚C until Pluronic F127 was completely dissolved.  Pluronic F127 water solutions 
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at the concentrations of 5, 8, 10, 11, 12, 13, 14, 14.5, 15, 16, and 17% by weight were 
prepared.  The viscosity of each sample was measured using a Brookfield RVDV-III Ultra 
Cone and Plate Rheometer (Brookfield Engineering Laboratories, Inc., Middleboro, MA, 
USA) with cone spindles CPE-40, CPE42, or CPE-52 according to the viscosity range of the 
samples.  Each sample was equilibrated to the desired temperature for 20 min before 
measurements. The sample temperature during measurement was controlled by connecting 
to a Brookfield TC-502 Programmable Controller Water Bath. The accuracy of the RVDV-III 
Ultra CP Rheometer was verified using Brookfield Viscosity Standard Fluids.  The viscosity 
of Pluronic F127 solutions was measured as a function of temperature.  
 
3.3.3  Phase diagram construction 
Based on our earlier work [178], a pseudo-ternary phase diagram was constructed 
using Miglyol 812, Capmul MCM, Tween 80, and 14% (w/w) Pluronic F127 water solution.  
Miglyol 812 and Capmul MCM were mixed at the weight ratio of 65:22.  Each sample was 
prepared by weighing out appropriate amounts of Miglyol 812/Capmul MCM (65:22, w/w), 
Tween 80, and 14% Pluronic F127 into screw-capped scintillation vials.  The mixtures were 
thoroughly mixed at room temperature by magnetic stirring.  After equilibration at room 
temperature for at least 48 h, samples were examined in terms of clarity upon visual 
inspection.  The microemulsion window was defined as the region where clear and 
transparent formulations were obtained.  All samples were stored at room temperature and 
the stability of each sample was further accessed in terms of clarity over time.  
 
3.3.4  Characterization of W/O microemulsions with Pluronic F127 
Based on the phase diagram constructed, several formulations containing 5 or 6% 
aqueous phase in the microemulsion window were prepared and characterized in terms of 
viscosity, droplet diameter, polydispersity index (PI), absorbance at 750 nm and appearance.  
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The sample viscosity was measured using the same instrument and method as described 
under “Materials and Methods – 3.3.2”. 
 
Photon Correlation Spectroscopy  
The droplet diameter of W/O microemulsion with or without Pluronic F127 was 
measured by Photon Correlation Spectroscopy (PCS) using a Zetasizer Nano ZS (Malvern 
Instruments Inc., Worcestershire, UK) by backscattering at a fixed angle of 173°.  Samples 
were pre-incubated to the desired temperature in a water bath, and then equilibrated and 
measured in the temperature-controlled Malvern Zetasizer.  All the samples were measured 
in triplicates without dilution.  
 
Conductivity 
The conductivity of the microemulsions was measured using YSI 3200 Conductivity 
Instrument (Yellow Spring Instruments Co. Inc., Yellow Springs, OH, USA) coupled to YSI 
3252 Dip Cell with a cell constant of 1.0 cm-1.  The instrument was calibrated using YSI 
conductivity calibrators.  Conductivity measurements were made after samples were 
equilibrated to the desired temperature. 
 
Turbidity at absorbance of 750 nm 
The absorbance at 750 nm was used as an indication of sample turbidity.  The 
measurements were performed at 25 and 37˚C, respectively, using a Beckman Coulter DU® 
800 UV-Vis Spectrophotometer coupled with a Beckman Coulter Peltier Temperature 
Controller.  Samples were incubated to the desired temperature and then loaded to the 
spectrophotometer and equilibrated for 20 min before measurement.  An average value of 8 
readings for each sample was reported. 
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Freeze-Etch Electron Microscopy  
Several microliters of W/O microemulsion with Pluronic F127 were positioned on 
gold freeze-etch mounts and frozen in liquid nitrogen-cooled freon and held in liquid nitrogen.  
The specimens were transferred to the stage of a Balzers BAF400T Freeze-Fracture Plant 
at liquid nitrogen temperature with a high vacuum established in the unit.  The temperature 
of the specimen stage was raised to -100˚C and the microtome arm was cooled to -170˚C.  
The frozen droplets of the specimen were shaved with a liquid nitrogen-cooled blade which 
was retracted a short distance following the last cutting cycle and positioned over the 
fractured specimens for a five-minute etch interval.  After etching, the microtome was cycled 
out of position and an evaporative coat of platinum/carbon was applied to the fractured and 
etched surfaces at an angle of 30°.  A support layer of carbon was then evaporated over the 
specimens from an angle of 90°.  The specimens were removed from the unit and replicas 
were floated onto a distilled water surface and subsequently washed in 5% sodium 
dichromate in 50% sulfuric acid.  The replicas were retrieved from distilled water onto 300 
mesh copper grids and examined and photographed using a Zeiss EM900 Transmission 
Electron Microscope and Gatan Digital Camera. 
 
3.3.5  In vitro enzymatic stability studies  
Modified Simulated Intestional Fluid (MSIF) 
MSIF was prepared as described previously [178].  Briefly, pancreatin from porcine 
pancreas (8 × USP specifications) was dissolved in potassium phosphate buffer of pH 6.8 
according to USP 34 (Solutions/Test Solutions), and then diluted in phosphate buffer of pH 
6.8 (10 mM) by 1,000-fold.   
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Sample preparation   
Lyophilized TAMRA-TAT was reconstituted in deionized water and weighed out into 
an amber vial.  Then, a defined amount of Pluronic F127 was added and dissolved in 
TAMRA-TAT solution in an icy water bath.  Miglyol 812, Capmul MCM and Tween 80 were 
added and mixed well to form TAMRA-TAT W/O microemulsion with Pluronic F127.  
TAMRA-TAT W/O microemulsion was prepared with the same oil and surfactant weight ratio 
but using TAMRA-TAT stock solution as the aqueous phase instead of the TAMRA-TAT 
solution with Pluronic F127.  TAMRA-TAT solution with equivalent TAMRA-TAT 
concentration by weight served as the control.    
 
In vitro stability studies 
The enzymatic in vitro stability study was designed similarly to our previous studies 
[178].  TAMRA-TAT microemulsion with Pluronic F127 was weighed out into centrifuge 
tubes (~58 mg/tube), and equilibrated to 37˚C in a water bath.  Then, 116 mL of MSIF at 
37˚C was added and the mixture was incubated at 37˚C.  At predetermined time points, the 
sample was put on ice, and the reaction was stopped by adding 300 µL of acetone with 2% 
(v/v) trifluoroacetic acid.  The clear TAMRA-TAT fraction was collected after centrifugation at 
16,000 × g for 10 min at 4˚C, and then frozen on dry ice, lyophilized (see Table 3.1) and 
reconstituted in acetonitrile/water with 0.1% (v/v) trifluoroacetic acid (19/81, v/v).  TAMRA-
TAT in the reconstituted sample was determined by HPLC with fluorescence detection [178].  
Briefly, TAMRA-TAT was detected using a reverse-phase column (Vydac 238 MS C18 5 µm, 
4.6 × 250 mm, Grace Davison, Deerfield, IL, USA) on a Thermo Finnigan Surveyor Plus 
HPLC system with a FL Plus detector using a binary gradient elution.  Mobile phase A was 
0.1% trifluoroacetic acid in acetonitrile and mobile phase B was 0.1% trifluoroacetic acid in 
deionized water.  The initial eluent contained 19% phase A and 81% phase B, and then 
phase A was increased to 37% in 14.5 min. The flow rate was kept constant at 1 mL/min.  
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The sample injection volume was 10 µL and the excitation and emission wavelengths were 
545 and 579 nm, respectively.  
 
Sample processing recovery studies  
To determine whether TAMRA-TAT in W/O microemulsion (ME) with Pluronic F127 
can be recovered using the sample processing method described under “in vitro stability 
studies – 3.3.6”, a total of three recovery studies were designed and preformed.   
In the first study, the recovery of TAMRA-TAT in ME with 14% Pluronic F127 after 
the sample extraction, lyophilization, and reconstitution process was examined.  Placebo 
W/O ME with Pluronic F127 was prepared, and added to a known amount of TAMRA-TAT 
stock solution to make a final TAMRA-TAT W/O ME with 14% Pluronic F127.  Then, 100 mg 
of TAMRA-TAT ME with 14% Pluronic F127 was incubated at 37˚C for 5 min, and diluted 
with 200 µL of phosphate buffer of pH 6.8.  Next, acetone with 2% trifluoroacetic acid was 
added to stop the reaction.  After centrifugation at 16,000 × g for 10 min at 4˚C, the TAMRA-
TAT fraction was collected, lyophilized, reconstituted and detected by HPLC. 
In the second study, the recovery of TAMRA-TAT in ME with 14% Pluronic F127 
after different incubation time at 37˚C was determined.  In this study, TAMRA-TAT ME with 
14% Pluronic F127 was weighed out (50 mg/tube), and incubated with 100 µL of phosphate 
buffer of pH 6.8 at 37˚C for 5, 10, 20, 30, 45 and 60 min, respectively.  Then, acetone with 2% 
trifluoroacetic acid was added, and the sample was processed in the same way as 
described above and detected by HPLC. 
In the third study, the recovery of TAMRA-TAT from 14% Pluronic F127 after 
incubation at 37˚C for different amount of time was determined.  TAMRA-TAT in 14% 
Pluronic F127 was weighed out (50 mg/tube) and incubated with 100 µL of  phosphate 
buffer of pH 6.8 at 37˚C for 5, 10, 20, 30, 45 and 60 min, respectively.  After incubation, 
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acetone with 2% trifluoroacetic acid was added, and the sample was processed in the same 
way as described above and detected by HPLC. 
In all three studies, TAMRA-TAT stock solution diluted in acetonitrile/water with 0.1% 
(v/v) trifluoroacetic acid (19/81, v/v) served as the control (n = 3). 
 
3.4  Results and Discussion 
3.4.1  Viscosity study of Pluronic F127 
Pluronic F127 shows thermoreversible micellization and gelation properties as 
illustrated in Figure 3.5 and Figure 3.6. Its gelation process is both temperature and 
concentration dependent. To find a suitable Pluronic F127 concentration for hydrogel 
nanoparticle formation in the W/O microemulsion, the viscosity of Pluronic F127 was 
measured as a function of temperature and concentration.  As shown in Figure 3.7, when 
the Pluronic F127 concentration was lower than 14% (wt %), the viscosity did not increase 
much as the temperature increased, and for 13% Pluronic F127, the viscosity was only 57 
cP at 37˚C.  However, when the Pluronic F127 concentration was at or above 14%, the 
viscosity increased more dramatically when the temperature increased (Figure 3.7A).  
Based on these results, 14% Pluronic F127 was selected as the starting concentration to 
engineer hydrogel nanoparticles in the W/O microemulsion. 
 
3.4.2  Phase diagram 
Figure 3.8 shows the pseudo-ternary phase diagram constructed with Miglyol 
812/CapmulMCM/Tween 80/14% Pluronic F127.  In this phase diagram, the weight ratio of 
Miglyol 812 and Capmul MCM was kept at 65:22, based on earlier work [178].  Miglyol 812 
was the oil phase, Tween 80 was the water-soluble surfactant, Capmul MCM was the oil-
soluble cosurfactant, 14% Pluronic F127 in water was the aqueous phase.  Similarly, the red 
dots are turbid samples and the green dots represent clear samples, and the blue shaded 
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area is the microemulsion window defined at room temperature for this system.  When 
compared to the microemulsion window from our previous study with the same Miglyol 
812/Capmul MCM weight ratio (65:22) [178], the microemulsion window shifted more toward 
the center of the phase diagram.  There was a narrow gap region between the side opposite 
to the 14% Pluronic F127 apex and the microemulsion window, where the weight 
percentage of 14% Pluronic F127 in each sample was low and samples appeared turbid.  
This turbid region became wider with the increase of Tween 80 concentration.  There was 
no clear explanation for this phenomenon.  It was speculated that when 14% Pluronic F127 
was added to the Tween 80-rich oil and surfactant mixture, very small water droplets formed 
spontaneously, and when the water droplet size was smaller than the size of the Pluronic 
F127 micelle (approximately 10 nm in hydrodynamic radius [180]), Pluronic F127 became 
insoluble and precipitated out.  This would be the case when the water fraction was very 
small. 
 
3.4.3  Formulation characterization 
The goal of this study was to find an optimal W/O microemulsion with a certain 
amount of Pluronic F127 that is more protective to the peptide incorporated than the W/O 
microemulsion when challenged by an enzyme-containing system.  Based on the phase 
diagam constructed, several microemulsion formulations with 14% Pluronic F127 were 
prepared and characterized as shown in Table 3.2.  Formulations of F1 to F5 contained 5% 
(wt.%) water, and the formulation F6 contained 6% (wt.%) water.  They were all Newtonian 
fluids with a low viscosity ranging from 56-73 cP at 25˚C.  Formulations of F1-4 and F6 
showed uniform size distribution ranging from 30-60 nm in diameter with small polydispersity 
indices, while F5 was more polydispersed with a relatively larger PI.   
The turbidity of the F1-6 was evaluated via absorption measurements at 750 nm.  
The absorbance of F1-4 and F6 at 750 nm was all negligible, while the absorbance of F5 
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was one order of magnitude larger than others at 25°C.  Turbidity is the cloudiness or 
haziness of a fluid caused by particles in a sample.  In the absence of a turbidimeter, the 
sample turbidity was estimated by measuring absorbance in a UV-Vis Spectrophotometer 
[204, 205].  The particles in the sample block the photons and appear as absorbance.  
Goodner [204] developed a model to evaluate the correlation of UV-Vis absorption and 
turbidity, and observed a linear relationship between turbidity and absorbance at 750 nm, 
which confirmed that the absorption at 750 nm could be used as a valid indication of sample 
turbidity.  In combination with visual examination, the absorbance at 750 nm in this study 
was used to compare the turbidity of various formulations at different temperatures, which 
was an important piece of data to help formulation optimization and interpret the following in 
vitro stability data.  
Based on the appearance, absorption at 750 nm, and the Photon Correlation 
Spectroscopy (PCS) results at 25˚C, F3 and F6 were selected for the current stage and their 
viscosity, particle size and absorption at 750 nm were further examined at 37˚C.  Results 
(Table 3.2) showed that the viscosity of both F3 and F6 decreased somewhat when the 
temperature increased to 37˚C.  However, significant changes occurred with particle size.  
The droplet diameter of both formulations of F3 and F6 increased from nanometer size to 
micrometer size, which was sort of consistent with their dramatic absorption increase at 750 
nm.  
In addition, F3 and F6 were characterized via Freeze-Etch Electron Microscopy 
(FEEM).  Gold nanoparticles were processed via the same procedure to validate the FEEM 
method in this study.  As shown in Figure 3.9, both formulations appeared to be spherical 
droplets/particles, and their droplet/particle diameters were consistent with the 
corresponding PCS results, i.e., around 40 and 50 nm in diameter for F3 and F6, 
respectively.  The images obtained from FEEM were metal replicas of samples after they 
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were frozen in liquid nitrogen and etched at -170°C.  Due to the special sample processing 
technique, it was hard to obtain images representing their morphology at 37°C.   
The formulation of F6 was selected for further in vitro evaluation.  Its viscosity and 
conductivity were both measured as a function of temperature compared to the 
corresponding W/O microemulsion without Pluronic F127.  Results (Figure 3.10A) showed 
that the viscosity of both W/O microemulsion with 14% Pluronic F127 and without Pluronic 
F127 decreased with the temperature increase.  The conductivity (Figure 3.10B) of the W/O 
microemulsion increased gradually with the increase of temperature, while the conductivity 
of W/O microemulsion with 14% Pluronic F127 decreased as the temperature increased. 
 
3.4.4  In vitro enzymatic stability studies  
After initial formulation screening, W/O microemulsion with 14% Pluronic F127 was 
evaluated in vitro using TAMRA-TAT as a model peptide [178].  Similarly, Modified 
Simulated Intestinal Fluid (MSIF) was used as the enzyme-containing medium and the same 
sample processing and detection method was applied.  
 
Recovery studies  
To make sure the TAMRA-TAT in W/O microemulsion with Pluronic F127 can be well 
recovered even when hydrogel nanoparticles are formed at 37˚C, a total of three recovery 
studies were carried out.  The first recovery study examined the spike-recovery of TAMRA-
TAT in the presence of W/O microemulsion with 14% Pluronic F127 after the same sample 
processing method described under “Materials and Methods” and showed an average 
recovery of 97.61 ± 1.14% (n = 3) (Table 3.3).  The second recovery study examined the 
influence of different incubation time on the recovery of TAMRA-TAT in W/O microemulsion 
with Pluronic F127 at 37˚C. The results (Figure 3.11A) showed an average recovery of 
89.02% from all seven time points, and no significant difference was observed across the 
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recoveries after different incubation time. The third recovery study investigated the influence 
of pure 14% Pluronic F127 and different incubation time on the recovery of TAMRA-TAT, 
and similar results (Figure 3.11B) were obtained, which showed an average recovery of 
83.82% from all seven time points with no significant difference observed for the recovery 
after different incubation time. These recovery studies supported the feasibility of the sample 
processing method in this study. 
 
Stability studies to evaluate W/O MEs with 14% Pluronic F127 
During the in vitro stability studies, the degradation profiles of TAMRA-TAT in 
microemulsion with 14% Pluronic F127, TAMRA-TAT in W/O microemulsion and TAMRA-
TAT in solution in the presence of MSIF at 37˚C were compared.  The kinetics of TAMRA-
TAT followed pseudo-first-order rates in all three preparations.  As shown in Figure 3.12A 
and Table 3.4, the half life (t1/2) calculated from the resulting rate constant was 6.7, 19.4 and 
13.2 min for TAMRA-TAT in solution, W/O microemulsion and microemulsion with 14% 
Pluronic F127, respectively.  These results were different from what we had expected based 
on our hypothesis.  To confirm these results, the stability experiment was repeated.  Similar 
trends were obtained as shown in Figure 3.12B and Table 3.5.  The t1/2 of TAMRA-TAT in 
solution and the W/O microemulsion and microemulsion with 14% Pluronic F127 was 5.7, 
14.7 and 10.8 min, respectively.  It was noticed that the t1/2 of TAMRA-TAT in all three 
preparations was a little less than that from the first experiment, which was probably due to 
the activity difference in the MSIF used.  Both the W/O microemulsion and microemulsion 
with 14% Pluronic F127 were more protective to the TAMRA-TAT incorporated compared 
the naked solution.  However, the t1/2 of TAMRA-TAT in the microemulsion with 14% 
Pluronic F127 was less than that in the W/O microemulsion.  We then sought to explain 
these findings by investigating the physical/chemical properties of the systems.  The W/O 
microemulsion with 14% Pluronic F127 (F6) contained 6% (wt.%) of aqueous phase, which 
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was 14% Pluronic F127 in water.  The droplet diameter of F6 increased from around 50 nm 
to around 3 µm when the temperature increased from 25˚C to 37˚C, which suggested when 
the temperature increased to near 37˚C, the droplets containing Pluronic F127 might 
aggregate together and Pluronic F127 precipitated out.  This speculation was further 
supported by the absorption increase at 750 nm and the viscosity and conductivity 
measurements as well.  Figure 3.10A shows that the viscosity of ME with 14% Pluronic 
F127 was always higher than the corresponding W/O ME without Pluronic F127 until the 
temperature reached near and beyond 37˚C.  Figure 3.10B observed a conductivity 
decrease for the ME with 14% Pluronic F127 when the temperature increased to 37˚C, 
which was opposite to the conductivity change of the corresponding W/O ME without 
Pluronic F127.  If Pluronic F127 precipitation happened, both the viscosity and the 
conductivity would be lower than expected.  During the precipitation process, some of the 
TAMRA-TAT in the W/O ME with 14% Pluronic F127 could fall out of the microemulsion 
droplets by association with the Pluronic F127 precipitates, and thus would be exposed to 
the challenging enzyme system and degraded more rapidly.  Therefore, the protective effect 
from the W/O ME with 14% Pluronic F127 was decreased compared to the W/O ME without 
Pluronic F127. 
 
Stability studies to evaluate W/O MEs with 8% Pluronic F127 
Based on the above results, it was speculated that if the W/O ME with an appropriate 
amount of Pluronic F127 could stay clear at 37˚C without precipitation, it might provide 
better protection if hydrogels are formed inside the water droplets or at least similar 
protective effect if no hydrogels are formed in the W/O ME.  To confirm this idea, several 
W/O MEs with different amount of Pluronic F127 were prepared and characterized.  The 
purpose was to find a W/O ME with as much Pluronic F127 as possible, which could still 
stay clear when the temperature was increased to around 37˚C, and then the selected 
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formulation would be further evaluated using in vitro stability studies as described earlier.  
As shown in Table 3.6, W/O ME without Pluronic F127, with 5, 8, 9, 10 and 12% of Pluronic 
F127 by weight were prepared and characterized in terms of viscosity, droplet diameter, PI, 
absorption at 750 nm and physical appearance at both 25 and 37˚C.  Water-in-oil ME with 8% 
Pluronic F127 showed to be the one with the highest Pluronic F127 amount that could still 
stay clear and stable at both temperatures. This formulation was further evaluated via 
viscosity and conductivity measurements, respectively. Its viscosity (Figure 3.13A) 
decreased with temperature increase similar to the W/O ME, and stayed a little bit higher 
than the viscosity of the W/O ME at all the temperature included.  Its conductivity (Figure 
3.13B) increased with the increase of temperature, which was similar to the W/O ME as well.   
Water-in-oil ME with 8% Pluronic F127 was further evaluated using TAMRA-TAT as 
the model peptide and challenged by MSIF at 37˚C.  Results are shown in Figure 3.12C and 
Table 3.5.  The degradation profile of TAMRA-TAT in the ME with 8% Pluronic F127 almost 
overlapped with that in the W/O ME, and the estimated t1/2 of TAMRA-TAT was very close to 
that in the W/O ME as well.  This result supported our earlier speculation that the shorter t1/2 
of TAMRA-TAT in the ME with 14% Pluronic F127 compared to the W/O ME was indeed 
due to the formation of precipitation at 37˚C.  Without precipitation, the protective effect of 
the W/O ME was not compromised by the addition of Pluronic F127.  However, W/O ME 
with 8% Pluronic F127 did not provide better protective effect to the TAMRA-TAT 
incorporated compared to the W/O ME without Pluronic F127, which indicated that the 
Pluronic F127 concentration might be too low to form hydrogels in the W/O MEs.   
The thermoreversible gelation process of Pluronic F127 is a complex process 
influenced by temperature, polymer concentration and the presence of many additives like 
salts or other polymers.  Yang et al. reported that higher molar ratio of Tween 80 in a mixed 
micelle gel led to higher gel formation temperature when the molar ratio of Pluronic F127 to 
Tween 80 changed from 1:2 to 1:6 [190].  In our W/O ME with 8% Pluronic F127 system, the 
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weight percentage of Tween 80 was more than 20-fold higher than that of Pluronic F127,  
which might have influenced the gellation process of Pluronic F127.  On the other hand, in 
the W/O ME with Pluronic F127, the hydrogel formation was expected to be confined to the 
tiny nano-sized water droplets, and how does the gelation process happen in the W/O ME 
system is not clear yet.  It has been reported that [206] the hydrodynamic micellar radius of 
Pluronic F127 in water, as calculated from diffusion data at the CMC, was around 10.2 nm 
over the temperature range of 35-45˚C.  However, the droplet diameter of our W/O ME with 
Pluronic F127, as measured by PCS, was in the range of 20-60 nm; the gelation capacity 
might be limited by how many micelles each water droplet could hold.  It is not clear whether 
the space inside each droplet of the W/O ME system is large enough for the Pluronic F127 
gel formation.   
Originally, Pluronic F127 was thought to stay inside the water droplets after being 
incorporated into the W/O MEs considering it is a water-soluble polymer.  However, Pluronic 
F127 is amphiphilic with an HLB value of 18-23, so some of the Pluronic F127 could 
possibly partition into or be associated with the surfactant layer.  It has been reported that 
when temperature increased, the micelles of Pluronic F127 progressively became 
dehydrated [206], and the apparent micellar radius increased [180].  Therefore, it was 
possible that when temperature increased to around 37°C, the micellar size of Pluronic F127 
became larger than the water droplet size, and Pluronic F127 micelles between droplets 
interacted and aggregated together, causing the disruption of the W/O ME system.           
 
3.4.5  Attempts with other polymers in the W/O ME system 
During the formulation development process, we also explored the feasiblility of 
using several other polymers for the purpose of nanoparticle formation in the W/O MEs, 
such as hydroxypropylcellulose (HPC) and poly(N-isopropylacrylamide) (PNIPAM).  HPC is 
a nonionic water-soluble cellulose ether with a versatile of properties and wide applications 
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in the pharmaceutical field [207].  It is soluble in water below 38˚C and insoluble in water 
above 45˚C.  The idea was to dissolve a certain amount of HPC in the aqueous phase of the 
W/O ME, and when the temperature increased to the HPC precipitation temperature, HPC 
would become insoluble and form HPC nanoparticles inside the W/O ME droplets.  
KLUCEL® HPC of different average molecular weight at 80,000, 95,000, 140,000, 370,000, 
and 850,000, corresponding to KLUCEL® grades of EF, LF, JF, GF, and MF, at the 
concentration of 0.5% (wt.%) in water were titrated into the mixture of Miglyol 812/Capmul 
MCM/Tween 80 (62.8/21.2/11, w/w).  At different grades, around 6-7% of HPC could be 
incorporated to form clear W/O ME.  However, all the clear W/O MEs with HPC became 
cloudy when the temperature increased to their precipitation temperature, i.e., around 38-
40˚C, indicating HPC might have aggregated and precipitated out of the water droplets of 
the W/O MEs.  The viscosity of these HPC solutions was quite low and ranged from 1.1to 
7.3 cP at 25˚C, so the capacity of incorporating various grades of HPC into our W/O ME 
system seemed quite limited. 
PNIPAM is a thermosensitive water-soluble polymer that exhibits a cloud point at 
approximately 32˚C [208].  At temperature below the cloud point, PNIPAM is hydrophilic, 
while at temperature above the cloud point the polymer becomes hydrophobic and collapses 
into globules or aggregates, and for samples with high polymer concentration precipitation 
or gelation is observed [209].  PNIPAM with a weight average molecular weight (Mw) in the 
range of 19,000-30,000 (Sigma-Aldrich Co., St. Louis, MO, USA) at the concentration of 0.5, 
1, 2, and 5% (wt.%) was investgated in this work.  The PNIPAM solution at each 
concentration was titrated into the mixture of Miglyol 812/Capmul MCM/Tween 80 
(63.5/21.5/15, w/w) to form a clear W/O ME.  Results showed samples titrated with 5% and 
2% of PNIPAM always appeared cloudy, and samples titrated with 1% and 0.5% of PNIPAM 
looked clear when the weight percentage of PNIPAM solution was lower than 1.6% and 
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2.5%, respectively.  Overall, the W/O ME system could not incorporate a sufficient amount 
of PNIPAM in the system. 
Thermal reversible gelation is observed in several nonionic polymer systems, such 
as hydroxypropylmethylcellulose [210, 211], hydroxypropylcellulose [212], poly(N-
isopropylacrylamide) and derivatives [213, 214], and Pluronics [180, 215].  These polymers 
contain both hydrophilic and hydrophobic segments, and can form structures like a 
hydrophobic core surrounded by a hydrophilic shell.  The mechanisms behind thermal 
gelation have been investigated by many groups and several mechanisms reported include 
partial crystallization, coil-to-helix transition, hydrophobic association, and micelle packing 
[209, 216-218].  However, these mechanisms were proposed based on various instrumental 
techniques and observations, and this field is overall still controversial.  The gel formation is 
a macroscopic property, and gels are defined as three-dimentional polymeric networks with 
increased viscosity and a solid like behavior under small deformation.  The minimum 
molecule number and polymer density required for gel formation in the W/O ME with 
nanosized water droplets is hard to define based on the current understanding.  The overall 
impression is that the small size of the water droplets in the W/O MEs might be one of the 
limiting factors for a stable macroscopic hydrogel formation, but there is no direct evidence 
to prove or connect the microenvironment to the macroscopic gel phase yet.  
 
3.5  Summary  
In summary, to develop improved formulations for peptide oral local intestinal 
delivery, a thermal reversible gelling polymer Pluronic F127 was investigated to engineer 
hydrogel nanoparticles in W/O MEs.  Various characterization techniques and tools were 
utilized in this work.  Water-in-oil MEs with different amount of Pluronic F127 was evaluated 
based on Pluronic F127 viscosity studies, phase diagram construction, conductivity 
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measurement, turbidity measurement, photon correlation spectroscopy, freeze-etch electron 
microscopy (FEEM), and in vitro enzymatic stability studies.   
The FEEM study was a good technique to examine the morphology of W/O MEs with 
different amount of Pluronic F127 at low temperature, but not able to capture their 
temperature-dependent morphology at higher temperatures like at 37˚C.  The in vitro 
enzymatic stability studies showed the W/O ME with 14% Pluronic F127 could not provide 
better protective effect to the model peptide incorporated compared to the W/O ME.  
Meanwhile, the W/O ME with 8% Pluronic F127 showed same protective effect compared to 
the W/O ME.  So far, the engineering of hydrogel nanoparticles in the W/O MEs was still at 
the development and discovery stage.  More experiments are needed to better understand 
the temperature-dependent microstructure of W/O MEs with Pluronic F127 and/or other 
polymers, and to further improve the formulation.   
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Table 3.1  Lyophilization cycle of TAMRA-TAT samples. 
 
Thermal Treatment 
Step 1 -40˚C 30 min Hold 
Freeze, Condenser, Vacuum phases 
Freeze - 40˚C 
Additional Freeze 0 
Condenser - 60˚C 
Vacuum 100 mTorr 
Drying Cycle Steps 
 Temperature (ºC) Time (min) R/H Vacuum (mTorr) 
Step 1 -35 30 Hold 100 
Step 2 -30 30 Hold 100 
Step 3 -25 30 Hold 100 
Step 4 -20 30 Hold 100 
Step 5 -15 60 Hold 100 
Step 6 -10 180 Hold 100 
Step 7 -5 60 Hold 100 
 
Note: 
 
A bench-top VirTis AdVantage Freeze Dryer 2.0 liter XL (SP Industries VirTis, Gardiner, NY, 
USA) was used for the sample lyophilization. 
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Table 3.2  Composition and physical characterization of different W/O microemulsions with 
14% Pluronic F127 (PF127). 
 
Formulations 
F1 
(%,w/w) 
F2 
(%,w/w) 
F3 
(%,w/w) 
F4 
(%,w/w) 
F5 
(%,w/w) 
F6 
(%,w/w) 
Miglyol 812/Capmul MCM 
(65:22, w/w) 
80.0 81.5 82.5 83.5 85.0 83.0 
Tween 80 15.0 13.5 12.5 11.5 10.0 11.0 
14% PF127 5.0 5.0 5.0 5.0 5.0 6.0 
25˚C 
Viscosity (cP) 72.8 66.4 65.8 59.8 56.5 62.0 
Droplet diameter (nm) 39.4 ± 0.3 44.0 ± 1.2 43.5 ± 0.8 52.3 ± 1.3 288.9 ± 289.1 48.3 ± 0.9 
Polydispersity Index 0.195 ± 0.030 0.048 ± 0.053 0.034 ± 0.029 0.220 ± 0.073 0.534 ± 0.048 0.082 ±0.062 
Absorbance at 750 nm 0.0010 0.0006 0.0011 0.0000 0.0218 0.0030 
37˚C 
Viscosity (cP) – – 36.1 – – 33.1 
Droplet diameter (nm) – – 1998.0 ± 86.6 – – 2762.0 ± 135.5 
Polydispersity Index – – 1.000 – – 1.000 
Absorbance at 750 nm – – 0.0425 – – 0.2046 
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Table 3.3  TAMRA-TAT recovery from W/O microemulsion with 14% PF127. 
 
 
Theoretical 
value (µg/mL) 
Experimental 
value (µg/mL) 
Recovery 
(%) 
Mean recovery 
(%) 
SD 
Sample 1 0.7522 0.7263 96.56   
Sample 2 0.7522 0.7332 97.47 97.61 1.14 
Sample 3 0.7522 0.7433 98.82   
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Table 3.4  Parameters of TAMRA-TAT kinetic profile in MSIF (the first study). 
 
Formulations Equation R
2
 t1/2 (min) 
TAMRA-TAT Soln. y = 96.78 e
-0.1034 t
 0.9977 6.7 
TAMRA-TAT ME y = 91.56 e
-0.0357 t
 0.9910 19.4 
TAMRA-TAT ME 14% PF127 y = 96.46 e
-0.0526 t
 0.9886 13.2 
 
Note: 
 
The composition of TAMRA-TAT ME was Miglyol 812/Capmul MCM/Tween 80/TAMRA-TAT 
water solution at the weight ratio of 62.8/21.2/7/9.  The TAMRA-TAT ME with 14% PF127 
contained Miglyol 812/Capmul MCM/Tween 80/TAMRA-TAT PF127 solution at the weight 
ratio of 60.5/20.5/12/7. TAMRA-TAT Soln. contained an equivalent concentration of 
TAMRA-TAT by weight compared to TAMRA-TAT ME and TAMRA-TAT ME with 14% 
PF127. 
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Table 3.5  Parameters of TAMRA-TAT kinetic profile in MSIF (the second study). 
 
Formulations Equation R
2
 t1/2 (min) 
TAMRA-TAT Soln. y = 89.11 e
-0.1216 t
 0.9868 5.7 
TAMRA-TAT ME y = 95.31 e
-0.0470 t
 0.9888 14.7 
TAMRA-TAT ME 14% PF127 y = 97.82 e
-0.0641 t
 0.9876 10.8 
TAMRA-TAT ME 8% PF127 y = 99.78 e
-0.0489 t
 0.9955 14.2 
 
Note: 
 
The composition of TAMRA-TAT ME was Miglyol 812/Capmul MCM/Tween 80/TAMRA-TAT 
solution at the weight ratio of 62/21/11/6.  For TAMRA-TAT ME with 14% PF127 and with 8% 
PF127, the TAMRA-TAT solution was replaced by TAMRA-TAT in 14% PF127 or TAMRA-
TAT in 8% PF127, respectively.  TAMRA-TAT Soln. contained an equivalent concentration 
of TAMRA-TAT by weight as all other TAMRA-TAT preparations. 
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Table 3.6  Characterization of W/O microemulsion with different amount of Pluronic F127. 
 
Temperature Formulations 
Viscosity 
(cP) 
Droplet 
diameter (nm) 
Polydispersity 
index 
Absorbance 
750 nm 
Appearance 
25˚C 
W/O ME 55.1 ± 0.1 21.8 ± 0.5 0.063 ± 0.019 0.0000 clear 
W/O ME 5% PF127 56.8 ± 0.2 26.7 ± 0.8 0.275 ± 0.190 0.0014 clear 
W/O ME 8% PF127 58.2 ± 0.2 29.0 ± 0.1 0.039 ± 0.025 0.0091 clear 
W/O ME 9% PF127 58.6 ± 0.2 31.1 ± 0.5 0.031 ± 0.025 0.0054 clear 
W/O ME 10% PF127 54.3 ± 0.2 38.5 ± 1.4 0.082 ± 0.057 0.0036 clear 
W/O ME 12% PF127 58.6 ± 0.3 43.8 ± 0.3 0.017 ± 0.010 0.0104 clear 
37˚C 
W/O ME 33.1 ± 0.2 30.0 ± 0.6 0.037 ± 0.035 0.0015 clear 
W/O ME 5% PF127 34.3 ± 0.1 38.0 ± 0.7 0.042 ± 0.040 0.0059 clear 
W/O ME 8% PF127 34.4 ± 0.5 55.2 ± 1.1 0.132 ± 0.088 0.0089 clear 
W/O ME 9% PF127 36.3 ± 0.2 57.7 ± 1.3 0.146 ± 0.164 0.0565 almost clear 
W/O ME 10% PF127 34.7 ± 0.2 104.3 ± 52.6 0.522 ± 0.414 0.0676 a little hazy 
W/O ME 12% PF127 35.7 ± 0.1 1688.7 ± 223.7 1.000 0.2131 turbid 
 
Note: 
 
The composition of W/O ME was Miglyol 812/Capmul MCM/Tween 80/water at the weight 
ratio of 62/21/11/6.  For W/O ME with different amount of PF127, the water fraction was 
replaced by 5, 8, 9, 10, and 12% (w/w) of PF127, while the other components were kept at 
the same weight ratio as the W/O ME. 
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Figure 3.1  Schematic representation of three common microemulsions: (A) oil-in-water; (B) 
bicontinuous; and (C) water-in-oil microemulsion. (Modified from reference [136]).  
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Figure 3.2  Chemical structure of Pluronic F127. 
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Figure 3.3  Pluronic PEO-PPO-PEO copolymers arranged in the “Pluronic grid” (Reprinted 
with permission from reference [180].  Copyright © 1995, Elsevier). 
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Figure 3.4  An illustration of the formation of hydrogel nanoparticles in the W/O ME at 37°C 
in the proposed hypothesis.  (A) a W/O ME droplet; (B) a W/O ME droplet with a defined 
amount of PF127 at room temperature (RT); (C) PF127 hydrogel formation inside a water 
droplet of the W/O ME at 37°C. 
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Figure 3.5  Temperature-dependent critical micellization concentration (CMC) of Pluronic 
F127 (constructed from the data in reference [219]).  
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Figure 3.6  An illustration of the Pluronic F127 thermal gelling process. 
Micellization
Temperature Temperature
Gelation
116 
 
20 25 30 35 40
0
200
400
600
800
1000
2000
4000
6000
8000
80000
90000
100000
10%
13%
14%
14.5%
15%
16%
17%
Model: RVDV-III U CP
Pluronic F127
      (w/w)
(A)
Temperature (°C)
V
is
c
o
s
it
y
 (
c
P
)
 
15 20 25 30 35 40
0
20
40
60
5%
8%
10%
11%
12%
13%
Pluronic F127
      (w/w)
(B)
Temperature (°C)
V
is
c
o
s
it
y
 (
c
P
)
 
 
Figure 3.7  Viscosity of Pluronic F127 as a function of temperature and concentration. (A) 
the viscosity of Pluronic F127 at the concentrations of 10, 13, 14, 14.5, 15, 16, and 17% 
(w/w); (B) the viscosity of Pluronic F127 at the concentrations of 5, 8, 10, 11, 12, and 13% 
(w/w). 
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Figure 3.8  A pseudo-ternary phase diagram of Miglyol 812/Capmul MCM/Tween 80/14% 
Pluronic F127. 
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Figure 3.9  The freeze-etch electron microscopy 
(FEEM) and PCS of W/O MEs with 14% PF127 (F6 
and F3 in Table 3.2).  (A) The FEEM of F6; (B) the 
FEEM of F3; (C) the FEEM of gold nanoparticles as 
a technique control; (D) the PCS result of F6; (E) 
the PCS result of F3. 
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Figure 3.10  Viscosity and conductivity studies of a W/O ME and W/O ME with 14% PF127.  
(A) The viscosity of the W/O ME and W/O ME with 14% PF127 as a function of temperature; 
(B) the conductivity of the W/O ME and W/O ME with 14% PF127 at different temperatures. 
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Figure 3.11  TAMRA-TAT recovery study results. (A) The TAMRA-TAT recovery from W/O 
microemulsion with 14% PF127 after incubation at 37˚C for different times (n = 3); (B) the 
TAMRA-TAT recovery from 14% PF127 after incubation at 37˚C for different time (n = 3).  
The difference across all 7 time points in both A and B were analyzed using one-way 
ANOVA and no significant difference was found for the data set in A or B.  p < 0.05 is 
considered significant. 
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Figure 3.12  TAMRA-TAT degradation profiles in solution, W/O ME, W/O ME with 14% 
PF127 and W/O ME with 8% PF127 at 37°C in MSIF.  The remaining TAMRA-TAT was 
normalized with respect to the initial concentration.  Three samples were prepared for each 
time point for all the preparations.  Data are presented as mean ± SD (n = 3) on a 
logarithmic scale.  TAMRA-TAT degradation in all the preparations followed pseudo-first-
order kinetics.  (A) The first stability study of TAMRA-TAT ME with 14% PF127 as shown in 
Table 3.4; (B) the second stability study of TAMRA-TAT ME with 14% PF127 as shown in 
Table 3.5; (C) the degradation profile of TAMRA-TAT in ME with 8% PF127 compared to 
that in other preparations (Table 3.5). 
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Figure 3.13  Viscosity and conductivity studies of a W/O ME, W/O ME with 8% PF127 and 
W/O ME with 14% PF127. (A) The viscosity of the W/O ME, W/O ME with 8% PF127 and 
W/O ME with 14% PF127 at different temperatures; (B) the conductivity of the W/O ME, 
W/O ME with 8% PF127 and W/O ME with 14% PF127 at different temperatures. 
  
 
 
Chapter IV 
 
Conclusions and Future Prospects 
 
 
The ultimate goal of the present studies was to develop effective oral formulations for 
the local intestinal delivery of therapeutic peptides to treat local pathologies, like 
inflammatory bowel disease.  A combined formulation strategy was proposed, which 
included: 1) the development of W/O microemulsions and hydrogel nanoparticles in W/O 
microemulsions as the delivery vehicle; and 2) further incorporation of the W/O 
microemulsions and hydrogel nanoparticles in W/O microemulsions into enteric-coated 
capsules to enhance site-specific delivery.  The local intestinal delivery approach has well-
accepted advantages as being able to maximize local drug concentration and minimize 
systemic side effects.  The current studies focused on the first part of this combined strategy 
with the intention to develop an effective W/O microemulsion-based delivery vehicle first.  
Based on the prior research, W/O microemulsions and W/O microemulsions with Pluronic 
F127 were developed and explored.   
The hypotheses driving these studies were:  
1) the W/O microemulsion system may provide better protection to the peptide 
incorporated compared to peptide water solution when challenged in vitro and in vivo;  
2) the W/O microemulsion with Pluronic F127 may form hydrogel nanoparticles in the 
W/O microemulsion when temperature increases to close to body temperature at 37˚C, 
which may provide better protection to the peptide incorporated compared to the W/O 
124 
 
microemulsion without Pluronic F127 or an aqueous solution when challenged by an 
enzyme-containing system at 37˚C. 
 
4.1  W/O Microemulsions 
Water-in-oil microemulsions were developed using Miglyol 812, Capmul MCM, 
Tween 80 and water.  Miglyol 812 was the oil phase, Capmul MCM was the co-surfactant, 
Tween 80 was the surfactant, and water was the aqueous phase.  Three phase diagrams 
were constructed to guide the formulation optimization.  Water-in-oil microemulsions in the 
selected phase diagram were extensively characterized in terms of rheological properties, 
droplet diameter, polydispersity index, conductivity, morphology, and phase inversion 
studies, etc.  The selected W/O microemulsion was further evaluated in vitro and in vivo 
using a model peptide TAMRA-TAT.  The in vitro studies showed the half life of TAMRA-
TAT in the W/O microemulsion was three-fold greater than that in water solution when 
challenged by MSIF at 37˚C.  The in vivo studies in C57/BL6 mice showed that after oral 
gavage, TAMRA-TAT microemulsion resulted in greater fluorescence intensity in all intestine 
sections (duodenum, jejunum, ileum and colon) compared to the TAMRA-TAT solution or 
placebo microemulsion as examined by fluorescence microscopy.  The in vitro and in vivo 
studies together suggested the W/O microemulsions developed in this study were more 
protective to the peptide incorporated compared to controls, and may serve as a potential 
delivery vehicle for local intestinal delivery of water-soluble peptides after their further 
incorporation into enteric-coated capsules.  
The W/O microemulsions developed in this study were thermodynamically stable, 
and formed spontaneously at room temperature with minimal energy input.  These systems 
may be potentially used as a platform for the oral delivery of a wide range of water-soluble 
and heat-labile peptides or proteins.  However, there is still room for formulation 
improvement and additional experiments will be necessary before their applications to the 
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clinic.  The protective effect of the W/O microemulsions to the peptide incorporated has 
been shown in vitro and in vivo, but the underlying mechanism was proposed without solid 
proof yet.  The peptide incorporated in the W/O microemulsion was shown to be better 
protected, but the protection was not optimized.  One of the formulation strategies to 
improve this protection is the inclusion of protease inhibitors.  A comprehensive list of 
various pancreatic and brush-border membrane-bound proteases and their inhibitors has 
been reported by Sood et al. [2].  After both qualitative and quantitative considerations, 
enzyme inhibitors might work together with W/O microemulsions to provide better protection 
to the peptide or protein incorporated after oral delivery.  Although there are concerns that 
protease inhibitors might interfere with digestive enzymes in the GI-tract and disrupt proper 
digestions of nutritive proteins, the site-specific delivery to restrict protease inhibitors to the 
large intestine would make this approach more feasible.  A second strategy for potential 
formulation improvement is to engineer nanoparticles in the W/O microemulsions in situ, and 
as mentioned earlier, nanoparticles in the W/O microemulsion will provide further protection 
to the cargo incorporated even when phase inversion happens.  The third strategy would be 
the combination with the enteric-coating approach.  Water-in-oil microemulsions will be 
incorporated into enteric-coated capsules, which will enhance the local intestinal delivery to 
the target region of interest.  Some compatibility experiments between excipients in the W/O 
micremulsions and hard gelation capsules were performed and showed promising results.  
However, more comprehensive design and experiments will be necessary before the 
capsule selection, like determination of the water exchange, the possible brittleness change 
and capsule behaviors under accelerated stability conditions.  In vivo disintegration 
experiments in rats using different Eudragit polymer coated capsules containing W/O 
microemulsions also showed site-specific delivery as expected.  The coating materials, 
coating technique and stability of the peptide or protein in the W/O microemulsions during 
the coating process, will all need to be evaluated when therapeutic cargos are included.  
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Another important aspect of the formulation that needs to be evaluated is their short-term 
and long-term potential toxicities to the local intestinal epithelium.  So far, the in vivo animal 
experiments were performed in mice and further evaluation of the optimized formulation with 
therapeutic peptide in larger animal models is necessary and included in the future plan.    
 
4.2  W/O Microemulsions with Pluronic F127 
To overcome the limitation of the current W/O microemulsion system, i.e., phase 
inversion after oral administration, and to improve the protective effect to the peptide or 
protein incorporated, W/O microemulsions with Pluronic F127 were explored.  Viscosity 
studies as a function of temperature and concentration were completed using 14% (wt.%) 
Pluronic F127 as the microemulsion aqueous phase.  Phase diagram construction directed 
the optimization of W/O microemulsions with 14% Pluronic F127.  Freeze-etch electron 
microscopy was proven to be a useful tool to confirm the morphology of W/O 
microemulsions with different amount of Pluronic F127 at low temperature, but was not able 
to be employed to assess their morphology at elevated temperature like 37˚C.  Viscosity, 
conductivity, particle size, polydispersity index and turbidity (absorbance at 750 nm) 
together served as characterization parameters to help understand the temperature-
dependent properties of W/O microemusions with different amount of Pluronic F127.  The 
protective effects of the W/O microemulsion with 14% Pluronic F127 and W/O 
microemulsion with 8% Pluronic F127 were evaluated in in vitro enzymatic stability studies 
using TAMRA-TAT as the model peptide.  Results showed that the t1/2 of TAMRA-TAT in the 
W/O microemulsion with 14% Pluronic F127 was two-fold greater than that in water solution, 
but shorter than that in the W/O microemulsion without Pluronic F127, which was almost 
three-fold greater than that in water solution.  On the contrary, the degradation profile of 
TAMRA-TAT in the W/O microemulsion with 8% Pluronic F127 was almost superimposed 
with that in the W/O microemulsion without Pluronic F127. The calculated half lives in the 
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W/O microemulsion and the W/O microemulsion with 8% Pluronic F127 were almost the 
same as well.  The results from the W/O ME with 14% Pluronic F127 were not what we 
expected, but all were explained by the physical/chemical characterization data.  The large 
increase in droplet diameter, polydispersity index, and absorbance at 750 nm, and the 
significant decrease in conductivity all indicated that there might be Pluronic F127 
aggregation and droplet coalescence occurring for the W/O ME with 14% Pluronic F127 
when temperature increased to around 37˚C.  While for the W/O microemulsion with 8% 
Pluronic F127, these parameters were all similar or showing similar trends with temperature 
compared to the W/O ME without Pluronic F127.  Therefore, it was believed that the 
aggregation or potential precipitation of Pluronic F127 from the W/O ME with 14% Pluronic 
F127 might have exposed more TAMRA-TAT associated with it to enzymes, and thus 
reduced the protection effect. 
To develop a more protective W/O ME-based formulation, some suggestions include: 
(1) exploring different Pluronic polymer as the gellation agent; (2) or using combination of 
different Pluronics; (3) or using combination of Pluronic polymer with other polymers like 
carbopol.  Yong et al. [191] utilized the combination of Pluronic F127 and F68, and obtained 
a solution with a gel transition temperature at 35.7 ± 0.3°C, which offered an interesting 
perspective to optimize formulations. Carbopol, sodium alginate and polycarbophil have 
been shown to lower the gelation temperature of Pluronic F127, and increase the gel 
strength [220].  The combination of Pluronic F127 and carbopol has been investigated for 
buccal mucosal delivery as well [221].  However, the large molecular weight of these 
polymers may be a limiting factor for how much polymer can be incorporated into our W/O 
ME template.  Another potential strategy to improve the formulation is to modify the W/O ME 
template to improve the droplet size.  According to our speculation, the very small droplet 
size in the current W/O MEs might be a limiting factor for successful gelation.  If this is true, 
a W/O ME system with a larger droplet size might help the gel formation inside the W/O ME.  
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To form nanoparticles in a W/O ME, alternative nanoparticle formation methods may also be 
explored.  Watnasirichaikul et al. [222, 223] investigated interfacial polymerization method to 
engineer nanocapsules using a W/O microemulsion template similar to Constantinides et al. 
reported [138]. They prepared poly(ethyl 2-cyanoacrylate) nanocapsules by adding Ethyl 2-
cyanoacrylate monomers in chloroform to a W/O microemulsion under mechanical stirring, 
and resulted in nanocapsules with a central cavity surrounded by a polymer wall and a 
mean particle size around 150 nm.  Encapsulted insulin was released in water at pH 2.5 
within 3 h and no further evaluation was available. 
As mentioned, there is an increasing need to deliver peptides and proteins orally to 
treat local diseases of the GI-tract, such as inflammatory bowel diseases.  It is concluded 
that the type of systems proposed herein are attractive strategies to meet this need.  
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Appendices 
 
This section contains the following three sections: 
 
Appendix A  In vivo evaluation of water-in-oil microemulsions containing recombinant firefly 
luciferase  
 
Appendix B  Gastrointestinal distribution and disintegration of enteric-coated capsules 
containing water-in-oil microemulsions in rats 
 
Appendix C  Standard operation procedure: Preparation of a water-in-oil microemulsion 
containing 8K-NBD 
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Appendix A 
 
In Vivo Evaluation of Water-in-Oil Microemulsions Containing  
Recombinant Firefly Luciferase 
 
A.1  Introduction 
 Firefly luciferase has been widely used in numerous biomedical, pharmaceutical and 
bioanalytical applications [224]. It catalyzes luciferin oxidation to oxyluciferin in the presence 
of ATP and magnesium, resulting in bioluminescence.  The luciferin-firefly luciferase assay 
system has the highest quantum efficiency among the known chemiluminescence reactions 
[225]. 
To evaluate whether the W/O microemulsion system developed in this work (Chapter 
II) could provide protection to proteins after oral intestinal delivery, Quantilum® recombinant 
luciferase (Luc) expressed from a cloned gene of the North American firefly (Photinus pyralis) 
was used as a model protein.  A selected W/O microemulsion containing Luc was evaluated 
in vivo in mice.  
 
A.2  Methods 
 To assess the relationship of bioluminescence obtained using the IVIS® Kinetic 
Imaging System (Caliper Life Sciences, Hopkinton, MA, USA) versus the Quantilum® 
recombinant luciferase (Luc, Promega Corp., Madison, WI, USA) concentration, Luc was 
serially diluted in luciferase cell lysis buffer (New England BioLabs Inc., Ipswich, MA, USA) 
containing 1 mg/mL of BSA, and then imaged immediately after the addition of Luciferase 
Assay Reagent (Promega Corp., Madison, WI, USA), which contained the substrate D-
luciferin, magnesium and ATP etc.  The resulting luminescence was integrated and plotted 
against Luc concentration.  As shown in Figure A.1, the luminescence was linearly 
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correlated to the Luc concentration over the range of 1.07 to 34.38 pg/µL using the IVIS 
Kinetic Imaging System. 
 C57/BL6 female mice were obtained from the Charles River Labs and maintained in 
specific pathogen-free conditions. All experiments involving mice were carried out according 
to the protocol approved by the UNC Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill.  Twelve-week-old C57/BL6 female mice (18-20 g) 
were fed with standard chow, and fasted for 2 h before the experiments.  Mice had free 
access to water ad libitum.  Luc W/O microemulsion (ME) was prepared, and orally gavaged 
to mice at the dose of 8.8 mg/kg.  The composition of Luc W/O ME is shown in Table A.1.  
Luc diluted in PBS buffer was orally administered to mice at the same dose level (8.8 mg/kg).  
Placebo ME with the aqueous phase replaced by PBS buffer was orally administered as a 
control.  At predetermined time points following oral administration, mice were given D-
luciferin (Caliper Life Sciences, Hopkinton, MA, USA) by i.p. injection at a dose level of 150 
mg/kg of mouse weight.  Five minutes after the administration of D-luciferin, mice were 
sacrificed, mouse gastrointestinal tracts were harvested and imaged immediately using the 
IVIS Kinetic Imaging System. 
 
A.3  Results and Discussion 
 The bioluminescence images of mouse GI-tract 30 min, 1 h and 4 h following oral 
administration were shown in Figure A.2-4, respectively.  The integrated luminescence was 
analyzed and shown in Figure A.5.  Both 30 min and 1 h following oral administration, 
significant luminescence was observed from the GI-tract of mice treated with Luc ME 
compared to Luc buffer or the placebo ME.  Four hours after oral administration, there was 
no much luminescence observed along the GI-tract of mice treated with either Luc ME, Luc 
buffer or placebo ME.  However, most of the luminescence observed following Luc ME 
administration was around the stomach area, which could be because (1) the luminescence 
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intensity was too low to be detected as Luc was diluted during the intestinal transit, or (2) 
Luc was mostly degraded as it passed down the intestinal tract.  These results together 
indicated that Luc was better protected by the W/O microemulsion formulation compared to 
the PBS buffer in vivo.  
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Table A.1  Luc W/O microemulsion composition. 
Ingredients % (Wt.) 
Miglyol 812/Capmul MCM (65:22, w/w) 84.0 
Tween 80 10.0 
Luc stock (14.37 mg/mL, Cat #: E1702) 6.0 
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Figure A.1  In vitro bioluminescence imaging of recombinant firefly luciferase (Luc) in buffer 
as a function of concentration.  (A) The bioluminescence image of Luc at different 
concentrations after serial dilution in luciferase cell lysis buffer.  (B) The linear relationship of 
luminescence versus Luc concentration. 
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Figure A.2  The bioluminescence images of mouse GI-tract 30 min following oral 
administration.  The top panel shows the results from mice treated with Luc ME, and the 
lower panel shows the results from mice treated with Luc buffer. 
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Figure A.3  The bioluminescence images of mouse GI-tract 1 h following oral administration.  The top panel shows the results 
from mice treated with Luc ME, and the lower panel shows the results from mice treated with Luc buffer. 
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Figure A.4  The bioluminescence images of mouse GI-tract 4 h following oral administration.  
The top panel shows the results from mice treated with Luc ME, the middle panel shows the 
results from mice treated with Luc buffer, and the lower panel shows the image from the 
mouse treated with placebo ME. 
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Figure A.5  Comparison of the luminescence from the GI-tract of mice following oral 
administration of Luc ME, Luc buffer and placebo ME, respectively.  
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Appendix B 
 
Gastrointestinal Distribution and Disintegration of Enteric-Coated Capsules 
Containing Water-in-Oil Microemulsions in Rats 
 
B.1  Introduction 
 After water-in-oil (W/O) microemulsions were developed and optimized, the 
microemulsion-based formulations containing therapeutic peptides or proteins would be 
encapsulated into enteric-coated capsules to facilitate site-specific local intestinal delivery.  
Based on the work reported in Chapter II, pilot studies in rats on the GI transit time and in 
vivo disintegration of the enteric-coated hard gelatin capsules containing W/O MEs were 
designed.  The purpose of these studies was to provide proof-of-concept information for 
future efficacy studies in animal models.  
 
B.2  Methods 
In these studies, two fluorescent molecules TAMRA-TAT and 1,1'-dioctadecyl-
3,3,3',3'-tetramethylindotricarbocyanine Iodide ('DiR', Invitrogen, Grand Island, NY, USA) 
were used as fluorescent markers to help visualize the in vivo capsule transit and 
disintegration process.  Torpac® size 9 gelatin minicapsules (Torpac Inc., Fairfield, NJ, USA) 
were used as the W/O ME carriers.  Four rat studies were performed and summarized as 
follows.  All studies involving rats were carried out according to the protocol approved by the 
UNC Institutional Animal Care and Use Committee at the University of North Carolina at 
Chapel Hill. 
The composition of TAMRA-TAT ME is shown in Table B.1.  Eudragit L100-55 
coated capsules containing TAMRA-TAT ME (20-25 µL/capsule) were prepared by a two-
step coating process.  After being loaded with TAMRA-TAT ME, capsules were first dip-
coated with coating solution F1 (Table B.2) five times, and then painted using a brush with 
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coating solution F7 (Table B.2) five times.  Coated capsules were dried at room temperature 
(RT) using a five-inch desk air fan.   
Eudragit L100 coated capsules containing TAMRA-TAT ME (20-25 µL/capsule) were 
prepared using a similar coating process.  TAMRA-TAT ME loaded capsules were first dip-
coated with coating solution F9 (Table B.3, five times), then painted with coating solution 
F10 (Table B.3, five times), and dried at RT using a five-inch desk air fan. 
The composition of ‘DiR’ ME is shown in Table B.4.  Eudragit L100 coated capsules 
containing ‘DiR’ ME (20-25 µL/capsule) were coated in the same way as described above 
for the preparation of Eudragit L100 coated TAMRA-TAT ME-containing capsules . 
Eudragit S100 coated capsules containing ‘DiR’ ME (20-25 µL/capsule) were 
prepared similarly.  ‘DiR’ ME loaded capsules were first dip-coated with coating solution F11 
(Table B.5, five times), then painted with coating solution F12 (Table B.5, five times), and 
dried at RT using a five-inch desk air fan. 
Male Sprague-Dawley rats (Charles River Labs) were fasted over night before and 
throughout the experiments, but with free access to water ad libitum.  Enteric-coated 
capsules containing TAMRA-TAT ME or ‘DiR’ ME were administered to rats orally using a 
dosing syringe (Torpac Inc., Fairfield, NJ, USA).  At predetermined time points following oral 
administration, rats were sacrificed, the rat GI tracts were taken out and imaged using the 
IVIS Kinetic Imaging System via fluorescence detection.  The detection wavelengths for 
TAMRA-TAT and ‘DiR’ were (Ex/Em) 535/580 nm and (Ex/Em) 745/800 nm, respectively.  
After the imaging, the rat GI tracts were cut open and capsules were physically searched 
and located. 
 
B.3  Results and Discussion 
 The first study showed the GI distribution and in vivo disintegration of Eudragit L100-
55 coated capsules containing TAMRA-TAT ME in rats (Figure B.1A).  Two hours following 
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oral administration, all three capsules were found intact in the rat stomach.  Four hours 
following oral administration, one capsule was found partially disintegrated in the jejunum, 
while the rest of the capsules stayed intact in the stomach.  Eight hours following oral 
administration, bright fluorescence was found at the entry of the cecum and no capsules 
were found throughout the whole GI tract.  Figure B.1B shows the images of capsules 
containing TAMRA-TAT ME before and after enteric coating, and their morphology after they 
were found in the rat GI tract following oral administration.  
 The second study showed the GI distribution and in vivo disintegration of Eudragit 
L100 coated capsules containing TAMRA-TAT ME in rats (Figure B.2).  Similar to the first 
study, 2 h and 4 h following oral administration, all the capsules were found intact in the rat 
stomach, while 8 h after dosing, bright fluorescence was found at the distal small intestine 
before the cecum, which indicated one of the capsules might have disintegrated at the ileum 
region.  After the capsules stayed in the rat stomach for 2 h and 4 h, respectively, they 
appeared intact without any deformation.  Compared to capsules coated with Eudragit L100-
55, capsules coated with Eudragit L100 seemed to be more stable in the acidic environment.  
An in vitro disintegration test using Eudragit L100 coated size 9 capsules showed that these 
capsules stayed intact in the 0.1 M HCl for more than 4.5 h.  After being transferred to 
phosphate buffer of pH 6.5, the capsules disintegrated within 10 min.  The slow stomach 
emptying of these enteric coated size 9 capsules was probably due to the relatively large 
size of the capsules compared to the narrow passage of the rat intestinal tract.  This slow 
stomach emptying of size 9 minicapsules in rats was also reported by Saphier et al. [226].   
 ‘DiR’ is a near infrared fluorescent, lipophilic molecule.  The fluorescence emitted 
from ‘DiR’ is much stronger and easier to penetrate through tissues compared to TAMRA-
TAT.  In the third study, Eudragit L100 coated capsules containing ‘DiR’ ME were orally 
administered to rats.  The GI distribution and in vivo disintegration of these capsules are 
shown in Figure B.3.  To avoid the potential interference of stomach emptying between 
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capsules, each rat received one capsule in this study.  The results showed that 4 h following 
oral administration, the capsule stayed intact in the stomach.  In contrast, 5, 6, 7 and 8 h 
following oral administration, all the capsules disintegrated in the lower small intestine, 
respectively, and no intact capsules were found.  In combination with the second study, the 
results indicated Eudragit L100 coated capsules could be emptied from the rat stomach 4 h 
following oral administration, and then disintegrate in the lower rat small intestine. 
 In the fourth study, the GI distribution and in vivo disintegration of Eudragit S100 
coated capsules containing ‘DiR’ ME were investigated in rats.  As shown in Figure B.4, 5 h 
following oral administration, the capsule still stayed intact in the stomach.  In contrast, 6 h 
following oral administration, strong fluorescence was found in the lower small intestine 
before the cecum.  Seven hours following oral administration, some fluorescence was found 
in the cecum and no fluorescence was found in the small intestine.  Eight hours following 
oral administration, some fluorescence was found in the colon.  Theses results indicated 
that the Eudragit S100 coated capsules could better facilitate colon-specific drug delivery.  
 In summary, with the help of fluorescent molecules and IVIS Kinetic Imaging System, 
the GI distribution and in vivo disintegration of various enteric coated minicapsules 
containing W/O MEs were visualized in the rat GI tract.  These results confirmed that the 
enteric-coating strategy may facilitate site-specific delivery of W/O MEs containing theraptic 
peptides to the lower GI tract, such as the colon.  These data provided helpful information 
for future efficacy studies of drug loaded W/O MEs in enteric coated capsules in animals.  
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Table B.1  TAMRA-TAT W/O microemulsion formulation. 
Ingredients Weight (mg) 
Miglyol 812/Capmul MCM (65:22, w/w) 840 
Tween 80 100 
TAMRA-TAT water stock (4 mg/mL) 60 
 
Table B.2  Eudragit L100-55 coating solutions. 
Per 100 g F1 (g) F7 (g) 
Eudragit L100-55 12.5 15 
Triethyl citrate* 6.25 (50%) 3.75 (25%) 
Talc 0 3.75 
Acetone:IPA (60:40,v/v) 81.25 77.5 
               *  Calculated based on the weight of Eudragit L100-55. 
 
Table B.3  Eudragit L100 coating solutions. 
Per 100 g F9 (g) F10 (g) 
Eudragit L100 12.5 15 
Triethyl citrate* 6.25 (50%) 3.75 (25%) 
Talc 0 3.75 
Acetone:IPA (60:40,v/v) 81.25 77.5 
               *  Calculated based on the weight of Eudragit L100. 
 
Table B.4  ‘DiR’ W/O microemulsion formulation. 
Ingredients Weight (mg) 
Miglyol 812/Capmul MCM (65:22, w/w) 840 
Tween 80 100 
Water 60 
‘DiR’ 0.4 
 
Table B.5  Eudragit S100 coating solutions. 
Per 100 g F9 (g) F10 (g) 
Eudragit S100 12.5 15 
Triethyl citrate* 6.25 (50%) 3.75 (25%) 
Talc 0 3.75 
Acetone:IPA (60:40,v/v) 81.25 77.5 
               *  Calculated based on the weight of Eudragit S100. 
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Figure B.1  (A) Rat GI distribution of Eudragit L100-55 coated capsules containing TAMRA-
TAT ME 2, 4 and 8 h following oral administration.  Each rat received 3 capsules in this 
study, and the rat weight ranged from 390-410 g.  The top panel shows images of intact rat 
GI tracts.  The lower panel shows images of the corresponding rat GI tracts after they were 
cut open to faciliate physical location of the capsules.  (B) Pictures of TAMRA-TAT capsules 
before and after enteric coating (top panel), and after staying in the rat GI tract for indicated 
time period (lower panel).  
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Figure B.2  Rat GI distribution of Eudragit L100 coated capsules containing TAMRA-TAT 
ME 2, 4 and 8 h following oral administration.  Each rat received 3 capsules in this study, 
and the rat weight ranged from 420-470 g.  The top panel shows images of intact rat GI 
tracts.  The lower panel shows images of the corresponding rat GI tracts after they were cut 
open to faciliate physical location of the capsules. 
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Figure B.3  Rat GI distribution of Eudragit L100 coated capsules containing ‘DiR’ ME after oral administration.  All the GI tracts 
shown here were intact.  Each rat received one capsule in this study, and the rat weight ranged from 250-290 g. 
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Figure B.4  Rat GI distribution of Eudragit S100 coated capsules containing ‘DiR’ ME after oral administration.  All the GI tracts 
shown here were partially cut open.  Each rat received 1 capsule in this study, and the rat weight ranged from 320-400 g. 
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Appendix C 
 
Standard Operation Procedure: 
Preparation of a Water-in-Oil Microemulsion Containing 8K-NBD 
 
 
 
C.1  Objective 
 This standard operation procedure describes the process to prepare 100 g of W/O 
microemulsion containing 8K-NBD at a final concentration of 1 mg/g in the microemulsion. 
 
C.2  Materials 
Miglyol 812, neutral oil, Sasol Germany GmbH (Eatontown, NJ, USA) 
Capmul MCM NF, Abitec Corporation (Janesville, WI, USA) 
Tween 80, Spectrum Chemical MFG. Corporation (Gardena, CA, USA) 
8K-NBD, TheraLogics, Inc.   
Deionized water, Milli-Q Advantage System  
 
C.3  Procedure 
1.   To prepare an 8K-NBD stock solution at 16.67 mg/g in deionized water, weigh out 110 
mg of 8K-NBD into a 20 mL scintillation vial, and then add 6.49 g of deionized water and 
shake well to dissolve 8K-NBD completely in deionized water. 
2.   Weigh out 62.76 g of Miglyol 812 and 21.24 g of Capmul MCM into a 125 mL Wheaton 
glass bottle.  
3.   Add 10 g of Tween 80 to the Wheaton glass bottle in step 2. 
4.   Add 6 g of 8K-NBD stock solution from step 1 to the Wheaton glass bottle in step 3. 
5.   Add a magnetic stir bar to the Wheaton glass bottle in step 4, and stir in an ice water 
bath for 20-30 minutes until the microemulsion becomes homogeneous and clear. 
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